| Drug |
zidovudine |
233 |
1999 |
| Drug |
ritonavir |
185 |
2013 |
| placebo |
placebo |
155 |
2013 |
| Drug |
lamivudine |
149 |
2016 |
| Drug |
didanosine |
89 |
2006 |
| Drug |
efavirenz |
89 |
2010 |
| Drug |
stavudine |
85 |
2016 |
| Drug |
lopinavir |
83 |
2016 |
| Drug |
nevirapine |
80 |
2014 |
| Drug |
indinavir sulfate |
60 |
1999 |
| Drug |
raltegravir |
59 |
2010 |
| Drug |
emtricitabine |
58 |
2013 |
| Drug |
lopinavir/ritonavir |
58 |
2009 |
| Drug |
nelfinavir mesylate |
55 |
1999 |
| Drug |
saquinavir |
51 |
1999 |
| Drug |
atazanavir |
45 |
2013 |
| Drug |
tenofovir |
44 |
2016 |
| Drug |
abacavir sulfate |
41 |
2005 |
| Drug |
tenofovir disoproxil fumarate |
40 |
2016 |
| Drug |
maraviroc |
34 |
2010 |
| Drug |
zalcitabine |
33 |
1999 |
| Drug |
darunavir |
31 |
2016 |
| Drug |
lamivudine/zidovudine |
30 |
2012 |
| Drug |
amprenavir |
29 |
1999 |
| Biological |
rgp120 |
27 |
1999 |
| Drug |
ftc |
26 |
2010 |
| Drug |
tdf |
26 |
2010 |
| Drug |
abacavir |
25 |
2008 |
| Drug |
dolutegravir |
25 |
2014 |
| Behavioral |
standard care |
23 |
2010 |
| Drug |
aldesleukin |
21 |
2005 |
| Drug |
3tc |
19 |
2005 |
| Drug |
ribavirin |
19 |
2013 |
| Drug |
dtg |
16 |
2013 |
| Drug |
e |
16 |
2013 |
| Drug |
taf |
16 |
2013 |
| Drug |
truvada |
16 |
2015 |
| Drug |
delavirdine mesylate |
15 |
1999 |
| Drug |
emtricitabine/tenofovir disoproxil fumarate |
15 |
2008 |
| Drug |
enfuvirtide |
15 |
2015 |
| Biological |
hiv-1 sf-2 |
15 |
1999 |
| Drug |
r |
15 |
2013 |
| Biological |
rgp120/hiv-1 sf-2 |
15 |
1999 |
| Drug |
adefovir dipivoxil |
14 |
1999 |
| Drug |
bms-663068 |
14 |
2014 |
| Drug |
c |
13 |
2013 |
| Drug |
f |
13 |
2013 |
| Biological |
hiv-1mn |
13 |
1999 |
| Biological |
rgp120/hiv-1mn |
13 |
1999 |
| Biological |
alvac-hiv mn120tmg (vcp205) |
12 |
2000 |
| Biological |
alvac(2)120(b,mn)gnp (vcp1452) |
12 |
2001 |
| Drug |
fosamprenavir |
12 |
2010 |
| Drug |
ftc/tdf |
12 |
2010 |
| Drug |
hydroxyurea |
12 |
2006 |
| Drug |
atv |
11 |
2010 |
| Drug |
gsk1349572 |
11 |
2010 |
| Drug |
haart |
11 |
2008 |
| Drug |
lamivudine (3tc) |
11 |
2016 |
| Drug |
abacavir/lamivudine |
10 |
2010 |
| Drug |
etravirine |
10 |
2010 |
| Drug |
tenofovir df |
10 |
2007 |
| Biological |
vrc-hivadv014-00-vp |
10 |
2008 |
| Drug |
abc |
9 |
2017 |
| Biological |
alvac-rg rabies glycoprotein (vcp65) |
9 |
2000 |
| Drug |
e/c/f/taf |
9 |
2013 |
| Drug |
efavirenz (efv) |
9 |
2009 |
| Biological |
hiv-1 |
9 |
2001 |
| Drug |
kaletra |
9 |
2005 |
| Biological |
mf59 |
9 |
1999 |
| Biological |
mn rgp120 |
9 |
2001 |
| Drug |
rtv |
9 |
2010 |
| Drug |
tipranavir |
9 |
2007 |
| Biological |
vrc01 |
9 |
2015 |
| Biological |
aluminum hydroxide |
8 |
2002 |
| Drug |
atazanavir/ritonavir |
8 |
2011 |
| Drug |
levocarnitine |
8 |
1999 |
| Drug |
lpv |
8 |
2006 |
| Drug |
bms-955176 |
7 |
2014 |
| Drug |
capravirine |
7 |
2000 |
| Drug |
cobi |
7 |
2010 |
| Drug |
drv |
7 |
2011 |
| Drug |
efv |
7 |
2011 |
| Drug |
emtricitabine (ftc) |
7 |
2009 |
| Biological |
gp160 vaccine (microgenesys) |
7 |
1999 |
| Biological |
hiv-1 immunogen |
7 |
1999 |
| Drug |
interleukin-2 |
7 |
2005 |
| Drug |
r) |
7 |
2014 |
| placebo |
tdf placebo |
7 |
2010 |
| Drug |
thalidomide |
7 |
2003 |
| Drug |
10-1074 |
6 |
2018 |
| Biological |
aidsvax b |
6 |
2013 |
| Drug |
cobicistat |
6 |
2017 |
| Behavioral |
control |
6 |
2019 |
| Behavioral |
counseling |
6 |
2018 |
| Combination Product |
dapivirine vaginal ring |
6 |
2016 |
| Drug |
darunavir/ritonavir |
6 |
2009 |
| Drug |
e/c/f/tdf |
6 |
2013 |
| Drug |
fluconazole |
6 |
2014 |
| Drug |
foscarnet sodium |
6 |
1999 |
| Biological |
gne8 rgp120 |
6 |
2000 |
| Drug |
isoniazid |
6 |
2013 |
| Biological |
mn rgp120/hiv-1/gne8 rgp120/hiv-1 |
6 |
2000 |
| placebo |
placebo vaginal ring |
6 |
2016 |
| Drug |
ritonavir (lpv |
6 |
2014 |
| Drug |
sargramostim |
6 |
1999 |
| Drug |
stribild |
6 |
2010 |
| Drug |
tmc114 |
6 |
2009 |
| Behavioral |
treatment interruption |
6 |
2015 |
| Drug |
trizivir |
6 |
2007 |
| Drug |
vicriviroc |
6 |
2008 |
| Drug |
zidovudine (zdv) |
6 |
2014 |
| Drug |
2 nrtis |
5 |
2003 |
| Drug |
3bnc117 |
5 |
2016 |
| Drug |
atripla |
5 |
2010 |
| Drug |
azithromycin |
5 |
2013 |
| Biological |
blood sample |
5 |
2011 |
| Drug |
cab la |
5 |
2016 |
| Drug |
combivir |
5 |
2012 |
| Drug |
dapivirine |
5 |
2010 |
| Drug |
didanosine (ddi) |
5 |
2005 |
| Drug |
dolutegravir 50 mg |
5 |
2011 |
| Drug |
doravirine |
5 |
2012 |
| Drug |
epoetin alfa |
5 |
2005 |
| Behavioral |
general health promotion |
5 |
2010 |
| Biological |
gp160 vaccine (immuno-ag) |
5 |
1999 |
| Drug |
gsk1265744 |
5 |
2013 |
| Drug |
gsk3640254 |
5 |
2019 |
| Other |
laboratory biomarker analysis |
5 |
2015 |
| placebo |
placebo gel |
5 |
2010 |
| Drug |
pyrazinamide |
5 |
2002 |
| Drug |
rifabutin |
5 |
2010 |
| Drug |
rilpivirine |
5 |
2015 |
| Drug |
rosuvastatin |
5 |
2010 |
| Drug |
saquinavir/ritonavir |
5 |
2006 |
| Drug |
sof |
5 |
2012 |
| placebo |
taf placebo |
5 |
2013 |
| Drug |
tenofovir alafenamide |
5 |
2002 |
| Drug |
tenofovir disoproxil fumarate (tdf) |
5 |
2009 |
| Behavioral |
testing |
5 |
2015 |
| Drug |
thymopentin |
5 |
1999 |
| Drug |
valacyclovir |
5 |
2010 |
| Biological |
vrc-hivdna009-00-vp |
5 |
2012 |
| Biological |
vrc-hivdna016-00-vp |
5 |
2005 |
| Biological |
vrc07-523ls |
5 |
2018 |
| Biological |
a244 rgp120 |
4 |
2000 |
| Drug |
abacavir (abc) |
4 |
2010 |
| Drug |
acyclovir |
4 |
2004 |
| Behavioral |
affect management |
4 |
2010 |
| Biological |
ags-004 |
4 |
2014 |
| Biological |
aidsvax b/e |
4 |
2013 |
| Biological |
alvac-hiv |
4 |
2013 |
| Drug |
amphotericin b |
4 |
1999 |
| Biological |
apl 400-003 |
4 |
1999 |
| Drug |
atevirdine mesylate |
4 |
1999 |
| Biological |
bivalent subtype c gp120 |
4 |
2017 |
| Biological |
dna-hiv-pt123 vaccine |
4 |
2016 |
| Drug |
dtg 50 mg |
4 |
2015 |
| Drug |
e/c/f/tdf placebo |
4 |
2013 |
| Drug |
elvucitabine |
4 |
2008 |
| Drug |
emtricitabine/tenofovir |
4 |
2015 |
| Drug |
enfuvirtide [fuzeon] |
4 |
2008 |
| Biological |
env 2-3 |
4 |
1999 |
| Drug |
filgrastim |
4 |
1999 |
| Drug |
ftc 200 mg |
4 |
2012 |
| Biological |
gp160 mn |
4 |
2002 |
| Biological |
gp160 mn/lai-2 |
4 |
2002 |
| Drug |
gsk2248761 |
4 |
2010 |
| Biological |
hepatitis a vaccine (inactivated) |
4 |
2002 |
| Biological |
hiv-1iiib |
4 |
1999 |
| Drug |
indinavir |
4 |
1999 |
| Drug |
interferon alfa-2a |
4 |
1999 |
| Drug |
interferon alfa-n3 |
4 |
1999 |
| Drug |
interleukin-12 |
4 |
1999 |
| Biological |
lai-2 |
4 |
2002 |
| Drug |
lopinavir/ritonavir (lpv/r) |
4 |
2014 |
| Drug |
maraviroc (uk-427,857) |
4 |
2004 |
| Drug |
methadone |
4 |
2011 |
| Biological |
mf59 vaccine |
4 |
2016 |
| Biological |
mn rgp120/hiv-1/a244 rgp120/hiv-1 |
4 |
2000 |
| Biological |
mtp-pe |
4 |
1999 |
| Biological |
mtp-pe/mf59 |
4 |
1999 |
| Drug |
nevirapine (nvp) |
4 |
2014 |
| Drug |
nystatin |
4 |
1999 |
| Biological |
pol |
4 |
2009 |
| Drug |
pravastatin |
4 |
2009 |
| Drug |
pro 2000 |
4 |
2000 |
| Drug |
pyridoxine hydrochloride |
4 |
1999 |
| Drug |
raltegravir potassium |
4 |
2009 |
| Biological |
rgp120/hiv-1iiib |
4 |
1999 |
| Drug |
rifampin |
4 |
2010 |
| Drug |
rpv |
4 |
2014 |
| Drug |
sofosbuvir |
4 |
2013 |
| Behavioral |
structured treatment interruption |
4 |
2009 |
| Drug |
sulfamethoxazole-trimethoprim |
4 |
1999 |
| Drug |
tdf) |
4 |
2017 |
| Drug |
tenofovir gel |
4 |
2011 |
| Drug |
tenofovir/emtricitabine |
4 |
2008 |
| Dietary Supplement |
vitamin d |
4 |
2010 |
| Drug |
abacavir sulfate, lamivudine |
3 |
2002 |
| Drug |
abacavir sulfate, lamivudine/zidovudine |
3 |
2002 |
| Biological |
aidsvax b/e placebo |
3 |
2013 |
| Drug |
alovudine |
3 |
1999 |
| Drug |
amdoxovir |
3 |
2007 |
| Drug |
ampligen |
3 |
1999 |
| Drug |
anti-hiv immune serum globulin (human) |
3 |
1999 |
| Drug |
aprepitant |
3 |
2014 |
| Drug |
apricitabine |
3 |
2006 |
| Drug |
art |
3 |
2018 |
| Drug |
as-101 |
3 |
1999 |
| Drug |
atazanavir / ritonavir |
3 |
2006 |
| Drug |
atazanavir sulphate |
3 |
2006 |
| Drug |
atovaquone |
3 |
1999 |
| Biological |
b |
3 |
2011 |
| Drug |
buprenorphine |
3 |
2007 |
| Drug |
butyldeoxynojirimycin |
3 |
1999 |
| Dietary Supplement |
calcium carbonate |
3 |
2003 |
| Drug |
car |
3 |
2015 |
| Other |
care |
3 |
2009 |
| Drug |
celgosivir hydrochloride |
3 |
1999 |
| Behavioral |
cell phone intervention |
3 |
2010 |
| Behavioral |
community mobilization |
3 |
2011 |
| placebo |
comparator: placebo |
3 |
2009 |
| Drug |
cyclophosphamide |
3 |
2014 |
| Drug |
dapivirine (tmc120) vaginal gel |
3 |
2006 |
| Drug |
dolutegravir (dtg) |
3 |
2016 |
| placebo |
e placebo |
3 |
2013 |
| Drug |
e/c/f/taf placebo |
3 |
2013 |
| Drug |
emivirine |
3 |
1999 |
| Drug |
emtricitabine (tdf |
3 |
2016 |
| Drug |
emtricitabine 200 mg |
3 |
2018 |
| Drug |
emtricitabine/tenofovir disoproxil fumarate (ftc/tdf) |
3 |
2017 |
| Behavioral |
enhanced counseling |
3 |
2019 |
| Biological |
ep hiv-1090 |
3 |
2005 |
| Drug |
etravirine (etr) |
3 |
2011 |
| Drug |
ftc/tdf placebo |
3 |
2010 |
| Behavioral |
hct |
3 |
2008 |
| Drug |
highly active antiretroviral therapy (haart) |
3 |
2009 |
| Behavioral |
hiv |
3 |
2015 |
| Biological |
hiv-1 c4-v3 polyvalent peptide vaccine |
3 |
2000 |
| Biological |
hiv-1 peptide vaccine, microparticulate monovalent |
3 |
1999 |
| Behavioral |
hiv counseling |
3 |
2015 |
| Drug |
interferon alfa-n1 |
3 |
1999 |
| Drug |
interferon gamma-1b |
3 |
1999 |
| Drug |
interleukin-2, polyethylene glycolated |
3 |
1999 |
| Drug |
kaletra (lopinavir |
3 |
2010 |
| Drug |
kivexa |
3 |
2015 |
| Procedure |
leukapheresis |
3 |
2009 |
| Drug |
levofloxacin |
3 |
2002 |
| Biological |
lipo-5 |
3 |
2014 |
| Drug |
lpv/r |
3 |
2008 |
| placebo |
matching placebo |
3 |
2007 |
| Drug |
midazolam |
3 |
2009 |
| Biological |
mva-cmdr |
3 |
2014 |
| Biological |
mva-mbn32 |
3 |
2007 |
| Drug |
nonoxynol-9 |
3 |
2006 |
| Drug |
norvir |
3 |
2015 |
| Drug |
oral cab |
3 |
2018 |
| Drug |
peginterferon alfa-2b |
3 |
2001 |
| Drug |
pegylated interferon alfa-2a |
3 |
2004 |
| Biological |
pennvax-b |
3 |
2010 |
| Drug |
pentamidine isethionate |
3 |
1999 |
| Drug |
pi |
3 |
2011 |
| Biological |
qs-21 |
3 |
1999 |
| Behavioral |
questionnaire |
3 |
2008 |
| placebo |
raltegravir placebo |
3 |
2010 |
| Drug |
ritonavir (rtv) |
3 |
2014 |
| Drug |
ritonavir 100 mg |
3 |
2011 |
| Drug |
rpv 25 mg |
3 |
2015 |
| placebo |
rtv placebo |
3 |
2010 |
| Drug |
saquinavir [invirase] |
3 |
2012 |
| Biological |
sb-728-t |
3 |
2010 |
| Behavioral |
standard counseling |
3 |
2010 |
| Biological |
t cells |
3 |
2018 |
| Biological |
tat |
3 |
2012 |
| Drug |
telmisartan |
3 |
2010 |
| Drug |
tenofovir disoproxil fumarate (ftc |
3 |
2017 |
| placebo |
tenofovir disoproxil fumarate placebo |
3 |
2008 |
| Drug |
tmc125 |
3 |
2005 |
| Drug |
tmc278 |
3 |
2011 |
| Drug |
vesnarinone |
3 |
1999 |
| Drug |
vm-1500 |
3 |
2015 |
| Drug |
voriconazole |
3 |
2019 |
| Drug |
vorinostat |
3 |
2017 |
| Biological |
vrc01ls |
3 |
2018 |
| Drug |
wf10 |
3 |
1999 |
| Drug |
zidovudine (azt) |
3 |
2008 |
| Drug |
12h |
2 |
2012 |
| Behavioral |
2 antibody test |
2 |
2010 |
| Biological |
2 pdna vaccine |
2 |
2018 |
| Drug |
3bnc117-ls |
2 |
2017 |
| Drug |
3tc fdc |
2 |
2014 |
| Drug |
3tc) |
2 |
2012 |
| Combination Product |
aait |
2 |
2015 |
| Drug |
abacavir 600 mg |
2 |
2012 |
| Drug |
abacavir 600 mg/lamivudine 300 mg |
2 |
2012 |
| Drug |
abacavir sulfate, lamivudine, |
2 |
2004 |
| Drug |
abacavir sulfate, lamivudine,/zidovudine |
2 |
2004 |
| Drug |
abacavir/lamivudine placebo |
2 |
2010 |
| Drug |
abc/3tc |
2 |
2010 |
| Drug |
abx464 |
2 |
2015 |
| Biological |
ad26.mos.hiv |
2 |
2016 |
| Biological |
ad35-grin |
2 |
2009 |
| Biological |
ad35-grin/env |
2 |
2011 |
| Drug |
adefovir |
2 |
1999 |
| Biological |
advax |
2 |
2009 |
| Biological |
aidsvax b/e vaccine |
2 |
2016 |
| Drug |
alendronate |
2 |
2009 |
| Biological |
alvac-hiv (vcp2438) |
2 |
2017 |
| placebo |
alvac-hiv placebo |
2 |
2013 |
| Biological |
alvac-hiv vcp1521 |
2 |
2004 |
| Drug |
alvircept sudotox |
2 |
1999 |
| Drug |
amd11070 |
2 |
2006 |
| Drug |
amprenavir/ritonavir |
2 |
2002 |
| Other |
analytical treatment interruption |
2 |
2016 |
| Drug |
antiretroviral therapy |
2 |
2000 |
| Biological |
apl 400-047 |
2 |
1999 |
| Drug |
aspirin |
2 |
2014 |
| Drug |
atazanavir-ritonavir |
2 |
2004 |
| Drug |
atazanavir (reyataz) |
2 |
2009 |
| Drug |
atazanavir 300 mg |
2 |
2011 |
| Drug |
atazanavir sulphate / ritonavir |
2 |
2006 |
| Drug |
atazanavir/ritonavir/tenofovir |
2 |
2006 |
| placebo |
atripla placebo |
2 |
2010 |
| placebo |
atv placebo |
2 |
2010 |
| Drug |
atv/r |
2 |
2010 |
| Biological |
avx101 |
2 |
2004 |
| Drug |
bi 201335 |
2 |
2011 |
| Drug |
bictegravir |
2 |
2018 |
| Drug |
bictegravir/emtricitabine/tenofovir alafenamide |
2 |
2018 |
| Biological |
biobank |
2 |
2011 |
| Biological |
bivalent subtype c gp120/mf59 |
2 |
2017 |
| Biological |
blood |
2 |
2019 |
| Other |
blood draw |
2 |
2016 |
| Drug |
boceprevir |
2 |
2013 |
| Drug |
buffergel |
2 |
2003 |
| Drug |
bupropion |
2 |
2019 |
| Drug |
cabotegravir - injectable suspension (cab la) |
2 |
2016 |
| Drug |
cabotegravir (cab) tablet |
2 |
2016 |
| Drug |
cabotegravir tablets |
2 |
2016 |
| Drug |
capsaicin dermal patch |
2 |
2003 |
| Drug |
cd4-igg |
2 |
1999 |
| Drug |
cd4 antigens |
2 |
1999 |
| Drug |
cenicriviroc |
2 |
2013 |
| Drug |
chloroquine |
2 |
2009 |
| Drug |
ci-1012 |
2 |
1999 |
| Drug |
cidofovir |
2 |
1999 |
| Procedure |
circumcision |
2 |
2015 |
| Biological |
clade c gp140 |
2 |
2016 |
| placebo |
cobi placebo |
2 |
2010 |
| Behavioral |
cognitive behavioral therapy |
2 |
2016 |
| Drug |
combination antiretroviral therapy (cart) |
2 |
2017 |
| Drug |
comparator: efavirenz |
2 |
2004 |
| Behavioral |
contingency management |
2 |
2016 |
| Behavioral |
control app |
2 |
2018 |
| Combination Product |
conventional |
2 |
2015 |
| Combination Product |
conventional/aait |
2 |
2015 |
| Drug |
crofelemer |
2 |
1999 |
| Drug |
cyclosporine |
2 |
2002 |
| Dietary Supplement |
cysteine (as n-acetylcysteine) |
2 |
2015 |
| Dietary Supplement |
cysteine (as n-acetylcysteine)/glycine |
2 |
2015 |
| Drug |
d |
2 |
2012 |
| Drug |
d/c/f/taf |
2 |
2012 |
| Drug |
dapivirine gel |
2 |
2017 |
| Drug |
dapsone |
2 |
1999 |
| Drug |
darunavir (drv) |
2 |
2014 |
| Biological |
dermavir |
2 |
2008 |
| Combination Product |
descovy |
2 |
2019 |
| Drug |
dextran sulfate |
2 |
1999 |
| Drug |
didanosine, ddi (drug) |
2 |
2005 |
| Drug |
dinitrochlorobenzene |
2 |
1999 |
| Drug |
disulfiram |
2 |
2013 |
| Drug |
dolutegravir 50 mg tablet |
2 |
2011 |
| Drug |
dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg |
2 |
2012 |
| Drug |
dolutegravir dispersible tablet |
2 |
2019 |
| Drug |
dor |
2 |
2020 |
| Drug |
dor/isl |
2 |
2020 |
| Drug |
doravirine (dor) |
2 |
2017 |
| Biological |
e vaccine |
2 |
2016 |
| Behavioral |
education |
2 |
2005 |
| Behavioral |
education attention control |
2 |
2010 |
| Drug |
efavirenz (drug) |
2 |
2005 |
| Drug |
efavirenz 600mg |
2 |
2009 |
| Drug |
elvitegravir |
2 |
2008 |
| Drug |
emtricitabine) |
2 |
2006 |
| Drug |
emtricitabine, ftc (drug) |
2 |
2005 |
| Drug |
emtricitabine/tenofovir (ftc/tdf (truvadaâ®)) |
2 |
2013 |
| Drug |
emtricitabine/tenofovir disoproxil fumarate placebo |
2 |
2008 |
| Biological |
entyvio (vedolizumab) |
2 |
2018 |
| Biological |
env |
2 |
2011 |
| Drug |
epivir |
2 |
2005 |
| Behavioral |
esteem |
2 |
2015 |
| Drug |
ethinyl estradiol |
2 |
2009 |
| Drug |
famotidine |
2 |
2006 |
| Behavioral |
financial incentive |
2 |
2018 |
| Drug |
fosamprenavir/ritonavir |
2 |
2009 |
| Drug |
ftc fdc) |
2 |
2016 |
| Drug |
ganciclovir |
2 |
1999 |
| Biological |
gla-se adjuvant |
2 |
2017 |
| Drug |
glecaprevir |
2 |
2017 |
| Drug |
glecaprevir/pibrentasvir |
2 |
2017 |
| Drug |
globulin, immune |
2 |
1999 |
| Dietary Supplement |
glycine |
2 |
2015 |
| Drug |
grazoprevir |
2 |
2017 |
| Drug |
gsk1265744 30 mg |
2 |
2012 |
| Drug |
gsk1265744 30mg |
2 |
2009 |
| placebo |
gsk1349572 placebo |
2 |
2010 |
| Drug |
gsk2838232 |
2 |
2017 |
| Drug |
gsk706769 |
2 |
2008 |
| Behavioral |
health promotion intervention |
2 |
2015 |
| Biological |
hepatitis b vaccine |
2 |
2013 |
| Biological |
hepatitis b vaccine (recombinant) |
2 |
1999 |
| Biological |
hiv-1 gag dna |
2 |
2005 |
| Biological |
hiv-1 peptide immunogen, multivalent |
2 |
1999 |
| Biological |
hiv-1mn monovalent octameric v3 peptide vaccine |
2 |
1999 |
| Biological |
hiv p24 |
2 |
1999 |
| Biological |
hiv p24/mf59 vaccine |
2 |
1999 |
| Behavioral |
home hiv self-testing with oraquick advanceâ® rapid hiv-1 |
2 |
2010 |
| Behavioral |
home hiv self-testing with oraquick advanceâ® rapid hiv-1/2 antibody test |
2 |
2010 |
| Drug |
hypericin |
2 |
1999 |
| Biological |
il-12 |
2 |
2010 |
| Biological |
il-12 dna adjuvant |
2 |
2005 |
| Biological |
il-12 pdna adjuvant |
2 |
2017 |
| Biological |
imvamune |
2 |
2006 |
| Behavioral |
incentives |
2 |
2016 |
| Drug |
inosine pranobex |
2 |
1999 |
| Behavioral |
integrated care centers |
2 |
2016 |
| Drug |
interleukin 2 |
2 |
2003 |
| Drug |
isentress |
2 |
2008 |
| Drug |
isl |
2 |
2020 |
| Drug |
isotretinoin |
2 |
1999 |
| Drug |
kaletra (lopinavir/ritonavir) |
2 |
2007 |
| Drug |
kaletra / isentress |
2 |
2008 |
| Drug |
keyhole-limpet hemocyanin |
2 |
2002 |
| Drug |
lamivudine 300 mg |
2 |
2012 |
| Drug |
lamivudine fdc |
2 |
2013 |
| placebo |
lamivudine placebo |
2 |
2010 |
| Drug |
ldv |
2 |
2017 |
| Drug |
levonorgestrel |
2 |
2014 |
| Drug |
lexiva (gw433908) |
2 |
2004 |
| Drug |
long-acting injectable cabotegravir (cab la) |
2 |
2018 |
| Drug |
lovaza |
2 |
2009 |
| Drug |
lpv/rtv |
2 |
2014 |
| Procedure |
male circumcision |
2 |
2008 |
| Procedure |
massage therapy |
2 |
2003 |
| Drug |
medroxyprogesterone acetate |
2 |
2000 |
| Drug |
methadone hydrochloride |
2 |
1999 |
| Biological |
mf59c.1 adjuvant |
2 |
2011 |
| Behavioral |
modified directly observed therapy |
2 |
2008 |
| Other |
monetary reinforcer |
2 |
2012 |
| Behavioral |
motivational interviewing |
2 |
2012 |
| Drug |
moxifloxacin |
2 |
2013 |
| Biological |
mrkad5 hiv-1 gag |
2 |
2006 |
| Biological |
mrkad5 hiv-1 gag/pol/nef |
2 |
2006 |
| Dietary Supplement |
multivitamins |
2 |
2005 |
| Biological |
mva |
2 |
2009 |
| Biological |
mva-mosaic |
2 |
2017 |
| Biological |
mva.hiva |
2 |
2011 |
| Biological |
nef |
2 |
2006 |
| Drug |
nelfinavir |
2 |
2006 |
| Drug |
nevirapine ir |
2 |
2009 |
| placebo |
nevirapine placebo |
2 |
2003 |
| Drug |
nevirapine xr |
2 |
2009 |
| Drug |
nicotine replacement therapy |
2 |
2008 |
| Drug |
nnrti |
2 |
2011 |
| Drug |
no intervention |
2 |
2010 |
| Drug |
nrtis |
2 |
2011 |
| Drug |
nucleoside reverse transcriptase inhibitors (nrtis) |
2 |
2014 |
| Drug |
nucleotide reverse transcriptase inhibitors (nrtis) |
2 |
2005 |
| Drug |
nvp |
2 |
2005 |
| Drug |
optimized background therapy |
2 |
2004 |
| Drug |
oral cabotegravir (cab) |
2 |
2018 |
| Other |
oral hiv self-testing |
2 |
2016 |
| Diagnostic Test |
oraquick hiv self test |
2 |
2017 |
| Drug |
ortho cyclen |
2 |
2014 |
| Biological |
p24ce1 |
2 |
2018 |
| Biological |
p24ce1/2 pdna vaccine |
2 |
2018 |
| Biological |
p3c541b lipopeptide |
2 |
1999 |
| Drug |
panobinostat |
2 |
2015 |
| Behavioral |
pcc |
2 |
2013 |
| Behavioral |
peer support |
2 |
2009 |
| Drug |
peginterferon alfa-2a |
2 |
2012 |
| Drug |
pembrolizumab |
2 |
2017 |
| Biological |
pga2 |
2 |
2009 |
| Biological |
pgdm1400 |
2 |
2019 |
| Biological |
pgt121 |
2 |
2019 |
| Other |
pharmacological study |
2 |
2009 |
| Drug |
pibrentasvir |
2 |
2017 |
| Drug |
pioglitazone |
2 |
2012 |
| placebo |
placebo control |
2 |
2010 |
| placebo |
placebo for aidsvax b |
2 |
2013 |
| Biological |
placebo for aidsvax b/e |
2 |
2013 |
| placebo |
placebo for cab la |
2 |
2016 |
| placebo |
placebo for vrc01 |
2 |
2015 |
| placebo |
placebo ivr |
2 |
2015 |
| placebo |
placebo ring |
2 |
2014 |
| Drug |
prednisolone |
2 |
2011 |
| Drug |
prednisone |
2 |
2011 |
| Drug |
pro 140 350mg weekly sq injection. |
2 |
2015 |
| Drug |
probenecid |
2 |
1999 |
| Behavioral |
promotion |
2 |
2019 |
| Biological |
rad5 |
2 |
2009 |
| Biological |
rad5 env a |
2 |
2010 |
| Biological |
rad5 env b |
2 |
2010 |
| Biological |
rad5 gag-pol |
2 |
2011 |
| Drug |
raltegravir (ral) |
2 |
2014 |
| Drug |
raltegravir 400 mg |
2 |
2011 |
| Drug |
raltegravir chewable tablet |
2 |
2012 |
| Drug |
ranitidine hydrochloride |
2 |
1999 |
| Drug |
rbv |
2 |
2012 |
| Device |
refresher training |
2 |
2019 |
| Behavioral |
relaxation response |
2 |
2007 |
| Biological |
rev |
2 |
2004 |
| Drug |
reyataz |
2 |
2010 |
| Biological |
rgp120/hiv-1mn monovalent octameric v3 peptide vaccine |
2 |
1999 |
| Drug |
rilpivirine - injectable suspension (rpv la) |
2 |
2016 |
| Drug |
rilpivirine (rpv) tablet |
2 |
2016 |
| Drug |
rilpivirine 25 mg |
2 |
2018 |
| Drug |
ritonavir (drug) |
2 |
2005 |
| Drug |
ritonavir (norvir) |
2 |
2009 |
| Drug |
romidepsin |
2 |
2013 |
| Drug |
rpv la |
2 |
2018 |
| Biological |
saline solution |
2 |
2011 |
| Biological |
self administered questionnaires |
2 |
2011 |
| Drug |
serostimâ® |
2 |
2006 |
| Drug |
sevirumab |
2 |
1999 |
| Drug |
simvastatin |
2 |
2010 |
| Behavioral |
social network |
2 |
2015 |
| Behavioral |
social network intervention |
2 |
2013 |
| Drug |
standard of care (soc) oral art |
2 |
2018 |
| Drug |
stavudine (d4t) |
2 |
2010 |
| Other |
sti |
2 |
2007 |
| placebo |
stribild placebo |
2 |
2010 |
| Biological |
sub c gp140 vaccine |
2 |
2011 |
| Drug |
sustiva |
2 |
2005 |
| Drug |
switch to dtg |
2 |
2017 |
| Drug |
tdf (truvadaâ®)) |
2 |
2013 |
| Drug |
telaprevir |
2 |
2011 |
| Drug |
tenofovir (ftc |
2 |
2013 |
| Drug |
tenofovir (tdf) |
2 |
2006 |
| Drug |
tenofovir 1% vaginal gel |
2 |
2008 |
| Drug |
tenofovir disoproxil fumarate 300 mg |
2 |
2020 |
| Drug |
tenofovir disoproxil fumarate 300 mg / emtricitabine 200 mg |
2 |
2020 |
| Drug |
tenofovir disoproxil fumarate/emtricitabine |
2 |
2015 |
| Drug |
tenofovir disoproxil fumarate/emtricitabine (tdf/ftc fdc) |
2 |
2016 |
| Drug |
tenofovir, emtricitabine, lopinavir |
2 |
2012 |
| Drug |
tenofovir, emtricitabine, lopinavir/r |
2 |
2012 |
| Biological |
tetanus toxoid vaccine |
2 |
2013 |
| Other |
text message |
2 |
2011 |
| Behavioral |
text messaging |
2 |
2015 |
| Biological |
tgaac09 |
2 |
2009 |
| Drug |
tipranavir high dose |
2 |
2014 |
| Drug |
tipranavir low dose |
2 |
2014 |
| Drug |
tmc114/rtv |
2 |
2005 |
| Drug |
truvadaâ® |
2 |
2010 |
| Biological |
tuti-16 (1.0 mg) |
2 |
2010 |
| Biological |
vaccination |
2 |
2011 |
| Drug |
valganciclovir |
2 |
2017 |
| Drug |
varenicline |
2 |
2009 |
| Behavioral |
vct |
2 |
2016 |
| Behavioral |
video |
2 |
2009 |
| placebo |
vrc-hivadv014-00-vp placebo |
2 |
2005 |
| Biological |
vrc-hivmab060-00-ab (vrc01) |
2 |
2015 |
| Behavioral |
NA |
1 |
2007 |
| Biological |
-18 |
1 |
2008 |
| Drug |
“kallunk oxide (immunotherapy)” |
1 |
2011 |
| Other |
“pop-up” electronic alert |
1 |
2019 |
| Drug |
(a) zidovudine, lamivudine |
1 |
2005 |
| Drug |
(a) zidovudine, lamivudine/nevirapine |
1 |
2005 |
| Drug |
(b) zidovudine, lamivudine |
1 |
2005 |
| Drug |
(b) zidovudine, lamivudine/efavirenz |
1 |
2005 |
| Drug |
(c) zidovudine, didanosine, |
1 |
2005 |
| Drug |
(c) zidovudine, didanosine,/nevirapine |
1 |
2005 |
| Procedure |
(cluster of differentiation 4) count |
1 |
2013 |
| Drug |
(d) zidovudine, didanosine, |
1 |
2005 |
| Drug |
(d) zidovudine, didanosine,/efavirenz |
1 |
2005 |
| Drug |
(e) stavudine, lamivudine, |
1 |
2005 |
| Drug |
(e) stavudine, lamivudine,/nevirapine |
1 |
2005 |
| Drug |
(f) stavudine, lamivudine |
1 |
2005 |
| Drug |
(f) stavudine, lamivudine/efavirenz |
1 |
2005 |
| Drug |
(fdc) elv |
1 |
2012 |
| Drug |
(fdc) elv/cobi/ftc/tdf |
1 |
2012 |
| Biological |
(pv) 23-valent pneumococcal polysaccharide vaccine |
1 |
2008 |
| Drug |
(tide) reverse transcriptase inhibitors (nrtis) |
1 |
2009 |
| Drug |
) cultured with okt3 (ortho) |
1 |
1999 |
| Drug |
[18f]f-arag (2’-deoxy-2’-fluoro-9-î²-d-arabinofuranosylguanine) |
1 |
2018 |
| Biological |
0.25 ml flsc vaccine group |
1 |
2016 |
| placebo |
0.25 ml placebo group |
1 |
2016 |
| Drug |
0.25%) |
1 |
2006 |
| Biological |
0.5 ml flsc vaccine group |
1 |
2016 |
| placebo |
0.5 ml placebo group |
1 |
2016 |
| Biological |
0.5ml intradermic, 3 shots |
1 |
2014 |
| Behavioral |
1-sided messages |
1 |
2010 |
| Drug |
1 solvazinc tablet, day 15 to day 28 |
1 |
2011 |
| Drug |
1 solvazinc tablet, day 2 to day 15 |
1 |
2011 |
| Drug |
1 transdermal testosterone (patch) |
1 |
2004 |
| Biological |
1.0 ml flsc vaccine group |
1 |
2016 |
| placebo |
1.0 ml placebo group |
1 |
2016 |
| Drug |
10-1074-ls |
1 |
2018 |
| Drug |
100% o2 |
1 |
2007 |
| Biological |
10mg |
1 |
2017 |
| Drug |
12 h |
1 |
2006 |
| Drug |
12 hours |
1 |
2006 |
| Biological |
1200î¼g mrna (900 î¼g hiv mrna |
1 |
2015 |
| Biological |
1200î¼g mrna (900 î¼g hiv mrna/300 î¼g trimix mrna) |
1 |
2015 |
| Drug |
1200mg tmc278la |
1 |
2011 |
| Combination Product |
123i radiolabeled 3bnc117 |
1 |
2018 |
| Drug |
12hours |
1 |
2011 |
| Drug |
150mg tmc278la |
1 |
2011 |
| Biological |
18) vaccine (gardasil) |
1 |
2009 |
| Drug |
2’,3’-dideoxyinosine |
1 |
1999 |
| Behavioral |
2-sided messages |
1 |
2010 |
| Behavioral |
2 detect for point of care infant testing |
1 |
2018 |
| Drug |
2 nrtis (delayed |
1 |
2005 |
| Drug |
2 nrtis (immediate switch group) |
1 |
2005 |
| Drug |
2 nrtis/an ini, nnrti,/pi |
1 |
2016 |
| Drug |
2 nucleoside |
1 |
2017 |
| Drug |
2 nucleoside reverse transcriptase inhibitors (nrtis) |
1 |
2011 |
| Biological |
2 pdna vaccine admixed with full-length p55^gag pdna vaccine |
1 |
2018 |
| placebo |
2 placebo patch |
1 |
2004 |
| Biological |
20 mg |
1 |
2017 |
| Drug |
200 mg (one tablet daily) |
1 |
2014 |
| Drug |
200 qd |
1 |
2012 |
| Biological |
20mg |
1 |
2017 |
| Biological |
23-valent pneumococcal conjugate vaccine (vaccine) |
1 |
2005 |
| Drug |
25 mg: product code ak |
1 |
2015 |
| Drug |
25 mg: product code am |
1 |
2015 |
| Drug |
25 mg: product code aq |
1 |
2015 |
| Drug |
25 mg: product code ar |
1 |
2015 |
| Drug |
25 mg: product code as |
1 |
2015 |
| Drug |
25mg fdc tablet |
1 |
2019 |
| Drug |
2n(t)rti |
1 |
2009 |
| Drug |
2nrtis |
1 |
2009 |
| Drug |
3-in-1 tablet (efv 400mg, tdf 300mg, 3tc 300mg) |
1 |
2018 |
| Drug |
3% w |
1 |
2006 |
| Drug |
3% w/w spl7013 gel (vivagelâ„¢) |
1 |
2006 |
| Drug |
30 |
1 |
2015 |
| Biological |
300 î¼g trimix mrna) |
1 |
2015 |
| Drug |
300 mg tablet (product code aa) |
1 |
2016 |
| Drug |
300 mg tablet (product code ab) |
1 |
2016 |
| Drug |
300mg tmc278la |
1 |
2011 |
| Biological |
30mg |
1 |
2017 |
| Drug |
35 |
1 |
2005 |
| Drug |
3bnc117 / 10-1074 |
1 |
2018 |
| Biological |
3m-052-af |
1 |
2019 |
| Biological |
3mg |
1 |
2017 |
| Behavioral |
3mv |
1 |
2012 |
| Drug |
3tc 300 mg oral tablet |
1 |
2018 |
| Drug |
3tc fdc dispersible tablet |
1 |
2016 |
| Drug |
3tc fdc tablet |
1 |
2015 |
| Drug |
3tc film-coated dispersible tablets |
1 |
2017 |
| Drug |
3tc immediate release tablets |
1 |
2017 |
| Drug |
3tc maintenance |
1 |
2013 |
| Drug |
3tc once daily |
1 |
2013 |
| Drug |
3tc str - tablet |
1 |
2016 |
| Drug |
3tc to tdf |
1 |
2006 |
| Drug |
3tc twice daily |
1 |
2013 |
| Drug |
3tc, tdf, nlv |
1 |
2006 |
| Drug |
3tc/ftc |
1 |
2005 |
| Drug |
4 |
1 |
2009 |
| Drug |
5 |
1 |
2005 |
| Drug |
5-aminosalicylic acid |
1 |
2003 |
| Drug |
5 gel |
1 |
2003 |
| Drug |
5 gel (p) |
1 |
2004 |
| Drug |
50mg |
1 |
2015 |
| Biological |
6-gag-tcr modified t cells |
1 |
2009 |
| Biological |
600î¼g mrna (300 î¼g hiv mrna |
1 |
2015 |
| Biological |
600î¼g mrna (300 î¼g hiv mrna/300 î¼g trimix mrna) |
1 |
2015 |
| Drug |
600mg tmc278la |
1 |
2011 |
| Biological |
7-valent pneumococcal conjugate vaccine (vaccine) |
1 |
2005 |
| Drug |
744 la injection |
1 |
2014 |
| Drug |
744 tablet |
1 |
2014 |
| Biological |
900î¼g mrna (600 î¼g hiv mrna |
1 |
2015 |
| Biological |
900î¼g mrna (600 î¼g hiv mrna/300 î¼g trimix mrna) |
1 |
2015 |
| Behavioral |
a beautiful future video |
1 |
2017 |
| Other |
a hiv poct program adapted for |
1 |
2017 |
| Other |
a hiv poct program adapted for/provided by community pharmacists |
1 |
2017 |
| Biological |
a peripheral blood sample |
1 |
2013 |
| Biological |
a sample of venous blood will also be collected |
1 |
2009 |
| Drug |
a single 800 mg dose of darunavirâ® |
1 |
2018 |
| Biological |
a1dc |
1 |
2018 |
| Biological |
a1dc / conserved hiv peptides |
1 |
2018 |
| Biological |
a1dc / inactivated whole autologous hiv |
1 |
2018 |
| Biological |
a1dc / no antigen |
1 |
2018 |
| Device |
ab combo |
1 |
2009 |
| Drug |
abacavir (abc)/lamivudine (3tc) |
1 |
2008 |
| Drug |
abacavir (abc)/lamivudine (3tc) / atazanavir (atv) |
1 |
2007 |
| Drug |
abacavir (abc)/lamivudine (3tc) / atazanavir (atv) / ritonavir (/r) |
1 |
2007 |
| Drug |
abacavir / didanosine / lopinavir/ritonavir (who recommended second line) |
1 |
2009 |
| Drug |
abacavir 600mg - lamivudine 300mg |
1 |
2005 |
| Drug |
abacavir free |
1 |
2009 |
| Drug |
abacavir/lamivudine (abc/3tc)/tenofovir/emtricitabine (tdf/ftc) |
1 |
2012 |
| Drug |
abacavir/lamivudine / darunavir/ritonavir |
1 |
2013 |
| Drug |
abacavir/lamivudine / raltegravir |
1 |
2013 |
| Drug |
abacavir/lamivudine/efavirenz |
1 |
2007 |
| Drug |
abacavir/lamivudine/zidovudine |
1 |
2002 |
| Procedure |
abbreviated hiv test counseling |
1 |
2007 |
| Drug |
abbv-181 |
1 |
2020 |
| Drug |
abc-3tc-efv once a day |
1 |
2010 |
| Drug |
abc fdc |
1 |
2015 |
| Drug |
abc once daily |
1 |
2013 |
| Drug |
abc twice daily |
1 |
2013 |
| Drug |
abc/dtg/3tc fdc |
1 |
2014 |
| Drug |
abc/dtg/3tc fdc tablet |
1 |
2015 |
| Drug |
abc/dtg/3tc film-coated dispersible tablets |
1 |
2017 |
| Drug |
abc/dtg/3tc immediate release tablets |
1 |
2017 |
| Drug |
abc/dtg/3tc str - tablet |
1 |
2016 |
| Other |
abrupt weaning at 4 months |
1 |
2006 |
| Drug |
abt-267 |
1 |
2013 |
| Drug |
abt-333 |
1 |
2013 |
| Drug |
abt-378 |
1 |
2005 |
| Drug |
abt-378/r (drug) |
1 |
2005 |
| Drug |
abt-450 |
1 |
2013 |
| Drug |
abt-450/r/abt-267 |
1 |
2013 |
| Drug |
abt-493 coformulated with abt-530 |
1 |
2016 |
| Drug |
abv (trizivir) |
1 |
2009 |
| Drug |
abx464 150mg |
1 |
2016 |
| Drug |
abx464 50mg |
1 |
2016 |
| Behavioral |
academic detailing |
1 |
2015 |
| Procedure |
accelerated art (antiretroviral therapy) initiation |
1 |
2013 |
| Other |
access to services) intervention |
1 |
2015 |
| Device |
accucirc |
1 |
2009 |
| Biological |
acellular pertussis vaccine adsorbed |
1 |
2000 |
| Drug |
acetaminophen |
1 |
1999 |
| Behavioral |
active control video |
1 |
2017 |
| Behavioral |
active outreach |
1 |
2019 |
| Procedure |
acupressure |
1 |
2001 |
| Procedure |
acupuncture |
1 |
2007 |
| placebo |
acyclovir placebo |
1 |
2004 |
| Biological |
ad26.enva.01 (rad26) |
1 |
2010 |
| Biological |
ad26.enva.01 hiv-1 vaccine |
1 |
2008 |
| Biological |
ad26.enva.01 vaccine |
1 |
2010 |
| Biological |
ad26.mos4.hiv |
1 |
2017 |
| Biological |
ad35-env vaccine |
1 |
2010 |
| Biological |
ad35-grin (0.5ml) |
1 |
2012 |
| Biological |
ad35 investigational hiv vaccine |
1 |
2010 |
| Biological |
ad4-envcn54 |
1 |
2018 |
| Biological |
ad5.enva.48 hiv-1 vaccine |
1 |
2008 |
| Behavioral |
adapted friendship bench |
1 |
2019 |
| Behavioral |
adapted personalized cognitive risk-reduction counseling intervention (pcc) |
1 |
2011 |
| Other |
adaptive wm cogmed training |
1 |
2015 |
| Drug |
addition of raltegravir 800 mg qd to haart |
1 |
2008 |
| Other |
additional blood sample |
1 |
2016 |
| Diagnostic Test |
additional blood sampling |
1 |
2019 |
| Behavioral |
adherence care |
1 |
2009 |
| Behavioral |
adherence counseling |
1 |
2006 |
| Behavioral |
adherence report |
1 |
2009 |
| Procedure |
adherence strategy community-based dot |
1 |
2005 |
| Procedure |
adherence strategy standard of care (soc) |
1 |
2005 |
| Device |
adherence tracker |
1 |
2003 |
| Biological |
adjuvanted a(h1n1)v influenza vaccine |
1 |
2009 |
| Biological |
adjuvanted gsk investigational hiv vaccine formulation 1 |
1 |
2010 |
| Biological |
adjuvanted gsk investigational hiv vaccine formulation 2 |
1 |
2010 |
| Biological |
adjuvanted influenza a(h1n1) vaccines |
1 |
2009 |
| Behavioral |
adolescent impact |
1 |
2005 |
| Procedure |
adoptive transfer of hiv-specific cd8 |
1 |
2005 |
| Procedure |
adoptive transfer of hiv-specific cd8/ t cells |
1 |
2005 |
| Behavioral |
advanced adherence counseling (advadh) |
1 |
2011 |
| Behavioral |
aerobic training |
1 |
2005 |
| Drug |
aged rpvâ€la |
1 |
2015 |
| Behavioral |
aids 101 workshop |
1 |
2006 |
| Behavioral |
aids epc package |
1 |
2013 |
| Behavioral |
aids epc package/mi |
1 |
2013 |
| Biological |
aidsvax |
1 |
2005 |
| placebo |
aidsvax placebo |
1 |
2005 |
| Biological |
aidsvaxâ® b |
1 |
2013 |
| Biological |
aidsvaxâ® b/e |
1 |
2013 |
| Behavioral |
aidsvu |
1 |
2017 |
| Drug |
al 721 |
1 |
1999 |
| Device |
alarm device |
1 |
2006 |
| Drug |
albendazole |
1 |
2013 |
| Drug |
albinterferon |
1 |
2007 |
| Drug |
albuferon |
1 |
2007 |
| Drug |
ald: combination of zidovudine, lamivudine |
1 |
2019 |
| Drug |
ald: combination of zidovudine, lamivudine/dolutegravir antiretroviral therapy |
1 |
2019 |
| Behavioral |
alere q hiv-1 |
1 |
2018 |
| Behavioral |
alere q hiv-1/2 detect for point of care infant testing |
1 |
2018 |
| Drug |
algeron |
1 |
2014 |
| Drug |
alirocumab |
1 |
2017 |
| Drug |
all-trans-retinoic acid with ifn-alpha2a |
1 |
1999 |
| Drug |
all licensed antiretroviral medications |
1 |
2009 |
| Biological |
allogeneic bk-specific cytotoxic t-lymphocytes |
1 |
2015 |
| Procedure |
allogeneic lymphocyte transfer |
1 |
1999 |
| Drug |
alovudine - high |
1 |
2014 |
| Drug |
alovudine - low |
1 |
2014 |
| Drug |
alovudine - medium |
1 |
2014 |
| Biological |
alpha-1-proteinase inhibitor |
1 |
2011 |
| Drug |
alpha lipoic acid |
1 |
2002 |
| Biological |
alum (aluminum hydroxide suspension) |
1 |
2019 |
| Biological |
aluminum hydroxide adjuvant |
1 |
2017 |
| Drug |
aluvia |
1 |
2009 |
| Drug |
aluvia / 2nrtis |
1 |
2009 |
| Drug |
aluvia / raltegravir |
1 |
2009 |
| Drug |
aluvia monotherapy |
1 |
2009 |
| Biological |
alvac |
1 |
2005 |
| Biological |
alvac-hiv (vcp1452) |
1 |
2004 |
| Biological |
alvac-hiv (vcp205) |
1 |
2004 |
| placebo |
alvac-hiv (vcp2438) placebo |
1 |
2015 |
| Biological |
alvac-hiv gp160mn (vcp125) |
1 |
1999 |
| Biological |
alvac-hiv mn120tmgnp (vcp300) |
1 |
1999 |
| Biological |
alvac-hiv vcp1521 / aidsvax |
1 |
2005 |
| Biological |
alvac hiv-1 vcp1521 |
1 |
2004 |
| Biological |
alvac hiv vaccine (vcp1452) |
1 |
2003 |
| placebo |
alvac placebo |
1 |
2005 |
| Other |
alvac placebo / aidsvax placebo |
1 |
2005 |
| Biological |
alvac(1)120(b,mn)gnp (vcp1433) |
1 |
1999 |
| placebo |
alvac(2)120(b,mn)gnp (vcp1452) placebo |
1 |
2001 |
| Drug |
amd070 |
1 |
2003 |
| Drug |
amikacin |
1 |
2002 |
| Drug |
amitriptyline hydrochloride |
1 |
1999 |
| Drug |
amphotericin b, lipid-based |
1 |
1999 |
| Drug |
amprenavir (drug) |
1 |
2005 |
| Drug |
amprenavir, efavirenz, abacavir, nelfinavir, ritonavir |
1 |
1999 |
| Drug |
an ini, nnrti, |
1 |
2016 |
| Drug |
antacid |
1 |
2009 |
| Drug |
anti-tnf |
1 |
1999 |
| Dietary Supplement |
antioxidants |
1 |
2008 |
| Drug |
antiretroviral (arv) medications |
1 |
2017 |
| Drug |
antiretroviral combinations |
1 |
2017 |
| Procedure |
antiretroviral drug combination switching criteria |
1 |
2005 |
| Drug |
antiretroviral drugs |
1 |
2017 |
| Drug |
antiretroviral therapy (art) (regimen will vary within countries |
1 |
2015 |
| Drug |
antiretroviral therapy (art) (regimen will vary within countries/by patient) |
1 |
2015 |
| Drug |
antiretroviral therapy alone |
1 |
2014 |
| Drug |
antiretroviral therapy/interleukin-2 |
1 |
2014 |
| Drug |
antiretroviral treatment |
1 |
2011 |
| Behavioral |
appointments |
1 |
2019 |
| Behavioral |
appreciative inquiry change agents (ca) program (namweza) |
1 |
2012 |
| placebo |
aprepitant placebo |
1 |
2010 |
| Dietary Supplement |
arabinoxylan rice bran |
1 |
2016 |
| Device |
architect hiv ag |
1 |
2009 |
| Device |
architect hiv ag/ab combo |
1 |
2009 |
| Drug |
arm a: abc |
1 |
2013 |
| Drug |
arm a: abc/3tc/nnrti |
1 |
2013 |
| Drug |
arm a: poly-iclc |
1 |
2014 |
| Drug |
arm b: normal saline |
1 |
2014 |
| Drug |
arm b: zdv |
1 |
2013 |
| Drug |
arm b: zdv/abc/3tc/nnrti->abc/3tc/nnrti maintenance |
1 |
2013 |
| Drug |
arm c: zdv |
1 |
2013 |
| Drug |
arm c: zdv/abc/3tc/nnrti->zdv/abc/3tc maintenance |
1 |
2013 |
| Drug |
art at 24 weeks |
1 |
2016 |
| Drug |
art initiation at time of hiv diagnosis |
1 |
2016 |
| Drug |
art intensification (maraviroc) |
1 |
2009 |
| Drug |
art intensification (raltegravir) |
1 |
2009 |
| Drug |
artemether |
1 |
2008 |
| Drug |
artemether/lumefantrine |
1 |
2008 |
| Dietary Supplement |
artemisia annua, moringa oleifera |
1 |
2017 |
| Drug |
arv treatment |
1 |
2016 |
| Biological |
as01(b) |
1 |
2017 |
| Biological |
as01b vaccine |
1 |
2016 |
| Drug |
as02a adjuvant |
1 |
2001 |
| Behavioral |
asha life |
1 |
2009 |
| Behavioral |
asha support |
1 |
2014 |
| Behavioral |
asha support / food |
1 |
2014 |
| Behavioral |
asha support / training |
1 |
2014 |
| Behavioral |
asha support / training / food |
1 |
2014 |
| Behavioral |
asha support only |
1 |
2014 |
| Drug |
assess safety |
1 |
2016 |
| Behavioral |
assessment mobile program |
1 |
2019 |
| Other |
assisted partner notification services |
1 |
2018 |
| Drug |
asunaprevir, daclatasvir, ribavirin |
1 |
2012 |
| Drug |
asunaprevir, daclatasvir, ribavirin/peginterferon alfa-2a |
1 |
2012 |
| Biological |
at w4, w8,w20 |
1 |
2005 |
| Drug |
atazanavir-ritonavir/ stavidine / lamivudine |
1 |
2004 |
| Drug |
atazanavir (atv) |
1 |
2007 |
| Drug |
atazanavir (atv) 300 mg |
1 |
2009 |
| Drug |
atazanavir (atv) 400 mg |
1 |
2009 |
| Drug |
atazanavir (immediate switch) |
1 |
2003 |
| Drug |
atazanavir (r |
1 |
2006 |
| Drug |
atazanavir (week 24 switch) |
1 |
2003 |
| Drug |
atazanavir / 2 nrtis |
1 |
2005 |
| Drug |
atazanavir / raltegravir |
1 |
2007 |
| Drug |
atazanavir / ritonavir / 2 nrtis |
1 |
2005 |
| Drug |
atazanavir / ritonavir / combivir |
1 |
2006 |
| Drug |
atazanavir / ritonavir / tenofovir / nucleoside |
1 |
2002 |
| Drug |
atazanavir / saquinavir / tenofovir / nucleoside |
1 |
2002 |
| Drug |
atazanavir 300mg boosted with ritonavir 50 mg |
1 |
2014 |
| Drug |
atazanavir arm |
1 |
2006 |
| Drug |
atazanavir capsules |
1 |
2010 |
| Drug |
atazanavir powder |
1 |
2010 |
| Drug |
atazanavir sulphate / ritonavir / efavirenz |
1 |
2006 |
| Drug |
atazanavir sulphate / ritonavir / rosiglitazone maleate |
1 |
2006 |
| Drug |
atazanavir sulphate / rosiglitazone maleate |
1 |
2006 |
| Drug |
atazanavir, norvir |
1 |
2008 |
| Drug |
atazanavir, norvir/truvada |
1 |
2008 |
| Drug |
atazanavir, ritonavir, lamivudine |
1 |
2012 |
| Drug |
atazanavir/ stavidine / lamivudine |
1 |
2004 |
| Drug |
atazanavir/cobicistat |
1 |
2002 |
| Drug |
atazanavir/cobicistat fdc |
1 |
2013 |
| Drug |
atazanavir/raltegravir |
1 |
2009 |
| Drug |
atazanavir/ritonavir / famotidine |
1 |
2006 |
| Drug |
atazanavir/ritonavir / tenofovir disproxil fumrarate / famotidine |
1 |
2006 |
| Drug |
atazanavir/ritonavir /2 nrtis (immediate switch group) |
1 |
2005 |
| Drug |
atazanavir/ritonavir/lopinavir/ritonavir |
1 |
2005 |
| Drug |
atazanavir/ritonavir/omeprazole |
1 |
2006 |
| Drug |
atazanavir/ritonavir/tenofovir/famotidine |
1 |
2006 |
| Drug |
atazanvir |
1 |
2005 |
| Drug |
atazanvir/ritonavir / efavirenz |
1 |
2005 |
| Device |
atomo diagnostic test |
1 |
2017 |
| Diagnostic Test |
atomo hiv self test - both |
1 |
2017 |
| Diagnostic Test |
atomo hiv self test - choice |
1 |
2017 |
| Drug |
atorvastatin |
1 |
2010 |
| Drug |
atorvastatin calcium |
1 |
1999 |
| Other |
atorvastatin, lipitorâ® |
1 |
2012 |
| Drug |
atripla (atr) consisting of efv 600 mg |
1 |
2008 |
| Drug |
atripla (atr) consisting of efv 600 mg/ftc 200 mg/tdf 300 mg |
1 |
2008 |
| Drug |
atriplaâ„¢ |
1 |
2015 |
| Drug |
atriplaâ® |
1 |
2010 |
| Drug |
atv) |
1 |
2006 |
| Biological |
autologous dendritic cell hiv vaccination |
1 |
2003 |
| Drug |
avx754 |
1 |
2005 |
| Behavioral |
awareness for sexual minorities |
1 |
2017 |
| Drug |
azt-3tc-lpv |
1 |
2010 |
| Drug |
azt-3tc-lpv/r twice a day |
1 |
2010 |
| Drug |
azt, d4t, tdf, ddc, azt) |
1 |
2002 |
| Drug |
azt/3tc/abv (trizivir) |
1 |
2009 |
| Drug |
azt/3tc/efv |
1 |
2006 |
| Drug |
azt/3tc/idv/rtv |
1 |
2006 |
| Drug |
azt/3tc/nvp, azt/d4t/nvp, truvada/nvp |
1 |
2008 |
| Drug |
b/ftc/taf |
1 |
2017 |
| Drug |
background arvs |
1 |
2006 |
| Drug |
background regimen |
1 |
2008 |
| Drug |
bacteriophage phi x 174 |
1 |
2000 |
| Behavioral |
bahamian focus on older youth (bfooy) |
1 |
2008 |
| Drug |
baseline drv- containing arv regimen |
1 |
2013 |
| Behavioral |
basic care |
1 |
2013 |
| Behavioral |
basic care/prevention package |
1 |
2013 |
| Drug |
bavituximab |
1 |
2007 |
| Biological |
bcg |
1 |
2014 |
| Drug |
bcv |
1 |
2012 |
| Behavioral |
be proud! be responsible! |
1 |
2009 |
| Behavioral |
becoming a responsible teen (bart) |
1 |
2009 |
| Drug |
bedaquiline |
1 |
2002 |
| Biological |
begrivacâ® |
1 |
2009 |
| Other |
behavioral counseling |
1 |
2007 |
| Behavioral |
behavioral hiv risk reduction package |
1 |
2017 |
| Behavioral |
behavioral intervention |
1 |
1999 |
| Behavioral |
behavioral intervention for alcohol use |
1 |
2012 |
| Behavioral |
behavioral intervention to reduce sexual risk among african-american men who have sex with men |
1 |
2008 |
| Drug |
benzathine penicillin |
1 |
2018 |
| Drug |
benztropine mesylate |
1 |
1999 |
| Dietary Supplement |
beta carotene |
1 |
2005 |
| Drug |
bevirimat |
1 |
2007 |
| Biological |
bg505 sosip.664 gp140 |
1 |
2019 |
| Biological |
bg505 sosip.664 gp140, adjuvanted |
1 |
2018 |
| Drug |
bi therapy - (boosted lopinavir |
1 |
2013 |
| Drug |
bi therapy - (boosted lopinavir/boosted darunavir) / lamivudine |
1 |
2013 |
| Drug |
bic |
1 |
2020 |
| Drug |
bic/ftc/taf |
1 |
2020 |
| Drug |
bictegravir 50mg |
1 |
2018 |
| Drug |
bictegravir 50mg/tenofovir af 25 mg/emtricitabine 200 mg |
1 |
2018 |
| Device |
bio-alcamid soft tissue endoprosthesis |
1 |
2006 |
| Device |
biojector |
1 |
2006 |
| Other |
biological control |
1 |
2008 |
| Other |
biological samples |
1 |
2019 |
| Biological |
biologically active recombinant tat protein |
1 |
2007 |
| Biological |
bivalent gp120 |
1 |
2015 |
| Biological |
bivalent gp120/mf59â® placebo |
1 |
2015 |
| Biological |
bivalent subtype c gp120 admixed with al(oh)3 suspension |
1 |
2017 |
| Biological |
bivalent subtype c gp120/as01(b) |
1 |
2017 |
| Biological |
bivalent subtype c gp120/as01b vaccine |
1 |
2016 |
| Biological |
bivalent subtype c gp120/mf59 vaccine |
1 |
2016 |
| Biological |
bivalent subtype c gp120/mf59â® |
1 |
2015 |
| Biological |
bleomycin sulfate |
1 |
2018 |
| Other |
blood draws |
1 |
2007 |
| Other |
blood draws for tenofovir pk, renal function |
1 |
2015 |
| Diagnostic Test |
blood glucose |
1 |
2017 |
| Diagnostic Test |
blood glucose/blood pressure testing |
1 |
2017 |
| Diagnostic Test |
blood pressure testing |
1 |
2017 |
| Other |
blood sample/recto-colic biopsies |
1 |
2013 |
| Biological |
blood sampling, |
1 |
2013 |
| Biological |
blood sampling, specific biological exams |
1 |
2010 |
| Biological |
blood sampling, specific biological exams/biobank/self administered questionnaires |
1 |
2010 |
| Biological |
blood test: conventional test |
1 |
2010 |
| Biological |
blood test: rapid finger-stick blood specimen test |
1 |
2010 |
| Procedure |
blood testing |
1 |
1999 |
| Procedure |
blood transfusion |
1 |
1999 |
| Diagnostic Test |
blood/feces samples |
1 |
2019 |
| Biological |
blood/semen sampling, specific biological exams/biobank/self administered questionnaires |
1 |
2011 |
| Procedure |
bmd measurement |
1 |
2005 |
| Drug |
bms-626529 |
1 |
2016 |
| Drug |
bms-663068 (1 tablet at 600 mg) |
1 |
2016 |
| Drug |
bms-663068 (4 tablets at 150 mg each tablet) |
1 |
2016 |
| Drug |
bms-663068 1200 mg |
1 |
2011 |
| Drug |
bms-663068 400 mg |
1 |
2011 |
| Drug |
bms-663068 600 mg |
1 |
2011 |
| Drug |
bms-663068 800 mg |
1 |
2011 |
| Drug |
bms-936559 |
1 |
2014 |
| Drug |
bms-955176/cyp/transporter probe substrates |
1 |
2015 |
| Drug |
bms955176 |
1 |
2016 |
| Procedure |
bone marrow transplant |
1 |
1999 |
| Drug |
boosted atazanavir |
1 |
2009 |
| Drug |
boosted darunavir |
1 |
2013 |
| Drug |
boosted darunavir) |
1 |
2013 |
| Drug |
boosted lexiva |
1 |
2008 |
| Drug |
boosted pi |
1 |
2007 |
| Drug |
boosted protease inhibitor |
1 |
2007 |
| Drug |
boosted protease inhibitor (bpi) |
1 |
2014 |
| Drug |
br |
1 |
2013 |
| Other |
bridge |
1 |
2016 |
| Behavioral |
brief hiv prevention counseling |
1 |
2019 |
| Behavioral |
brief intervention |
1 |
2016 |
| Diagnostic Test |
brief score at inclusion |
1 |
2019 |
| Behavioral |
bro hiv risk reduction intervention |
1 |
2015 |
| Procedure |
bronchoalveolar lavage |
1 |
1999 |
| Behavioral |
bruthas project |
1 |
2010 |
| Drug |
bryostatin 1 (10ug |
1 |
2014 |
| Drug |
bryostatin 1 (10ug/m2) |
1 |
2014 |
| Drug |
bryostatin 1 (20ug |
1 |
2014 |
| Drug |
bryostatin 1 (20ug/m2) |
1 |
2014 |
| Drug |
bupivacaine hydrochloride |
1 |
1999 |
| Drug |
buprenorphine, tipranavir |
1 |
2007 |
| Drug |
buprenorphine, tipranavir/ritonavir |
1 |
2007 |
| Drug |
buprenorphine/naloxone |
1 |
2011 |
| Drug |
buprenorphine/norbuprenorphine |
1 |
2016 |
| Drug |
busulfan |
1 |
2012 |
| Drug |
busulfan preconditioning |
1 |
2018 |
| Drug |
by patient) |
1 |
2015 |
| Biological |
c) |
1 |
2011 |
| Drug |
cab |
1 |
2015 |
| Drug |
cab-la loading dose |
1 |
2018 |
| Drug |
cab-la maintenance dose |
1 |
2018 |
| Drug |
cab la/rpv la |
1 |
2019 |
| placebo |
cab placebo tablets |
1 |
2016 |
| Drug |
cabotegravir |
1 |
2017 |
| Drug |
cabotegravir 30 mg |
1 |
2016 |
| Drug |
cabotegravir 30 mg current formulation |
1 |
2015 |
| Drug |
cabotegravir 30 mg micronized new formulation 500 m |
1 |
2015 |
| Drug |
cabotegravir 30 mg micronized new formulation 650 m |
1 |
2015 |
| Drug |
cabotegravir 30 mg unmicronized new formulation 500 u |
1 |
2015 |
| Drug |
cabotegravir 30 mg unmicronized new formulation 650 u |
1 |
2015 |
| Drug |
cabotegravir injectable suspension |
1 |
2017 |
| Drug |
cabotegravir injection 3 ml (200 mg |
1 |
2015 |
| Drug |
cabotegravir injection 3 ml (200 mg/ml) im given once on day 1. |
1 |
2015 |
| Drug |
cabotegravir tablet 30 mg once daily for 28 days. |
1 |
2015 |
| Drug |
cabozantinib s-malate |
1 |
2013 |
| Biological |
cal-1 modified cd4 |
1 |
2012 |
| Biological |
cal-1 modified cd4/ t lymphocytes |
1 |
2012 |
| Biological |
cal-1 modified hspc |
1 |
2012 |
| Drug |
calanolide a |
1 |
1999 |
| Dietary Supplement |
calcium |
1 |
2015 |
| Drug |
calcium carbonate 1200 mg |
1 |
2012 |
| Dietary Supplement |
calcium carbonate/vitamin d |
1 |
2009 |
| Dietary Supplement |
calorie supplement |
1 |
2005 |
| Behavioral |
cap-it |
1 |
2009 |
| Drug |
capreomycin |
1 |
2002 |
| Drug |
capsule) with nucleoside reverse transcriptase inhibitors (nrtis) |
1 |
2005 |
| Drug |
carbamazepine |
1 |
2006 |
| Drug |
carbamazepine/nevirapine |
1 |
2006 |
| Device |
carbon monoxide test |
1 |
2016 |
| Drug |
carbopol polymer |
1 |
2001 |
| Behavioral |
care/ |
1 |
2007 |
| Other |
care/ kenya brief computer risk assessment session |
1 |
2009 |
| Other |
care/ kenya computer counseling session |
1 |
2009 |
| Other |
care/ spanish brief computer risk assessment session |
1 |
2009 |
| Other |
care/ spanish computer counseling session |
1 |
2009 |
| Behavioral |
caribbean informed parents |
1 |
2008 |
| Behavioral |
caribbean informed parents/children together (cimpact) |
1 |
2008 |
| Drug |
carraguard (pc-515) |
1 |
2005 |
| Other |
case-management |
1 |
2011 |
| Other |
case management intervention |
1 |
2019 |
| Behavioral |
cash incentives |
1 |
2010 |
| Behavioral |
cbsm-smi |
1 |
2017 |
| Behavioral |
cbsm-smi control |
1 |
2017 |
| Behavioral |
cbt-based counseling |
1 |
2015 |
| Drug |
cbz |
1 |
2013 |
| Drug |
ccr5mab004 |
1 |
2005 |
| Biological |
cd34 stem cell selection therapy |
1 |
2013 |
| Drug |
cd4-igg2 |
1 |
1999 |
| Drug |
cd4-igg2 (pro 542) |
1 |
2003 |
| Other |
cdc hiv testing recommendations |
1 |
2007 |
| Behavioral |
cell phone reminders |
1 |
2012 |
| Behavioral |
cell phone sms text messaging |
1 |
2014 |
| Other |
cell phone text message |
1 |
2009 |
| Device |
cellectraâ„¢ 5psp |
1 |
2018 |
| Biological |
cells |
1 |
2018 |
| Behavioral |
cellular appointment reminders |
1 |
2013 |
| Behavioral |
cellular appointment reminders/follow-up |
1 |
2013 |
| Drug |
celsentriâ® |
1 |
2009 |
| Biological |
cemiplimab |
1 |
2018 |
| Drug |
central nervous system (cns) prophylaxis |
1 |
2007 |
| Biological |
cervarix |
1 |
2007 |
| Biological |
ch505 m5 |
1 |
2017 |
| Biological |
ch505tf |
1 |
2017 |
| Biological |
ch505w53 |
1 |
2017 |
| Biological |
ch505w78 |
1 |
2017 |
| Other |
chi-patients |
1 |
2009 |
| Behavioral |
chicas |
1 |
2018 |
| Drug |
chidamide |
1 |
2015 |
| Behavioral |
children together (cimpact) |
1 |
2008 |
| Drug |
chlorhexidine gluconate |
1 |
2000 |
| Dietary Supplement |
cholecalciferol |
1 |
2008 |
| Drug |
cholecalciferol (vit d3) |
1 |
2010 |
| Dietary Supplement |
cholecalciferol/calcium carbonate |
1 |
2008 |
| Drug |
chromium nicotinate |
1 |
2005 |
| Drug |
cimetidine |
1 |
1999 |
| Drug |
cisplatin |
1 |
2012 |
| Biological |
clade b gag dna |
1 |
2003 |
| Biological |
clade b gag dna/plg/env dna/plg microparticles |
1 |
2003 |
| Biological |
clade b recombinant, oligomeric gp140 |
1 |
2003 |
| Biological |
clade b recombinant, oligomeric gp140/mf59 adjuvant |
1 |
2003 |
| Biological |
clade c gp140 / mosaic gp140 |
1 |
2017 |
| Drug |
clarithromycin |
1 |
1999 |
| Behavioral |
client-centered representative payee |
1 |
2018 |
| Behavioral |
clients |
1 |
2006 |
| Behavioral |
clinic-based delivery |
1 |
2018 |
| Behavioral |
clinic-based hiv testing |
1 |
2018 |
| Other |
clinic based hiv counseling |
1 |
2017 |
| Other |
clinic based hiv counseling/testing (hct) |
1 |
2017 |
| Behavioral |
clinic referral for hiv |
1 |
2018 |
| Behavioral |
clinic referral for hiv/ men |
1 |
2018 |
| Other |
clinical evaluations |
1 |
2007 |
| Other |
clinical evaluations/blood draws |
1 |
2007 |
| Other |
clinical monitoring (lcm) |
1 |
2013 |
| Other |
clinically driven monitoring (cdm) |
1 |
2013 |
| Behavioral |
clinician training intervention |
1 |
2019 |
| Drug |
clofazamine |
1 |
2002 |
| Drug |
clopidogrel |
1 |
2015 |
| Behavioral |
cmht |
1 |
2016 |
| Behavioral |
cmm |
1 |
2015 |
| Biological |
cn54gp140 |
1 |
2018 |
| Biological |
cn54gp140 glycoprotein-hsp70 conjugate vaccine |
1 |
2011 |
| Biological |
cn54gp140 mixed with gla-af |
1 |
2013 |
| Biological |
cn54gp140/mpla |
1 |
2018 |
| Drug |
cobi 150 mg |
1 |
2017 |
| Drug |
cobicistat (fdc) |
1 |
2009 |
| Drug |
cobicistat fdc |
1 |
2013 |
| Drug |
coformulated elivitegravir (150mg), combicistat (150mg), emtricitabine (200mg), tenofovir df (300mg) |
1 |
2013 |
| Behavioral |
cognitive-based compassion training (cbct) |
1 |
2015 |
| Behavioral |
cognitive-behavioral hiv |
1 |
2008 |
| Behavioral |
cognitive-behavioral hiv/std risk reduction |
1 |
2008 |
| Behavioral |
cognitive-behavioral intervention |
1 |
2005 |
| Behavioral |
cognitive-behavioral relaxation (positively living) |
1 |
2002 |
| Behavioral |
cognitive-behavioral therapy |
1 |
2008 |
| Behavioral |
cognitive-behavioral, small-group format sessions |
1 |
2009 |
| Behavioral |
cognitive behavioral |
1 |
2007 |
| Behavioral |
cognitive behavioral coping effectiveness training |
1 |
2008 |
| Behavioral |
cognitive behavioral intervention |
1 |
2005 |
| Behavioral |
cognitive behavioral skills training |
1 |
2010 |
| Behavioral |
cognitive behavioral stress management training |
1 |
2007 |
| Behavioral |
cognitive behavioral therapy (cbt) intervention |
1 |
2016 |
| Behavioral |
cognitive behavioral therapy for adherence |
1 |
2016 |
| Behavioral |
cognitive behavioral therapy for adherence/depression |
1 |
2016 |
| Behavioral |
cognitive behavioral/standard care with healthy living |
1 |
2007 |
| Drug |
colchicine |
1 |
2015 |
| Behavioral |
collaboration with an it enabled nurse care manager |
1 |
2015 |
| Procedure |
colon biopsy, lymph node biopsy, lumbar puncture |
1 |
2011 |
| Biological |
combination vaccine (neftat |
1 |
2001 |
| Biological |
combination vaccine (neftat/gp120w61d) formulated with as02a |
1 |
2001 |
| Drug |
combined short-course zidovudine |
1 |
2005 |
| Drug |
combined short-course zidovudine/nevirapine |
1 |
2005 |
| Drug |
combivir (zidovudine |
1 |
2007 |
| Drug |
combivir/kaletra |
1 |
2006 |
| Drug |
combivir/reyataz |
1 |
2006 |
| Drug |
combivirâ® (lamivudine, zidovudine) |
1 |
2004 |
| Behavioral |
communication training |
1 |
2008 |
| Behavioral |
community-based directly observed therapy (dot) |
1 |
2004 |
| Behavioral |
community-based hiv vct |
1 |
2005 |
| Other |
community-based package of integrated hiv, srh |
1 |
2018 |
| Other |
community-based package of integrated hiv, srh/general health services |
1 |
2018 |
| Behavioral |
community-level intervention |
1 |
2005 |
| Behavioral |
community activities related to adolescent sexual health |
1 |
2005 |
| Other |
community adherence clubs |
1 |
2017 |
| Behavioral |
community home-based care intervention |
1 |
2018 |
| Drug |
comparator protease inhibitor (cpi) |
1 |
2003 |
| Drug |
comparator protease inhibitor(cpi) |
1 |
2005 |
| Drug |
comparator protease inhibitor(cpi)/low dose ritonavir(r) |
1 |
2005 |
| Drug |
comparator: lamivudine |
1 |
2004 |
| Drug |
comparator: mk0518 |
1 |
2005 |
| Drug |
comparator: mk0518 combination therapy |
1 |
2004 |
| Drug |
comparator: mk0518 monotherapy |
1 |
2004 |
| Drug |
comparator: nelfinavir mesylate |
1 |
2007 |
| Drug |
comparator: nelfinavir mesylate / duration of treatment: 48 weeks |
1 |
2007 |
| placebo |
comparator: placebo to efavirenz |
1 |
2006 |
| placebo |
comparator: placebo to mk-0518 |
1 |
2006 |
| placebo |
comparator: placebo to mrkad5 hiv-1 gag vaccine |
1 |
2009 |
| placebo |
comparator: placebo to the mrkad5 hiv-1 gag |
1 |
2009 |
| Other |
comparator: placebo to the mrkad5 hiv-1 gag/pol/nef vaccine |
1 |
2009 |
| placebo |
comparator: placebo to v526 |
1 |
2009 |
| Drug |
comparator: raltegravir |
1 |
2008 |
| Drug |
comparator: tenofovir |
1 |
2004 |
| Drug |
comparator: truvada |
1 |
2006 |
| Biological |
comparator: v520 (1x10^10 vp |
1 |
2009 |
| Biological |
comparator: v520 (1x10^10 vp/d) |
1 |
2009 |
| Biological |
comparator: v520 (1x10^9 vp |
1 |
2009 |
| Biological |
comparator: v520 (1x10^9 vp/d) |
1 |
2009 |
| Behavioral |
comparison |
1 |
2015 |
| Behavioral |
computer-based alcohol reduction intervention |
1 |
2017 |
| Behavioral |
comunicäƒ |
1 |
2019 |
| Behavioral |
concentration-controlled therapy |
1 |
2003 |
| Behavioral |
conditional economic incentive (cei) |
1 |
2018 |
| Other |
conditional lottery incentive |
1 |
2019 |
| Device |
condom |
1 |
2012 |
| Behavioral |
condom distribution |
1 |
2006 |
| Behavioral |
condom distribution/promotion |
1 |
2006 |
| Biological |
conserved hiv peptides |
1 |
2018 |
| Behavioral |
contingency management (cm) |
1 |
2017 |
| Behavioral |
contingency management for adherence |
1 |
2012 |
| Drug |
continue current antiretroviral regimen |
1 |
2014 |
| Drug |
continue on current dual boosted pi |
1 |
2007 |
| Drug |
continue the pi |
1 |
2013 |
| Drug |
continue the pi/r-containing haart. |
1 |
2013 |
| Other |
continue triple arvs |
1 |
2010 |
| Drug |
continue with triple therapy |
1 |
2017 |
| Drug |
continued cotrimoxazole prophylaxis |
1 |
2013 |
| Other |
continued exclusive breastfeeding |
1 |
2006 |
| Drug |
continuing azt |
1 |
2006 |
| Drug |
continuing azt/3tc/switching azt/3tc to tdf/ ftc |
1 |
2006 |
| Drug |
continuing lopinavir |
1 |
2005 |
| Behavioral |
control condition |
1 |
2016 |
| Drug |
conventional dolutegravir 10 mg tablet |
1 |
2017 |
| Drug |
conventional dolutegravir 25 mg tablet |
1 |
2017 |
| Drug |
conventional dolutegravir 50 mg tablet |
1 |
2017 |
| Device |
conventional intramuscular injection |
1 |
2007 |
| Device |
copper t intrauterine contraception device |
1 |
2008 |
| Device |
copper t intrauterine contraceptive device |
1 |
2006 |
| Device |
corrections tool) |
1 |
2012 |
| Drug |
cotrimoxazole |
1 |
2010 |
| Behavioral |
counsel, test, |
1 |
2013 |
| Behavioral |
counsel, test,/treat |
1 |
2013 |
| Behavioral |
counselor-based hiv screening |
1 |
2007 |
| Behavioral |
couples-based services |
1 |
2017 |
| Behavioral |
couples hiv counseling |
1 |
2006 |
| Behavioral |
couples hiv counseling/testing |
1 |
2006 |
| Behavioral |
couples vct |
1 |
2008 |
| Biological |
cpg 1018 |
1 |
2019 |
| Biological |
cpg 7909 |
1 |
2007 |
| Behavioral |
cps |
1 |
2018 |
| Drug |
crofelemer delayed-release tablets 125mg |
1 |
2019 |
| Drug |
cross-over arm |
1 |
2005 |
| Behavioral |
crowdsourced video |
1 |
2015 |
| Procedure |
ct scan |
1 |
2004 |
| Biological |
ctl mep |
1 |
2005 |
| Biological |
ctl mep/rc529-se/gm-csf (ctl mep vaccine) |
1 |
2005 |
| Behavioral |
cultural adaptation of a patient-provider communication tool |
1 |
2020 |
| Dietary Supplement |
curcumin |
1 |
2017 |
| Drug |
curdlan sulfate |
1 |
1999 |
| Drug |
current art |
1 |
2017 |
| Drug |
current dual nrti backbone |
1 |
2005 |
| Drug |
current failing arv regimen |
1 |
2013 |
| Drug |
current haart regimen |
1 |
2006 |
| Drug |
current regimen |
1 |
2005 |
| Drug |
cycloserine |
1 |
2002 |
| Biological |
cyd dengue vaccine |
1 |
2016 |
| Drug |
cyp |
1 |
2015 |
| Drug |
cyp/transporter probe substrates |
1 |
2015 |
| Drug |
cysteamine |
1 |
1999 |
| Dietary Supplement |
cysteine |
1 |
2011 |
| Dietary Supplement |
cysteine/glycine |
1 |
2011 |
| Drug |
cyt 107 |
1 |
2007 |
| Biological |
d) |
1 |
2009 |
| Behavioral |
d*health |
1 |
2016 |
| Behavioral |
d*star |
1 |
2016 |
| Drug |
d/c/f/taf placebo |
1 |
2012 |
| Drug |
d4t |
1 |
2008 |
| Drug |
daclatasvir |
1 |
2017 |
| Drug |
daclizumab |
1 |
2004 |
| Behavioral |
daily art-adherence sms reminder |
1 |
2017 |
| Drug |
daily dosing |
1 |
2010 |
| Drug |
daily tdf |
1 |
2007 |
| Drug |
daily tdf/ftc |
1 |
2007 |
| Drug |
daily trimethoprim |
1 |
2014 |
| Drug |
dapivirine-maraviroc vaginal ring |
1 |
2011 |
| Drug |
dapivirine (dpv) vaginal ring (vr) |
1 |
2019 |
| Drug |
dapivirine (tmc120) vaginal ring |
1 |
2006 |
| Drug |
dapivirine 4789 |
1 |
2008 |
| Drug |
dapivirine gel 4750, 0.05%, 2.5g |
1 |
2008 |
| Drug |
dapivirine gel 4759 |
1 |
2008 |
| Drug |
dapivirine gel 4789, 0.05%, 2.5g |
1 |
2008 |
| Drug |
dapivirine matrix intravaginal ring |
1 |
2007 |
| Drug |
dapivirine reservoir intravaginal ring |
1 |
2007 |
| Combination Product |
dapivirine ring |
1 |
2014 |
| Drug |
dapivirine vaginal film |
1 |
2012 |
| Drug |
dapivirine vaginal gel |
1 |
2012 |
| Combination Product |
dapivirine vaginal ring, 25 mg |
1 |
2012 |
| Drug |
darunavir (drv |
1 |
2007 |
| Drug |
darunavir (drv, tmc114) |
1 |
2007 |
| Drug |
darunavir (drv/r) |
1 |
2007 |
| Drug |
darunavir 600mg |
1 |
2008 |
| Drug |
darunavir 600mg / ritonavir 100mg twice day |
1 |
2008 |
| Drug |
darunavir 800 mg |
1 |
2007 |
| Drug |
darunavir 800 mg oral tablet |
1 |
2018 |
| Drug |
darunavir 800mg oad |
1 |
2011 |
| Drug |
darunavir 900mg |
1 |
2008 |
| Drug |
darunavir 900mg / ritonavir 100 mg once a day |
1 |
2008 |
| Drug |
darunavir ritonavir |
1 |
2007 |
| Drug |
darunavir with ritonavir |
1 |
2013 |
| Drug |
darunavir with ritonavir/fixed-dose viread/emtricitabine daily |
1 |
2013 |
| Drug |
darunavir(drv) |
1 |
2011 |
| Drug |
darunavir/cobicistat |
1 |
2002 |
| Drug |
darunavir/cobicistat (fdc) |
1 |
2009 |
| Drug |
darunavir/r |
1 |
2015 |
| Drug |
darunavir/r qd / tenofovir/emtricitabine qd (fixed dose combination) |
1 |
2010 |
| Drug |
darunavir/ritonavir (drv/r) |
1 |
2011 |
| Drug |
darunavir/ritonavir qd / raltegravir bid |
1 |
2010 |
| Drug |
darunavir/ritonavir then atazanavir/ritonavir |
1 |
2010 |
| Drug |
darunavir; ritonavir; emtricitabine |
1 |
2009 |
| Drug |
darunavir; ritonavir; emtricitabine/tenofovir |
1 |
2009 |
| Biological |
dc |
1 |
2016 |
| Biological |
dc10e6 |
1 |
2016 |
| Biological |
dc10e6/hiv-at2 |
1 |
2016 |
| Biological |
dc10e7 |
1 |
2016 |
| Biological |
dc10e7/hiv-at2 |
1 |
2016 |
| Drug |
dcv |
1 |
2014 |
| Biological |
dcv3 |
1 |
2016 |
| Biological |
dcv3 with peg-inf |
1 |
2016 |
| Drug |
deferiprone |
1 |
2014 |
| Drug |
delamanid |
1 |
2002 |
| Drug |
delavirdine (dlv) |
1 |
2014 |
| Other |
demographic questionnaire |
1 |
2014 |
| Biological |
dendritic cell vaccine |
1 |
2006 |
| Biological |
dendritic cells pulsed with hiv antigens |
1 |
2003 |
| Drug |
depo provera |
1 |
2008 |
| Behavioral |
depression |
1 |
2016 |
| Combination Product |
descovy/dolutegravir |
1 |
2019 |
| Procedure |
determine blood levels of anti-hiv drugs |
1 |
2000 |
| Drug |
dextromethorphan |
1 |
2009 |
| Drug |
dhea |
1 |
2003 |
| Drug |
didanosine (enteric-coated) |
1 |
2004 |
| Drug |
didanosine / lamivudine / efavirenz |
1 |
2005 |
| Drug |
didanosine, enteric-coated |
1 |
2005 |
| Behavioral |
diet |
1 |
2017 |
| Behavioral |
diet/lifestyle counseling |
1 |
2017 |
| Behavioral |
dietary intervention |
1 |
2009 |
| Drug |
diethylcarbamazine |
1 |
2006 |
| Drug |
different formulations of once-daily lopinavir |
1 |
2006 |
| Drug |
different formulations of once-daily lopinavir/ritonavir |
1 |
2006 |
| Behavioral |
digital cognitive behavioural therapy for insomnia (dcbt-i) |
1 |
2015 |
| Drug |
digoxin |
1 |
2010 |
| Biological |
diphtheria |
1 |
2000 |
| Biological |
diphtheria toxoids adsorbed |
1 |
2000 |
| Biological |
diphtheria/tetanus toxoids adsorbed |
1 |
2000 |
| Biological |
diphtheria/tetanus toxoids/acellular pertussis vaccine adsorbed |
1 |
2000 |
| Drug |
dipyridamole |
1 |
2014 |
| Procedure |
direct fluorescent oral visualization examination |
1 |
2016 |
| Behavioral |
directly observed therapy |
1 |
2015 |
| Behavioral |
directly observed therapy (dot) |
1 |
2005 |
| Other |
discontinue tmp |
1 |
2011 |
| Other |
discontinue tmp/smz prophylaxis |
1 |
2011 |
| Other |
discontinue triple arvs |
1 |
2010 |
| Behavioral |
discussion group |
1 |
2005 |
| Drug |
dispersible dolutegravir 5 mg tablet |
1 |
2017 |
| Behavioral |
distance training |
1 |
2008 |
| Behavioral |
distant healing |
1 |
2004 |
| Behavioral |
distribution |
1 |
2005 |
| Drug |
ditiocarb sodium |
1 |
1999 |
| Drug |
dm |
1 |
2017 |
| Drug |
dm/htn medications as needed |
1 |
2017 |
| Biological |
dna |
1 |
2009 |
| Biological |
dna-c |
1 |
2007 |
| Biological |
dna-hiv-pt123 |
1 |
2013 |
| Biological |
dna / hiv-rad5 vaccine |
1 |
2009 |
| Biological |
dna con-s env |
1 |
2014 |
| Biological |
dna hivis |
1 |
2011 |
| Biological |
dna hivis/mva-cmdr |
1 |
2011 |
| Biological |
dna mosaic env |
1 |
2014 |
| Biological |
dna nat-b env |
1 |
2014 |
| Biological |
dna vaccine |
1 |
2008 |
| placebo |
dna vaccine placebo |
1 |
2008 |
| Biological |
dna.hiva |
1 |
2011 |
| Drug |
dolutegravir (dtg) film-coated tablets |
1 |
2011 |
| Drug |
dolutegravir (tivicayâ®) - phase 1 |
1 |
2015 |
| Drug |
dolutegravir (tivicayâ®) - phase 2 |
1 |
2015 |
| Drug |
dolutegravir / lamivudine fdc |
1 |
2019 |
| Drug |
dolutegravir / lamivudine fdc formulation 1 |
1 |
2017 |
| Drug |
dolutegravir / lamivudine fdc formulation 2 |
1 |
2017 |
| Drug |
dolutegravir 50 mg (one tablet daily) |
1 |
2014 |
| Drug |
dolutegravir 50 mg oad |
1 |
2011 |
| Drug |
dolutegravir 50 mg oral granules |
1 |
2011 |
| Drug |
dolutegravir 50 mg oral tablet |
1 |
2018 |
| Drug |
dolutegravir 50 mg q12h |
1 |
2014 |
| Drug |
dolutegravir 50 mg q24h |
1 |
2014 |
| Drug |
dolutegravir 50 mg twice daily |
1 |
2012 |
| Drug |
dolutegravir antiretroviral therapy |
1 |
2019 |
| Drug |
dolutegravir film-coated dispersible tablets |
1 |
2017 |
| Drug |
dolutegravir film-coated tablets |
1 |
2017 |
| Drug |
dolutegravir oral solution |
1 |
2019 |
| Drug |
dolutegravir oral suspension |
1 |
2019 |
| Drug |
dolutegravir pediatric granules |
1 |
2014 |
| placebo |
dolutegravir placebo |
1 |
2010 |
| placebo |
dolutegravir placebo twice daily |
1 |
2012 |
| Drug |
dolutegravir/abacavir/lamivudine |
1 |
2016 |
| Drug |
dolutegravir/abacavir/lamivudine fdc |
1 |
2013 |
| Drug |
dolutegravir/descovy |
1 |
2018 |
| Drug |
dolutegravir/lamivudine 50 mg/300 mg tablet (product code aa) |
1 |
2016 |
| Drug |
dolutegravir/lamivudine 50 mg/300 mg tablet (product code ab) |
1 |
2016 |
| Drug |
doravirine/lamivudine/tenofovir |
1 |
2020 |
| Drug |
doravirine/lamivudine/tenofovir disoproxil fumarate (dor/3tc/tdf) |
1 |
2017 |
| Biological |
dose) |
1 |
2009 |
| Other |
dot-haart |
1 |
2010 |
| Drug |
dpc 817 |
1 |
2002 |
| Drug |
dronabinol |
1 |
2008 |
| Other |
drug holiday |
1 |
2009 |
| placebo |
drug placebo |
1 |
2008 |
| Drug |
drv 800 mg |
1 |
2017 |
| Drug |
drv 800 mg / cobi 150 mg / ftc 200 mg / taf 10 mg fdc |
1 |
2017 |
| Drug |
drv commercial formulation |
1 |
2010 |
| Drug |
drv commercial formulation/ drv new formulation/ rtv 100mg tab |
1 |
2010 |
| Drug |
drv new formulation |
1 |
2010 |
| placebo |
drv placebo |
1 |
2012 |
| Drug |
drv/r |
1 |
2008 |
| Drug |
dtg / 3tc |
1 |
2018 |
| Drug |
dtg dispersible tablets |
1 |
2011 |
| Drug |
dtg granules for suspension |
1 |
2011 |
| Drug |
dtg tablet |
1 |
2016 |
| Drug |
dtg/3tc fdc |
1 |
2019 |
| Drug |
dtg/3tc/abc fdc |
1 |
2015 |
| Drug |
dtg/abc/3tc fdc dispersible tablet |
1 |
2016 |
| Drug |
dtg/rpv 50 mg/25 mg: product code ak |
1 |
2015 |
| Drug |
dtg/rpv 50 mg/25 mg: product code am |
1 |
2015 |
| Drug |
dtg/rpv 50 mg/25 mg: product code aq |
1 |
2015 |
| Drug |
dtg/rpv 50 mg/25 mg: product code ar |
1 |
2015 |
| Drug |
dtg/rpv 50 mg/25 mg: product code as |
1 |
2015 |
| Drug |
dtg/rpv fdc |
1 |
2016 |
| Drug |
dual therapy |
1 |
2019 |
| Drug |
duration of treatment: 48 weeks |
1 |
2007 |
| Behavioral |
dvd intervention |
1 |
2014 |
| Biological |
e) |
1 |
2018 |
| Biological |
e) protein vaccine |
1 |
2018 |
| Drug |
e/c/f/taf (low dose) |
1 |
2013 |
| Procedure |
early antiretroviral treatment |
1 |
2005 |
| Other |
early art |
1 |
2012 |
| Drug |
early haart |
1 |
2011 |
| Procedure |
early initiation of highly active anti-retroviral therapy |
1 |
2007 |
| Drug |
echinacea |
1 |
2010 |
| Procedure |
echocardiogram |
1 |
2004 |
| Behavioral |
economic strengthening (impumelelo) |
1 |
2016 |
| Behavioral |
education model |
1 |
2010 |
| Behavioral |
education/academic detailing |
1 |
2015 |
| Other |
educational video on opiate overdose prevention |
1 |
2012 |
| Drug |
ee |
1 |
2014 |
| Drug |
ee/net |
1 |
2014 |
| Drug |
efavirenz (atripla) |
1 |
2007 |
| Drug |
efavirenz (efv) / didanosine (ddi) / emtricitabine (ftc) |
1 |
2006 |
| Drug |
efavirenz (efv), emtricitabine (ftc), tenofovir df (tdf) |
1 |
2006 |
| Drug |
efavirenz / 2 nrtis |
1 |
2004 |
| Drug |
efavirenz [or other nnrti (non-nucleoside reverse transcriptase inhibitor)] |
1 |
2009 |
| Drug |
efavirenz 400mg |
1 |
2009 |
| Drug |
efavirenz 600 mg |
1 |
2012 |
| Drug |
efavirenz(efv) |
1 |
2015 |
| Drug |
efavirenz, emtricitabine, |
1 |
2009 |
| Drug |
efavirenz, emtricitabine,/tenofovir |
1 |
2009 |
| Drug |
efavirenz, lamivudine, |
1 |
2006 |
| Drug |
efavirenz, lamivudine,/tenofovir |
1 |
2006 |
| Drug |
efavirenz, stavudine extended release, lamivudine |
1 |
2005 |
| Drug |
efavirenz/emtricitabin/tenofovir |
1 |
2009 |
| Drug |
efavirenz/emtricitabine/tenofovir disoproxil fumarate |
1 |
2017 |
| Drug |
efavirenz/lamivudine/zidovudine |
1 |
2009 |
| Drug |
efavirenz; didanosine ec; lamivudine |
1 |
2005 |
| Drug |
effect of drug on inflammatory biomarkers |
1 |
2016 |
| Drug |
effect of drug on t-cell count |
1 |
2016 |
| Drug |
effect of drug on viral load |
1 |
2016 |
| Drug |
efv 600 mg |
1 |
2014 |
| Drug |
efv only |
1 |
2015 |
| Other |
efv) initiation |
1 |
2011 |
| Drug |
efv/3tc/tdf |
1 |
2008 |
| Drug |
efv/ftc/tdf |
1 |
2013 |
| Drug |
efv/tdf |
1 |
2008 |
| Drug |
elbasvir |
1 |
2017 |
| Drug |
elbasvir 100mg |
1 |
2015 |
| Procedure |
electrocardiogram |
1 |
2004 |
| Behavioral |
electronic drug monitoring feedback data |
1 |
2008 |
| Device |
electronic medication reminder system |
1 |
2000 |
| Drug |
elvitegravir, cobicistat, emtricitabine, |
1 |
2007 |
| Drug |
elvitegravir, cobicistat, emtricitabine,/tenofovir alafenamid fumarate |
1 |
2007 |
| Drug |
elvitegravir/cobicistat |
1 |
2002 |
| Behavioral |
ema |
1 |
2011 |
| Behavioral |
email feedback |
1 |
2012 |
| Behavioral |
emergency staff member-based hiv screening |
1 |
2007 |
| Behavioral |
empowering |
1 |
2010 |
| Biological |
empty tbc-fpv |
1 |
2004 |
| Drug |
emtricitabin |
1 |
2009 |
| Drug |
emtricitabine-tenofovir 300 |
1 |
2014 |
| Drug |
emtricitabine-tenofovir 300/200 mg (one tablet daily) |
1 |
2014 |
| Drug |
emtricitabine-tenofovir disoproxil fumarate (truvada [trv]) |
1 |
2010 |
| Drug |
emtricitabine-tenofovir disoproxil fumarate (truvada [trv]) tail |
1 |
2010 |
| Drug |
emtricitabine (ftc)/tenofovir disoproxil fumarate (tdf) |
1 |
2008 |
| Drug |
emtricitabine (truvada) |
1 |
2007 |
| Drug |
emtricitabine / tenofovir |
1 |
2020 |
| Drug |
emtricitabine 200 mg qd |
1 |
2007 |
| Drug |
emtricitabine 200mg |
1 |
2010 |
| Drug |
emtricitabine 200mg - tenofovir 300mg |
1 |
2005 |
| Drug |
emtricitabine 200mg /tenofovir 300mg |
1 |
2010 |
| Drug |
emtricitabine daily |
1 |
2013 |
| Drug |
emtricitabine fdc |
1 |
2013 |
| placebo |
emtricitabine placebo |
1 |
2012 |
| Drug |
emtricitabine qd (fixed dose combination) |
1 |
2010 |
| Drug |
emtricitabine, lopinavir |
1 |
2009 |
| Drug |
emtricitabine/tenofovir (truvada) |
1 |
2006 |
| Drug |
emtricitabine/tenofovir / darunavir / ritonavir (second line strategy under evaluation) |
1 |
2009 |
| Drug |
emtricitabine/tenofovir / lopinavir/ritonavir (who recommended second line) |
1 |
2009 |
| Drug |
emtricitabine/tenofovir alafenamide |
1 |
2017 |
| Drug |
emtricitabine/tenofovir df |
1 |
2006 |
| Drug |
emtricitabine/tenofovir/abacavir/lamivudine |
1 |
2014 |
| Drug |
emtriva (emtricitabine) |
1 |
2005 |
| Behavioral |
endurance ad resistance training exercise |
1 |
2017 |
| Drug |
enfuvirtide (enf) |
1 |
2005 |
| Other |
enfuvirtide interrupton |
1 |
2005 |
| Drug |
engerix-b |
1 |
2017 |
| Biological |
engerix b |
1 |
2005 |
| Behavioral |
enhanced adherence intervention |
1 |
2014 |
| Behavioral |
enhanced adherence package |
1 |
2015 |
| Behavioral |
enhanced adherence support |
1 |
2006 |
| Behavioral |
enhanced behavioral motivation counseling |
1 |
2006 |
| Other |
enhanced computer alerts |
1 |
2008 |
| Behavioral |
enhanced friendship bench |
1 |
2019 |
| Behavioral |
enhanced group support |
1 |
2016 |
| Behavioral |
enhanced individual support |
1 |
2016 |
| Behavioral |
enhanced intervention with counselor support |
1 |
2017 |
| Behavioral |
enhanced linkage to care |
1 |
2008 |
| Behavioral |
enhanced services as usual |
1 |
2013 |
| Other |
enhanced standard care (control) |
1 |
2019 |
| Behavioral |
enhanced standard of care |
1 |
2017 |
| Behavioral |
entre culturas: navigating culture, identity, |
1 |
2009 |
| Behavioral |
entre culturas: navigating culture, identity,/hiv risk |
1 |
2009 |
| Biological |
env (a,b,c,a |
1 |
2018 |
| Biological |
env (a,b,c,a/e)/gag (c) dna vaccine |
1 |
2018 |
| Biological |
env a |
1 |
2011 |
| Biological |
env dna |
1 |
2003 |
| Biological |
envdna |
1 |
2005 |
| Biological |
envpro |
1 |
2004 |
| Biological |
ep-1233 |
1 |
2007 |
| Biological |
ep hiv-1043 |
1 |
2005 |
| Drug |
epivir (3tc) |
1 |
2004 |
| Drug |
epivir (lamivudine) |
1 |
2005 |
| Drug |
epivir â® tablet 150-mg single dose (drug reference) |
1 |
2015 |
| Behavioral |
epride |
1 |
2017 |
| Drug |
epzicom |
1 |
2010 |
| Drug |
epzicom (abc |
1 |
2016 |
| Drug |
epzicom (abc/3tc) |
1 |
2016 |
| Drug |
erythromycin |
1 |
1999 |
| Procedure |
erythropoietin, recombinant |
1 |
1999 |
| Behavioral |
estima intervention |
1 |
2014 |
| Drug |
estradiol 2mg |
1 |
2020 |
| Drug |
etanercept (enbrel) |
1 |
2004 |
| Drug |
ethambutol |
1 |
2002 |
| Drug |
ethambutol hydrochloride |
1 |
1999 |
| Drug |
ethinyl estadiol |
1 |
2014 |
| Drug |
ethinyl estradiol oral contraceptive |
1 |
2002 |
| Drug |
ethinyl estradiol/levogestrel |
1 |
2009 |
| Drug |
ethinyl estradiol/levonorgestrel |
1 |
2000 |
| Drug |
ethionamide |
1 |
2002 |
| Drug |
ethionamide/prothionamide |
1 |
2002 |
| Drug |
etonogestrel implant |
1 |
2002 |
| Drug |
etravirine (etr) 200 mg |
1 |
2009 |
| Drug |
etravirine (etr, tmc125) |
1 |
2009 |
| Drug |
etravirine (intelence) |
1 |
2009 |
| Drug |
euphorbia kansui extract powder prepared as tea |
1 |
2015 |
| Device |
eutrophill |
1 |
2010 |
| Drug |
event-driven dosing |
1 |
2010 |
| Drug |
evg |
1 |
2012 |
| Drug |
evg insert |
1 |
2019 |
| placebo |
evg placebo |
1 |
2008 |
| Drug |
evg/cobi/ftc/tdf |
1 |
2012 |
| Drug |
evolocumab |
1 |
2017 |
| Behavioral |
exercise |
1 |
2000 |
| Behavioral |
exercise program |
1 |
2009 |
| Behavioral |
exercise training |
1 |
2019 |
| Biological |
expanded unmodified autologous cd4 |
1 |
2018 |
| Biological |
expanded unmodified autologous cd4/ t cells |
1 |
2018 |
| Biological |
experimental |
1 |
2013 |
| Behavioral |
expressive writing |
1 |
2016 |
| Drug |
extended-release naltrexone |
1 |
2010 |
| Radiation |
external beam radiation therapy |
1 |
2012 |
| Procedure |
eye exam |
1 |
2004 |
| Drug |
ezetimibe |
1 |
2004 |
| Drug |
f/taf |
1 |
2016 |
| Drug |
f/taf placebo |
1 |
2016 |
| Drug |
f/tdf |
1 |
2016 |
| Drug |
f/tdf placebo |
1 |
2016 |
| Behavioral |
face-to-face training |
1 |
2008 |
| Behavioral |
face-to-face young women’s coop (ywc) |
1 |
2016 |
| Behavioral |
facilitated access to a specialist in addictions |
1 |
2015 |
| Behavioral |
facilitated referral |
1 |
2009 |
| Diagnostic Test |
facility hivst |
1 |
2017 |
| Drug |
failing arv regimen |
1 |
2019 |
| Other |
fam-care |
1 |
2018 |
| Behavioral |
family-based hiv prevention for latinos |
1 |
2007 |
| Behavioral |
family-based hiv prevention program |
1 |
2007 |
| Behavioral |
family-based risk reduction intervention |
1 |
2005 |
| Behavioral |
family centered advanced care planning (fcacp) sessions |
1 |
2008 |
| Behavioral |
family life curriculum (hfle) |
1 |
2008 |
| Behavioral |
family member |
1 |
2017 |
| Behavioral |
family member / peer support |
1 |
2017 |
| Drug |
fat emulsion 2% |
1 |
1999 |
| Drug |
fat emulsion 20% |
1 |
1999 |
| Drug |
fda approved antiretroviral therapy (see list below) |
1 |
2008 |
| Device |
fecal immunochemical test |
1 |
2016 |
| Diagnostic Test |
feces samples |
1 |
2019 |
| Device |
female condom |
1 |
2012 |
| Drug |
ferrous fumarate 324 mg |
1 |
2012 |
| Biological |
ffb |
1 |
2005 |
| Behavioral |
financial incentive/reminders |
1 |
2018 |
| Behavioral |
financial incentives |
1 |
2019 |
| Behavioral |
financial support |
1 |
2019 |
| Other |
finger prick screening for bbv infections |
1 |
2020 |
| Other |
finger prick screening for bbv infections/questionnaires by outreaching methodology |
1 |
2020 |
| Procedure |
fingerstick hiv screening |
1 |
2010 |
| Dietary Supplement |
fish oil that contains omega-3 fatty acids |
1 |
2014 |
| Behavioral |
fitt: family intervention - telephone tracking |
1 |
2005 |
| Drug |
fixed-dose viread |
1 |
2013 |
| Behavioral |
fixed adherence group |
1 |
2016 |
| Drug |
fleet enema |
1 |
2008 |
| Procedure |
flexible sigmoidoscopy |
1 |
2015 |
| Device |
flip technique of shang ring circumcision |
1 |
2015 |
| Drug |
flurbiprofen |
1 |
2009 |
| Biological |
fluzone |
1 |
2012 |
| Biological |
fluzone high dose |
1 |
2012 |
| Biological |
fluzoneâ® |
1 |
2010 |
| Biological |
fmt |
1 |
2016 |
| Biological |
focetriaâ® |
1 |
2009 |
| Behavioral |
focus group |
1 |
2011 |
| Behavioral |
focused tai chi |
1 |
2002 |
| Dietary Supplement |
folic acid |
1 |
2013 |
| Dietary Supplement |
folinic acid |
1 |
2013 |
| Behavioral |
follow-up |
1 |
2013 |
| Behavioral |
food |
1 |
2014 |
| Other |
formulation buffer |
1 |
2009 |
| Drug |
fos-amprenavir |
1 |
2006 |
| Drug |
fos-amprenavir/ritonavir |
1 |
2006 |
| Drug |
fosamprenavir (gw433908) |
1 |
2006 |
| Drug |
foscarnet |
1 |
1999 |
| Behavioral |
foyc |
1 |
2008 |
| Drug |
ftc-tdf prep |
1 |
2016 |
| Drug |
ftc 200 mg oral cap |
1 |
2018 |
| Drug |
ftc 200 mg/tdf 300 mg fixed-dose combination tablet |
1 |
2012 |
| Drug |
ftc 200 mg/tdf 300mg |
1 |
2007 |
| Drug |
ftc alone |
1 |
2006 |
| Drug |
ftc dose schedule for arm a |
1 |
2020 |
| Drug |
ftc dose schedule for arm b |
1 |
2020 |
| placebo |
ftc placebo tablets |
1 |
2016 |
| Drug |
ftc tablets |
1 |
2016 |
| Drug |
ftc) |
1 |
2012 |
| Drug |
ftc) alone |
1 |
2006 |
| Drug |
ftc) tablet |
1 |
2006 |
| Drug |
ftc/tdf / efv/lpv/r |
1 |
2007 |
| Drug |
ftc/tdf / efv/lpv/r /t20 |
1 |
2007 |
| Drug |
ftc/tdf/efv |
1 |
2005 |
| Biological |
full-length p55^gag pdna vaccine |
1 |
2018 |
| Drug |
full boosted fosamprenavir |
1 |
2006 |
| Behavioral |
full computerized cognitive training |
1 |
2009 |
| Drug |
fuzeon |
1 |
2004 |
| Biological |
gag |
1 |
2004 |
| Biological |
gag (c) dna vaccine |
1 |
2018 |
| Biological |
gag [tbc-f357] |
1 |
2005 |
| Biological |
gag [tbc-m358] |
1 |
2005 |
| Procedure |
galt biopsies |
1 |
2009 |
| Dietary Supplement |
ganedenbc30, gbi-30, pta-6086 |
1 |
2010 |
| Biological |
gardisil |
1 |
2008 |
| Procedure |
gastrointestinal instrumentation |
1 |
2006 |
| Drug |
gemfibrozil |
1 |
2002 |
| Behavioral |
gender equity |
1 |
2005 |
| Behavioral |
general health promotion curriculum |
1 |
2008 |
| Other |
general health services |
1 |
2018 |
| Drug |
generic acyclovir |
1 |
2005 |
| Drug |
generic lopinavir |
1 |
2008 |
| Drug |
generic lopinavir/ritonavir |
1 |
2008 |
| Biological |
genevax il-12-4532 |
1 |
2008 |
| Biological |
genevaxâ® il-12 (1000mcg) |
1 |
2011 |
| Biological |
genevaxâ® il-12 (100mcg) |
1 |
2011 |
| Behavioral |
genexpert hiv-1 qual for point of care infant testing |
1 |
2018 |
| Biological |
genhevac-b |
1 |
2008 |
| Biological |
genhevac b pasteur |
1 |
2007 |
| Drug |
genvoya |
1 |
2016 |
| Behavioral |
get connected |
1 |
2017 |
| Procedure |
gi endoscopy |
1 |
2009 |
| Procedure |
gi endoscopy/galt biopsies |
1 |
2009 |
| Drug |
gi265235 |
1 |
2007 |
| Drug |
ginkgo biloba multiple dose |
1 |
2010 |
| Biological |
gla-lsq |
1 |
2019 |
| Biological |
glucopyranosyl lipid adjuvant-stable emulsion (gla-se) |
1 |
2019 |
| Dietary Supplement |
glutamine |
1 |
2013 |
| Dietary Supplement |
glutathione precursors |
1 |
2009 |
| Drug |
glycovir |
1 |
1999 |
| Drug |
gm-csf |
1 |
2004 |
| Biological |
gm-csf (ctl mep vaccine) |
1 |
2005 |
| Behavioral |
goal for it (gfi) |
1 |
2008 |
| Biological |
gp120 (a,b,c,a |
1 |
2018 |
| Biological |
gp120 (a,b,c,a/e) protein vaccine |
1 |
2018 |
| Biological |
gp120w61d |
1 |
2001 |
| Biological |
gp120w61d) formulated with as02a |
1 |
2001 |
| Biological |
gp145 c.6980 vaccine |
1 |
2017 |
| Drug |
gpo-vir z30 tablet |
1 |
2008 |
| Drug |
grazoprevir/elbasvir |
1 |
2017 |
| Drug |
grazoprevir/elbasvir 100mg/50mg |
1 |
2015 |
| Drug |
griffithsin gel |
1 |
2016 |
| Behavioral |
group-based health promotion intervention |
1 |
2018 |
| Behavioral |
group-level training |
1 |
2019 |
| Behavioral |
group counseling intervention |
1 |
1999 |
| Behavioral |
group hiv risk behavior counseling sessions |
1 |
2007 |
| Behavioral |
group level adherence |
1 |
2015 |
| Drug |
group1 |
1 |
2005 |
| Drug |
group2 |
1 |
2005 |
| Drug |
gs-9137 - a novel hiv-1 integrase inhibitor |
1 |
2006 |
| Biological |
gsk biologicals’ hpv vaccine 580299 |
1 |
2009 |
| Drug |
gsk1265744 10 mg |
1 |
2012 |
| Drug |
gsk1265744 10 mg oral solution |
1 |
2008 |
| Drug |
gsk1265744 30 mg oral |
1 |
2012 |
| Drug |
gsk1265744 30mg oral |
1 |
2012 |
| Drug |
gsk1265744 400 mg (1 micro m) |
1 |
2012 |
| Drug |
gsk1265744 400 mg (200 nm) |
1 |
2012 |
| Drug |
gsk1265744 400 mg (5 micro m) |
1 |
2012 |
| Drug |
gsk1265744 5 mg tablet |
1 |
2008 |
| Drug |
gsk1265744 5mg |
1 |
2009 |
| Drug |
gsk1265744 60 mg |
1 |
2012 |
| Drug |
gsk1265744 free acid micronized capsules |
1 |
2012 |
| Drug |
gsk1265744 free acid nanomilled capsules |
1 |
2012 |
| Drug |
gsk1265744 injectable suspension |
1 |
2011 |
| Drug |
gsk1265744 lap 200mg intramuscular injection |
1 |
2012 |
| Drug |
gsk1265744 lap 200mg subcutaneous injection |
1 |
2012 |
| Drug |
gsk1265744 lap 400mg intramuscular injection |
1 |
2012 |
| Drug |
gsk1265744 lap 800mg intramuscular injection |
1 |
2012 |
| placebo |
gsk1265744 matching placebo |
1 |
2013 |
| Drug |
gsk1265744 na salt tablets |
1 |
2012 |
| Drug |
gsk1265744 new formulation 1 |
1 |
2014 |
| Drug |
gsk1265744 new formulation 2 |
1 |
2014 |
| Drug |
gsk1265744 oral |
1 |
2012 |
| Drug |
gsk1265744 reference formulation |
1 |
2014 |
| Drug |
gsk1265744 tablets |
1 |
2014 |
| Drug |
gsk1349572 (cohort i) |
1 |
2009 |
| Drug |
gsk1349572 (cohort ii) |
1 |
2009 |
| Drug |
gsk1349572 (dolutegravir) |
1 |
2010 |
| Drug |
gsk1349572 formulation ap |
1 |
2010 |
| Drug |
gsk1349572 formulation aw |
1 |
2010 |
| Drug |
gsk1349572 formulation ax |
1 |
2010 |
| Drug |
gsk2248761 / raltegravir |
1 |
2010 |
| Drug |
gsk2248761 formulation 1 |
1 |
2009 |
| Drug |
gsk2248761 formulation 2 |
1 |
2009 |
| Drug |
gsk2248761 formulation 2/4 |
1 |
2009 |
| Drug |
gsk2248761 formulation 3 |
1 |
2009 |
| Drug |
gsk2248761 reference formulation |
1 |
2009 |
| Drug |
gsk2248761 wbm capsule |
1 |
2010 |
| Drug |
gsk2248761 wbm tablet |
1 |
2010 |
| Drug |
gsk2248761 wbm tablet formulation 1 |
1 |
2010 |
| Drug |
gsk2248761 wbm tablet formulation 2 |
1 |
2010 |
| Drug |
gsk2248761 wbm tablet formulation 3 |
1 |
2010 |
| Drug |
gsk2838232 100 mg tablet |
1 |
2017 |
| Drug |
gsk2838232 50 mg capsule |
1 |
2017 |
| Drug |
gsk2838232 ir1 |
1 |
2016 |
| Drug |
gsk2838232 ir2 |
1 |
2016 |
| Drug |
gsk2838232 pib |
1 |
2016 |
| Drug |
gsk2838510 |
1 |
2012 |
| Drug |
gsk3640254 bis-hydrochloride salt capsule |
1 |
2018 |
| Drug |
gsk3640254 capsule |
1 |
2020 |
| Drug |
gsk3640254 mesylate salt capsule |
1 |
2018 |
| Drug |
gsk3640254 tablet |
1 |
2020 |
| Drug |
gsk364735 |
1 |
2006 |
| Drug |
gsk364735 oral solution |
1 |
2006 |
| Drug |
gsk364735 oral solution/oral tablets |
1 |
2006 |
| Drug |
gsk3732394 |
1 |
2019 |
| Drug |
gsk706769/kaletra |
1 |
2008 |
| Drug |
gsk744 |
1 |
2014 |
| Drug |
gsk744 la |
1 |
2014 |
| Biological |
gtuâ®-multihiv b: 0.5 ml im via biojectorâ® 2000 |
1 |
2014 |
| Biological |
gtuâ®-multihiv b: 0.5 ml im via biojectorâ® 2000/0.5ml intradermic, 3 shots |
1 |
2014 |
| Behavioral |
guidelines |
1 |
2005 |
| Drug |
gw433908 |
1 |
2003 |
| Drug |
gw640385 |
1 |
2005 |
| Drug |
gw695634 |
1 |
2004 |
| Drug |
gw810781 |
1 |
2002 |
| Drug |
gw873140 |
1 |
2004 |
| Biological |
h1n1 vaccination |
1 |
2010 |
| Drug |
haart / immunotherapy |
1 |
2009 |
| Biological |
haemophilus b conjugate vaccine |
1 |
2002 |
| Drug |
half-boosted fosamprenavir |
1 |
2006 |
| Drug |
hby 097 |
1 |
1999 |
| Drug |
he2000 |
1 |
1999 |
| Behavioral |
health |
1 |
2008 |
| Behavioral |
health counseling |
1 |
2010 |
| Behavioral |
health discussion |
1 |
2015 |
| Behavioral |
health education |
1 |
2007 |
| Behavioral |
health education control sessions |
1 |
2008 |
| Behavioral |
health education/support group |
1 |
2007 |
| Device |
health management app with symptom strategies |
1 |
2016 |
| Behavioral |
health promotion |
1 |
2015 |
| Behavioral |
health promotion - a |
1 |
2016 |
| Behavioral |
health promotion control |
1 |
2011 |
| Behavioral |
health/family life curriculum (hfle) |
1 |
2008 |
| Behavioral |
healthmindr app |
1 |
2018 |
| Behavioral |
healthmindr application |
1 |
2018 |
| Behavioral |
healthy choices - motivational enhancement intervention |
1 |
2005 |
| Behavioral |
healthy futures parent education |
1 |
2009 |
| Behavioral |
healthy love workshop |
1 |
2006 |
| placebo |
hec-based placebo gel |
1 |
2008 |
| placebo |
hec placebo |
1 |
2009 |
| Biological |
hepatitis a virus, inactivated |
1 |
2002 |
| Biological |
hexaximâ®: dtap-ipv-hb-prp-t |
1 |
2016 |
| Biological |
hexaximâ®: dtap-ipv-hb-prp-t/vaccine |
1 |
2016 |
| Other |
high-fat breakfast |
1 |
2014 |
| Drug |
high dose |
1 |
2007 |
| Drug |
high dose isoniazid (inh) |
1 |
2002 |
| Dietary Supplement |
high dose vitamin d |
1 |
2015 |
| Dietary Supplement |
high dose vitamin d/calcium |
1 |
2015 |
| Drug |
highly active antiretroviral therapy |
1 |
2007 |
| Drug |
highly active antiretroviral treatment (haart) |
1 |
2007 |
| Behavioral |
hip: hiv intervention for providers |
1 |
2005 |
| Device |
hiv-1 antibody test kit |
1 |
2007 |
| Biological |
hiv-1 dna plasmid vaccine |
1 |
2010 |
| Biological |
hiv-1 gag dna/il-12 dna adjuvant |
1 |
2005 |
| Biological |
hiv-1 nef |
1 |
2016 |
| Biological |
hiv-1 nef/tat/vif, env pdna vaccine |
1 |
2016 |
| placebo |
hiv-1 placebo |
1 |
2001 |
| Biological |
hiv-1 recombinant ad5 vaccine |
1 |
2010 |
| Diagnostic Test |
hiv-1 rna testing |
1 |
2018 |
| Other |
hiv-1 viral load testing |
1 |
2009 |
| Biological |
hiv-1sf2 |
1 |
1999 |
| Biological |
hiv-at2 |
1 |
2016 |
| Biological |
hiv-mag (3,000mcg) |
1 |
2011 |
| Biological |
hiv-mag vaccine |
1 |
2012 |
| Biological |
hiv-rad5 vaccine |
1 |
2009 |
| Behavioral |
hiv-related text messaging |
1 |
2008 |
| Behavioral |
hiv-screening advice |
1 |
2019 |
| Behavioral |
hiv-testing advice |
1 |
2019 |
| Behavioral |
hiv-testing advice/group-level training |
1 |
2019 |
| Device |
hiv-testing motivational videos |
1 |
2008 |
| Biological |
hiv-v (control) |
1 |
2010 |
| Biological |
hiv-v (high dose) |
1 |
2010 |
| Biological |
hiv-v (low dose) |
1 |
2010 |
| Drug |
hiv antiretroviral therapy |
1 |
2005 |
| Procedure |
hiv care |
1 |
2009 |
| Behavioral |
hiv counseling/education model |
1 |
2010 |
| Behavioral |
hiv counseling/testing |
1 |
2016 |
| Biological |
hiv ctl mep 1000 micrograms, 19 months per subject |
1 |
2005 |
| Biological |
hiv ctl mep administered with rc529-se adjuvant |
1 |
2004 |
| Behavioral |
hiv dna pcr testing (standard of care) |
1 |
2018 |
| Biological |
hiv dna plasmid vaccine |
1 |
2003 |
| Biological |
hiv dna plasmid vaccine/recombinant fowlpox vector |
1 |
2003 |
| Device |
hiv drug resistance tests based upon genotype testing |
1 |
2005 |
| Procedure |
hiv educational video |
1 |
2005 |
| Device |
hiv home tests |
1 |
2018 |
| Drug |
hiv immune globulin solution |
1 |
2008 |
| Biological |
hiv lfn-p24 |
1 |
2006 |
| Biological |
hiv p17 |
1 |
1999 |
| Biological |
hiv p17/p24:ty-vlp |
1 |
1999 |
| Behavioral |
hiv prevention |
1 |
2008 |
| Behavioral |
hiv prevention education (vhutshilo 2.2) |
1 |
2016 |
| Behavioral |
hiv prevention information |
1 |
2018 |
| Behavioral |
hiv prevention intervention - project prissma - hiv i have my eye on you |
1 |
2009 |
| Behavioral |
hiv prevention skills |
1 |
2007 |
| Behavioral |
hiv prevention videogame |
1 |
2016 |
| Other |
hiv quarterly global care |
1 |
2015 |
| Behavioral |
hiv risk |
1 |
2009 |
| Behavioral |
hiv risk reduction intervention |
1 |
2009 |
| Diagnostic Test |
hiv self-test |
1 |
2018 |
| Behavioral |
hiv self-testing |
1 |
2018 |
| Behavioral |
hiv sexual risk reduction |
1 |
2013 |
| Behavioral |
hiv sexual risk reduction/microfinance |
1 |
2013 |
| Behavioral |
hiv symptom education program |
1 |
2003 |
| Behavioral |
hiv testing |
1 |
2010 |
| Behavioral |
hiv testing in anc for pmtct |
1 |
2006 |
| Behavioral |
hiv testing/counseling |
1 |
2010 |
| Behavioral |
hiv transmission risk reduction |
1 |
2010 |
| Biological |
hiv vaccine 732461 |
1 |
2007 |
| Behavioral |
hiv/aids 101 workshop |
1 |
2006 |
| Behavioral |
hiv/std prevention curriculum |
1 |
2008 |
| Behavioral |
hiv/sti counseling/testing |
1 |
2015 |
| Biological |
hiv62 vaccine |
1 |
2009 |
| Biological |
hiv62b vaccine |
1 |
2016 |
| Biological |
hivac-1e |
1 |
1999 |
| Biological |
hivax |
1 |
2011 |
| Behavioral |
hola component 1 |
1 |
2019 |
| Behavioral |
hola component 2 |
1 |
2019 |
| Behavioral |
hola component 3 |
1 |
2019 |
| Behavioral |
hola component 4 |
1 |
2019 |
| Behavioral |
holistic health recovery program |
1 |
2015 |
| Other |
home-based art delivery |
1 |
2017 |
| Diagnostic Test |
home hiv rapid testing |
1 |
2019 |
| Diagnostic Test |
home hiv self-testing |
1 |
2019 |
| Diagnostic Test |
home hiv self-testing/rapid testing |
1 |
2019 |
| Other |
home visit by community care coordinators |
1 |
2006 |
| Behavioral |
home visits |
1 |
2018 |
| Drug |
hormonal contraception |
1 |
2006 |
| Diagnostic Test |
hpv genotyping |
1 |
2018 |
| Other |
hpv self-sampling test |
1 |
2016 |
| Biological |
hpv vaccine for strains -6, -11, -16, |
1 |
2008 |
| Biological |
hpv vaccine for strains -6, -11, -16,/-18 |
1 |
2008 |
| Biological |
hpv9v |
1 |
2018 |
| Drug |
htn medications as needed |
1 |
2017 |
| Biological |
hxtc |
1 |
2017 |
| Drug |
hydroxychloroquine |
1 |
2015 |
| Drug |
hyper-immune bovine colostrum |
1 |
2008 |
| placebo |
hyper-immune bovine colostrum placebo |
1 |
2008 |
| Biological |
î± |
1 |
2009 |
| Biological |
î±/6-gag-tcr modified t cells |
1 |
2009 |
| Drug |
ibalizumab 2000mg q4weeks |
1 |
2010 |
| Drug |
ibalizumab 800mg q2weeks |
1 |
2010 |
| Behavioral |
ibft |
1 |
2008 |
| Behavioral |
ibft /hiv prevention |
1 |
2008 |
| Drug |
ibudilast |
1 |
2013 |
| Device |
ichor medical systems intramuscular trigrid delivery system (tds-im) electroporation (ep) device |
1 |
2017 |
| Device |
ichor medical systems trigridâ„¢ delivery system (tds) electroporation (ep) device |
1 |
2012 |
| Drug |
idv |
1 |
2006 |
| Behavioral |
ihtc |
1 |
2020 |
| Biological |
il-12 dna plasmids |
1 |
2009 |
| Biological |
il-15 |
1 |
2007 |
| Biological |
il-15 adjuvant |
1 |
2008 |
| Biological |
il-15 dna adjuvant |
1 |
2005 |
| Drug |
il-2 |
1 |
1999 |
| Drug |
il-2/anti-tnf/thalidomide |
1 |
1999 |
| Drug |
il-7 |
1 |
2005 |
| Behavioral |
imara hiv prevention intervention |
1 |
2008 |
| Drug |
immediate arv treatment initiation with tdf |
1 |
2011 |
| Drug |
immediate arv treatment initiation with tdf/ftc/efv |
1 |
2011 |
| Drug |
immunoglobulins |
1 |
1999 |
| Drug |
immunotherapy |
1 |
2009 |
| Behavioral |
impart |
1 |
2019 |
| Biological |
imvamuneâ® |
1 |
2014 |
| Behavioral |
in-person hiv pre-test counseling |
1 |
2009 |
| Behavioral |
in-school sexual health education |
1 |
2005 |
| Behavioral |
in the mix |
1 |
2010 |
| Biological |
inactivated whole autologous hiv |
1 |
2018 |
| Drug |
incb009471 |
1 |
2006 |
| Behavioral |
incentive choice (ic) |
1 |
2011 |
| Behavioral |
increase condom use |
1 |
2006 |
| Diagnostic Test |
index hivst |
1 |
2017 |
| Drug |
indinavir (idv) |
1 |
2005 |
| Drug |
indinavir (mk-0639) |
1 |
1999 |
| Drug |
indinavir/ritonavir |
1 |
2006 |
| Drug |
indinavir/ritonavir/fosamprenavir |
1 |
2005 |
| Behavioral |
individual |
1 |
2007 |
| Behavioral |
individual therapy |
1 |
2006 |
| Behavioral |
individual vct |
1 |
2008 |
| Behavioral |
individual/group hiv risk behavior counseling sessions |
1 |
2007 |
| Behavioral |
individually tailored intervention |
1 |
2006 |
| Procedure |
infant feeding counseling that includes flash-heat |
1 |
2007 |
| Drug |
infant formula |
1 |
1999 |
| Drug |
infant nevirapine |
1 |
2005 |
| Biological |
influenza a (h1n1) 2009 monovalent vaccine |
1 |
2009 |
| Behavioral |
information |
1 |
2018 |
| Behavioral |
information-only control |
1 |
2017 |
| Behavioral |
information letter |
1 |
2010 |
| Behavioral |
information only |
1 |
2009 |
| Behavioral |
information provision |
1 |
2017 |
| Behavioral |
information support group |
1 |
2010 |
| Behavioral |
information/stigma-relieving |
1 |
2018 |
| Drug |
inh, rifampicin, ethambutol |
1 |
2008 |
| Drug |
inh, rifampicin, ethambutol/pyrazinamide |
1 |
2008 |
| Drug |
injectable anesthesia (lidocaine 1%) |
1 |
2015 |
| Drug |
injectable gsk1265744 |
1 |
2014 |
| Drug |
injectable naltrexone |
1 |
2013 |
| placebo |
injectable placebo for gsk1265744 |
1 |
2014 |
| Behavioral |
instrumental |
1 |
2010 |
| Behavioral |
instrumental/empowering |
1 |
2010 |
| Procedure |
integrated anc, pmtct, hiv services |
1 |
2009 |
| Procedure |
integrated family planning |
1 |
2009 |
| Procedure |
integrated family planning/hiv care/treatment services |
1 |
2009 |
| Drug |
intelence tablets |
1 |
2010 |
| Other |
intensified tb case finding (icf) |
1 |
2015 |
| Behavioral |
interactive injection |
1 |
2009 |
| Behavioral |
interactive injection risk intervention |
1 |
2009 |
| Behavioral |
interactive injection/sexual risk intervention |
1 |
2009 |
| Behavioral |
interactive sexual risk intervention |
1 |
2009 |
| Drug |
interferon |
1 |
1999 |
| Drug |
interferon alfa-2b |
1 |
1999 |
| Biological |
interleukin-12 (il-12) dna adjuvant |
1 |
2015 |
| Drug |
interleukin-2 (chiro |
1 |
1999 |
| Drug |
interleukin-2 (il-2) |
1 |
2005 |
| Drug |
interleukin-2 (il2) |
1 |
1999 |
| Drug |
interleukin-2 sa |
1 |
2003 |
| Drug |
interleukin-2/zidovudine (azt) |
1 |
1999 |
| Drug |
intermitent dosing |
1 |
2006 |
| Behavioral |
intermittent fasting |
1 |
2018 |
| Other |
interruption of enfuvirtide |
1 |
2005 |
| Behavioral |
intervention |
1 |
2016 |
| Behavioral |
intervention- home visits |
1 |
2015 |
| Device |
intervention arm (computer-based care |
1 |
2012 |
| Device |
intervention arm (computer-based care/ corrections tool) |
1 |
2012 |
| Behavioral |
intervention with microfinance for aids |
1 |
2005 |
| Behavioral |
intervention with microfinance for aids/gender equity |
1 |
2005 |
| Biological |
intramuscular mode of administration |
1 |
2005 |
| Procedure |
intrapartum hiv counseling |
1 |
2004 |
| Procedure |
intrapartum hiv counseling/testing |
1 |
2004 |
| Device |
intravaginal ring |
1 |
2007 |
| Drug |
intravenous deferiprone |
1 |
2015 |
| Drug |
invirase |
1 |
2006 |
| Behavioral |
invitation letter for male spouse |
1 |
2010 |
| Drug |
iohexol injection |
1 |
2010 |
| Behavioral |
ipod video |
1 |
2011 |
| Drug |
isentressâ® |
1 |
2009 |
| Drug |
isoniazid (inh) |
1 |
2019 |
| Drug |
isoniazid with ethambutol |
1 |
2006 |
| Drug |
itraconazole |
1 |
1999 |
| placebo |
iv placebo for vrc01 |
1 |
2014 |
| Biological |
js2 plasmid dna vaccine |
1 |
2002 |
| Biological |
js7 dna vaccine |
1 |
2009 |
| Drug |
juluca (dolutegravir |
1 |
2019 |
| Drug |
juluca (dolutegravir/rilpivirine) 50mg/25mg fdc tablet |
1 |
2019 |
| Drug |
kaletra (lopinavir/ritonavir) / combivir (zidovudine/lamivudine) |
1 |
2007 |
| Drug |
kaletra (lopinavir/ritonavir), african potato (hypoxis obtusa) |
1 |
2010 |
| Drug |
kaletra / current dual nrti backbone |
1 |
2005 |
| Drug |
kaletra dosed once daily |
1 |
2010 |
| Drug |
kaletra dosed twice daily |
1 |
2010 |
| Drug |
kaletra tablets |
1 |
2007 |
| Drug |
kaletra/intelence tablets |
1 |
2010 |
| Drug |
kaletraâ® (lopinavir |
1 |
2004 |
| Drug |
kaletraâ® (lopinavir/ritonavir) |
1 |
2004 |
| Drug |
kanamycin |
1 |
2002 |
| Drug |
kd-247 |
1 |
2009 |
| Behavioral |
keep it up! |
1 |
2009 |
| Other |
kenya brief computer risk assessment session |
1 |
2009 |
| Other |
kenya computer counseling session |
1 |
2009 |
| Biological |
kg |
1 |
2017 |
| Biological |
kg iv |
1 |
2016 |
| Biological |
kg iv) |
1 |
2017 |
| Biological |
kg sc |
1 |
2016 |
| Drug |
kivexa/sustiva |
1 |
2008 |
| Drug |
km-023 |
1 |
2011 |
| Drug |
kp-1461 |
1 |
2005 |
| Drug |
l-697,661 |
1 |
1999 |
| Drug |
l-756423 |
1 |
2000 |
| Other |
lab-based viral load testing |
1 |
2017 |
| Other |
laboratory |
1 |
2013 |
| Other |
laboratory/clinical monitoring (lcm) |
1 |
2013 |
| Drug |
lamiduvine (epivir) |
1 |
2009 |
| Drug |
lamivudine-zidovudine (3tc-zdv) |
1 |
2010 |
| Drug |
lamivudine (abc |
1 |
2012 |
| Drug |
lamivudine (combivir) |
1 |
2006 |
| Drug |
lamivudine (combivirâ®) |
1 |
2006 |
| Drug |
lamivudine (epivirâ®) - phase 2 |
1 |
2015 |
| Drug |
lamivudine (or emtricitabine) |
1 |
2009 |
| Drug |
lamivudine / abacavir sulfate |
1 |
2006 |
| Drug |
lamivudine 150-mg tablet single dose (drug test) |
1 |
2015 |
| Drug |
lamivudine 300 mg tablet |
1 |
2016 |
| Drug |
lamivudine 50 mg |
1 |
2016 |
| Drug |
lamivudine abacavir raltegravir |
1 |
2009 |
| Drug |
lamivudine fdc formulation 1 |
1 |
2017 |
| Drug |
lamivudine fdc formulation 2 |
1 |
2017 |
| Drug |
lamivudine(3tc) |
1 |
2015 |
| Drug |
lamivudine) |
1 |
2007 |
| Drug |
lamivudine, nevirapine, |
1 |
2006 |
| Drug |
lamivudine, nevirapine,/stavudine fixed-dose tablet |
1 |
2006 |
| Drug |
lamotrigine |
1 |
2008 |
| Procedure |
late antiretroviral treatment |
1 |
2005 |
| Drug |
late haart |
1 |
2011 |
| Biological |
lc002 high-dose vaccination |
1 |
2005 |
| placebo |
lc002 placebo vaccination |
1 |
2005 |
| Biological |
lc002 standard vaccination |
1 |
2005 |
| Drug |
ldmtx |
1 |
2013 |
| Drug |
ldv/sof |
1 |
2015 |
| Drug |
leader antacid |
1 |
2015 |
| Behavioral |
lecture-format presentation |
1 |
2009 |
| Drug |
ledipasvir fixed dose |
1 |
2014 |
| Drug |
leflunomide |
1 |
2005 |
| Drug |
lentinan |
1 |
1999 |
| Drug |
leucovorin calcium |
1 |
1999 |
| Procedure |
leukopheresis |
1 |
2007 |
| Drug |
levogestrel |
1 |
2009 |
| Device |
levonorgestrel-releasing intrauterine device (iud) |
1 |
2004 |
| Diagnostic Test |
lf-lam |
1 |
2019 |
| Behavioral |
life skills curriculum |
1 |
2010 |
| Behavioral |
life skills intervention |
1 |
2006 |
| Behavioral |
lifestyle counseling |
1 |
2017 |
| Behavioral |
lifestyle modifications |
1 |
2008 |
| Behavioral |
limited computerized cognitive training |
1 |
2009 |
| Other |
linc-ii |
1 |
2017 |
| Behavioral |
linc case management |
1 |
2012 |
| Drug |
linezolid |
1 |
2002 |
| Behavioral |
link coordination |
1 |
2012 |
| Behavioral |
linkage-to-care component: financial incentive (fi) |
1 |
2010 |
| Behavioral |
linkage-to-care component: standard of care (soc) |
1 |
2010 |
| Behavioral |
linkage to care for hiv |
1 |
2018 |
| Behavioral |
linkage to care for hiv/ men |
1 |
2018 |
| Biological |
lipid a, liposome-encapsulated monophosphoryl |
1 |
1999 |
| Biological |
lipid a, monophosphoryl |
1 |
1999 |
| Drug |
lipitor |
1 |
2014 |
| Biological |
lipopeptides lipo-4 |
1 |
2005 |
| Drug |
lisinopril |
1 |
2009 |
| Drug |
lithium |
1 |
2011 |
| Biological |
live attenuated vaccine- fluenz tretra |
1 |
2014 |
| Drug |
lobradimil |
1 |
1999 |
| Drug |
loestrin 1.5 |
1 |
2015 |
| Drug |
loestrin 1.5/30 |
1 |
2015 |
| Drug |
long-acting injectable rilpivirine (rpv la) |
1 |
2018 |
| Drug |
lopinavir-ritonavir (lpv-rtv) |
1 |
2010 |
| Drug |
lopinavir-rtv (kaletra): 3 capsules (600 mg) |
1 |
2006 |
| Drug |
lopinavir-rtv (kaletra): 3 capsules (600 mg)/12 h |
1 |
2006 |
| Drug |
lopinavir /ritonavir/two nucleosides |
1 |
2010 |
| Drug |
lopinavir 400 mg |
1 |
2010 |
| Drug |
lopinavir 400 mg/ritonavir 100mg |
1 |
2010 |
| Drug |
lopinavir in fixed combination with ritonavir |
1 |
2011 |
| Drug |
lopinavir with ritonavir in 1:1 ratio |
1 |
2014 |
| Drug |
lopinavir/efavirenz |
1 |
2006 |
| Drug |
lopinavir/r |
1 |
2005 |
| Drug |
lopinavir/r/saquinavir |
1 |
2007 |
| Drug |
lopinavir/ritonavir (drug) |
1 |
2005 |
| Drug |
lopinavir/ritonavir (kaletraâ®) |
1 |
2007 |
| Drug |
lopinavir/ritonavir (kaletraâ®) tablets |
1 |
2008 |
| Drug |
lopinavir/ritonavir (lpv/r) (tablet/capsule) with nucleoside reverse transcriptase inhibitors (nrtis) |
1 |
2005 |
| Drug |
lopinavir/ritonavir (lpv/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (nrtis) |
1 |
2006 |
| Drug |
lopinavir/ritonavir / 2 nrtis |
1 |
2004 |
| Drug |
lopinavir/ritonavir / tenofovir / nucleoside |
1 |
2002 |
| Drug |
lopinavir/ritonavir 4:1 |
1 |
2014 |
| Drug |
lopinavir/ritonavir low dose ( 70% of who recommended dosing table) |
1 |
2009 |
| Drug |
lopinavir/ritonavir simplification strategy |
1 |
2005 |
| Drug |
lopinavir/ritonavir standard dose according to who simplified dosing table |
1 |
2009 |
| Drug |
lopinavir/ritonavir with 2 nucleoside rtis |
1 |
2005 |
| Drug |
lopinavir/ritonavir with two nucleoside analogs |
1 |
2009 |
| Drug |
lopinavir/ritonavir/lamivudine/zidovudine |
1 |
2009 |
| Drug |
lopinavir/ritonavir/one nucleoside |
1 |
2010 |
| Drug |
lopinavir/ritonavir/raltegravir |
1 |
2008 |
| Drug |
losartan |
1 |
2012 |
| Drug |
low dose |
1 |
2007 |
| Drug |
low dose busulfan preconditioning |
1 |
2018 |
| Drug |
low dose kaletra tablets |
1 |
2008 |
| Drug |
low dose ritonavir(r) |
1 |
2005 |
| Drug |
lpv/r / tdf/ftc/tdf/3tc |
1 |
2008 |
| Drug |
lpv/r /2 nrtis (delayed/optional switch group) |
1 |
2005 |
| Drug |
ltb4 |
1 |
2005 |
| Drug |
lumefantrine |
1 |
2008 |
| Drug |
lumefantrine - lopinavir |
1 |
2008 |
| Drug |
lumefantrine - lopinavir/ritonavir drug interaction |
1 |
2008 |
| Drug |
lumefantrine only arm |
1 |
2008 |
| Drug |
lxr015-1 |
1 |
1999 |
| Biological |
lyme disease vaccine recombinant ospa |
1 |
2002 |
| Procedure |
lymph node biospy |
1 |
1999 |
| Drug |
lymphocytes, activated |
1 |
1999 |
| Drug |
m2) |
1 |
2014 |
| Drug |
maalox (mal) |
1 |
2013 |
| Behavioral |
mace |
1 |
2017 |
| Device |
male circumcision using the shang ring device |
1 |
2013 |
| Behavioral |
managed problem solving |
1 |
2005 |
| Behavioral |
mantram repetition |
1 |
2003 |
| Behavioral |
many men, many voices (3mv) |
1 |
2005 |
| Drug |
maraviroc (mvc) |
1 |
2015 |
| Drug |
maraviroc (selzentry) |
1 |
2009 |
| Drug |
maraviroc (selzentry, celsentri) |
1 |
2009 |
| Other |
maraviroc / trofile estaâ® (diagnose test) |
1 |
2010 |
| Drug |
maraviroc in combination |
1 |
2010 |
| Drug |
maraviroc in combination with 2 nrtis (dual nucleoside reverse transcriptase inhibitor) |
1 |
2009 |
| placebo |
maraviroc placebo |
1 |
2012 |
| Drug |
maraviroc vaginal ring |
1 |
2011 |
| Drug |
maraviroc/raltegravir in combination with 2 nrtis (dual nucleoside reverse transcriptase inhibitor) |
1 |
2009 |
| Behavioral |
mashia |
1 |
2018 |
| Dietary Supplement |
maternal protein |
1 |
2005 |
| Dietary Supplement |
maternal protein/calorie supplement |
1 |
2005 |
| Drug |
maternal zidovudine |
1 |
2005 |
| Drug |
maternal zidovudine/lamivudine/lopinavir-ritonavir |
1 |
2005 |
| Behavioral |
maximal control |
1 |
2010 |
| Behavioral |
mbsr |
1 |
2008 |
| Behavioral |
mbsr group |
1 |
2007 |
| Biological |
mdx-010 |
1 |
2018 |
| Biological |
measles, mumps, |
1 |
2005 |
| Biological |
measles, mumps,/rubella virus vaccine, live |
1 |
2005 |
| Dietary Supplement |
meat biscuit |
1 |
2007 |
| Behavioral |
medchec tablet computer |
1 |
2009 |
| Behavioral |
medchec tablet computer/adherence care |
1 |
2009 |
| Behavioral |
medication adherence |
1 |
2019 |
| Behavioral |
medication adherence/financial incentives |
1 |
2019 |
| Behavioral |
medication diaries |
1 |
2005 |
| Behavioral |
medication manager |
1 |
2000 |
| Device |
medication reminder system |
1 |
2003 |
| Device |
medication reminder system/adherence tracker |
1 |
2003 |
| Drug |
mefloquine |
1 |
2006 |
| Drug |
megestrol |
1 |
2000 |
| Other |
mems cap monitoring |
1 |
2008 |
| Behavioral |
men |
1 |
2018 |
| Behavioral |
men’s health |
1 |
2017 |
| Behavioral |
men-centered hiv testing |
1 |
2018 |
| Behavioral |
men making a difference hiv |
1 |
2011 |
| Behavioral |
men making a difference hiv/std risk reduction intervention |
1 |
2011 |
| Behavioral |
mentoring |
1 |
2009 |
| Biological |
merck’s human papillomavirus quadrivalent (types 6, 11, 16, |
1 |
2009 |
| Biological |
merck’s human papillomavirus quadrivalent (types 6, 11, 16,/18) vaccine (gardasil) |
1 |
2009 |
| Drug |
mesalamine (5-aminosalicylic acid, apriso) |
1 |
2010 |
| Drug |
metformin |
1 |
2012 |
| Drug |
metformin 500 mg q12h |
1 |
2014 |
| Drug |
methotrexate |
1 |
1999 |
| Drug |
metisoprinol |
1 |
2019 |
| Drug |
mexiletine hydrochloride |
1 |
1999 |
| Biological |
mf59 adjuvant |
1 |
2003 |
| Biological |
mf59â® |
1 |
2015 |
| placebo |
mf59â® placebo |
1 |
2015 |
| Behavioral |
mhealth young women’s coop (ywc) |
1 |
2016 |
| Behavioral |
mi |
1 |
2013 |
| Other |
mi-based hiv risk reduction |
1 |
2013 |
| Behavioral |
mi-prep |
1 |
2016 |
| Behavioral |
microenterprise |
1 |
2019 |
| Behavioral |
microfinance |
1 |
2013 |
| Dietary Supplement |
micronutrients |
1 |
2008 |
| Dietary Supplement |
micronutrients/antioxidants |
1 |
2008 |
| Drug |
mid dose |
1 |
2007 |
| Drug |
midazolam 3 mg oral |
1 |
2012 |
| Drug |
midazolam 3 mg oral / gsk1265744 30mg oral |
1 |
2012 |
| Drug |
mifepristone |
1 |
2004 |
| Behavioral |
mindfulness-based stress reduction (mbsr) |
1 |
2006 |
| Dietary Supplement |
minerals |
1 |
2008 |
| Behavioral |
minimal control |
1 |
2010 |
| Drug |
mintoxâ® maximum strength |
1 |
2012 |
| Drug |
mk-0518 |
1 |
2006 |
| Drug |
mk-0518 400mg twice a day |
1 |
2007 |
| Drug |
mk-1439a |
1 |
2015 |
| Device |
mk-2048 ivr |
1 |
2015 |
| Device |
mk-2048a ivr |
1 |
2015 |
| Drug |
mk-2048a ivr (low dose) |
1 |
2015 |
| Drug |
mk-2048a ivr (original dose) |
1 |
2015 |
| Drug |
mk-8527 |
1 |
2018 |
| Drug |
mk0518 |
1 |
2005 |
| Drug |
mk0639, indinavir sulfate |
1 |
2007 |
| Drug |
mk0639, indinavir sulfate / duration of treatment: 48 weeks |
1 |
2007 |
| Drug |
mk0831 |
1 |
2007 |
| Drug |
ml) |
1 |
2007 |
| Drug |
ml) im given once on day 1. |
1 |
2015 |
| Device |
mlab app |
1 |
2018 |
| Biological |
mn rgp120/hiv-1 |
1 |
2001 |
| Biological |
mn rgp120/hiv-1 placebo |
1 |
2001 |
| Behavioral |
mobile app to improve adherence to prep self-management |
1 |
2020 |
| Behavioral |
mobile interactive supervised therapy (mist) |
1 |
2018 |
| Behavioral |
mobile phone application |
1 |
2013 |
| Behavioral |
mobile phone intervention |
1 |
2008 |
| Other |
modified artas (antiretroviral treatment |
1 |
2015 |
| Other |
modified artas (antiretroviral treatment/access to services) intervention |
1 |
2015 |
| Behavioral |
modified directly observed therapy (mdot) |
1 |
2005 |
| Device |
mogen clamp |
1 |
2009 |
| Behavioral |
monitoring by an hiv-trained medical doctor |
1 |
2005 |
| Behavioral |
monitoring by an hiv-trained primary care nurse |
1 |
2005 |
| Behavioral |
monitoring by hiv-trained primary care nurses |
1 |
2004 |
| Drug |
monopi - boosted lopinavir |
1 |
2013 |
| Drug |
monopi - boosted lopinavir/boosted darunavir |
1 |
2013 |
| Drug |
monotherapy (lopinavir |
1 |
2009 |
| Drug |
monotherapy (lopinavir/ritonavir) |
1 |
2009 |
| Drug |
monotherapy (lopinavir/ritonavir) / abc/3tc |
1 |
2009 |
| Biological |
monovalent mrkad5 hiv-1 gag vaccine (1x10^9 vp |
1 |
2009 |
| Biological |
monovalent mrkad5 hiv-1 gag vaccine (1x10^9 vp/dose) |
1 |
2009 |
| Drug |
monthly dihydroartemisinin-piperaquine (dp) |
1 |
2014 |
| Drug |
monthly dihydroartemisinin-piperaquine (dp) / daily trimethoprim/sulfamethoxazole (ts) |
1 |
2014 |
| placebo |
monthly placebo |
1 |
2014 |
| Drug |
monthly placebo / daily trimethoprim/sulfamethoxazole (ts) |
1 |
2014 |
| Biological |
mosaic gp140 |
1 |
2017 |
| Behavioral |
motivational counseling |
1 |
2006 |
| Behavioral |
motivational enhancement therapy (met) intervention |
1 |
2016 |
| Behavioral |
motivational interview |
1 |
2008 |
| Behavioral |
motivational interviewing / cognitive behavioral skills training |
1 |
2010 |
| Behavioral |
motivational interviewing with cognitive behavioral therapy |
1 |
2008 |
| Biological |
mper-656 liposome vaccine |
1 |
2019 |
| Biological |
mpla |
1 |
2018 |
| Biological |
mrk ad5 hiv-1 gag vaccine |
1 |
2004 |
| Biological |
mrkad5 hiv-1 gag/pol/nef placebo |
1 |
2005 |
| Drug |
mulitvitamins |
1 |
2003 |
| Behavioral |
multi-modal delivery |
1 |
2018 |
| Dietary Supplement |
multi-strain probiotic |
1 |
2011 |
| Behavioral |
multidimensional family therapy cross-systems |
1 |
2013 |
| Behavioral |
multidisciplinary palliative care team met with patient |
1 |
2006 |
| Behavioral |
multimedia connect |
1 |
2013 |
| Dietary Supplement |
multiple micronutrients |
1 |
2005 |
| Dietary Supplement |
multivitamins-multiples of rda |
1 |
2005 |
| Dietary Supplement |
multivitamins-single rda |
1 |
2005 |
| Dietary Supplement |
multivitamins/minerals |
1 |
2008 |
| Drug |
mupirocin calcium ointment, 2% |
1 |
2008 |
| Biological |
mva-b |
1 |
2008 |
| Biological |
mva-cmdr vaccine |
1 |
2010 |
| Biological |
mva-cn54 |
1 |
2018 |
| Biological |
mva-mbn120b |
1 |
2008 |
| Biological |
mva-nef |
1 |
2005 |
| Biological |
mva 85a |
1 |
2007 |
| Biological |
mva hiv-b (mvatg17401) |
1 |
2014 |
| Biological |
mva/hiv62 vaccine |
1 |
2009 |
| Biological |
mva/hiv62b vaccine |
1 |
2016 |
| Drug |
mycophenolate mofetil |
1 |
2002 |
| Drug |
mycophenolate mofetil 500mg tab |
1 |
2017 |
| Behavioral |
mydex |
1 |
2016 |
| Behavioral |
mypeeps mobile |
1 |
2017 |
| Behavioral |
n’ap grandi |
1 |
2016 |
| Behavioral |
n’ap grandi - a |
1 |
2016 |
| Drug |
n(t)rtis |
1 |
2018 |
| Drug |
naloxone |
1 |
2011 |
| Drug |
naltrexone |
1 |
2012 |
| Drug |
naphthalene 2-sulfonate polymer |
1 |
2001 |
| Behavioral |
nc doc standard of care for stis |
1 |
2010 |
| Other |
ncm-plus |
1 |
2014 |
| Behavioral |
needs assessment followed by tailored intervention |
1 |
2005 |
| Biological |
nef-rt [tbc-f349]) |
1 |
2005 |
| Biological |
nef-rt [tbc-m335)]) |
1 |
2005 |
| Biological |
nef-rt) |
1 |
2004 |
| placebo |
nef placebo |
1 |
2005 |
| Other |
nef vaccine |
1 |
2009 |
| Biological |
nef vaccine (1x10^11 vp |
1 |
2009 |
| Biological |
nef vaccine (3x10^10 vp |
1 |
2009 |
| Biological |
nef vaccine (3x10^6 vp |
1 |
2009 |
| Biological |
nef vaccine (3x10^7 vp |
1 |
2009 |
| Biological |
nef vaccine (3x10^8 vp |
1 |
2009 |
| Biological |
nef vaccine (3x10^9 vp |
1 |
2009 |
| Biological |
neftat |
1 |
2001 |
| Drug |
nelfinavir (nfv) |
1 |
2004 |
| Drug |
nelfinavir mesylate, 625 mg |
1 |
2005 |
| Drug |
net |
1 |
2014 |
| Behavioral |
network leader training |
1 |
2008 |
| Procedure |
neuropsychological testing |
1 |
2004 |
| Behavioral |
neutral writing |
1 |
2016 |
| Drug |
nevirapine (nvp): antepartum mothers |
1 |
2010 |
| Drug |
nevirapine (nvp): infant extended |
1 |
2010 |
| Drug |
nevirapine (nvp): infant short-course |
1 |
2010 |
| Drug |
nevirapine (viramune) |
1 |
2006 |
| Drug |
nevirapine (viramune): 1 comp (200mg) |
1 |
2006 |
| Drug |
nevirapine (viramune): 1 comp (200mg)/12h |
1 |
2006 |
| Drug |
nevirapine / atazanavir/ritonavir |
1 |
2005 |
| Drug |
nevirapine 200 mg bid |
1 |
2007 |
| Drug |
nevirapine bid |
1 |
2006 |
| Drug |
nevirapine extended release (xr) |
1 |
2009 |
| Behavioral |
nevirapine from twice-a-day to once-a-day |
1 |
2007 |
| Drug |
nevirapine immediate release (ir) |
1 |
2009 |
| Drug |
nevirapine qd |
1 |
2006 |
| Drug |
nevirapine, stavudine, lamivudine |
1 |
2007 |
| Drug |
nevirapine/efavirenz |
1 |
2008 |
| Other |
nevirapine/lamivudine |
1 |
2016 |
| Drug |
nevirapine/mulitvitamins |
1 |
2003 |
| Drug |
nitazoxanide |
1 |
1999 |
| Drug |
nnrti->abc |
1 |
2013 |
| Drug |
nnrti->zdv |
1 |
2013 |
| Drug |
nnrti maintenance |
1 |
2013 |
| Drug |
nnrtis (efv, nvp) |
1 |
2002 |
| Other |
no access to the phr |
1 |
2009 |
| Biological |
no antigen |
1 |
2018 |
| Other |
no antiretroviral drug-free period (no ardfp) vs ardfp |
1 |
2002 |
| Device |
no flip technique of shang ring circumcision |
1 |
2015 |
| Procedure |
no haart |
1 |
2006 |
| Other |
no intervention for both groups |
1 |
2017 |
| Drug |
no intervention; observational study |
1 |
2005 |
| Other |
no participant choice of counselor |
1 |
2013 |
| Other |
no treatment |
1 |
2008 |
| Biological |
non-adjuvanted a(h1n1)v influenza vaccine |
1 |
2009 |
| Behavioral |
non-local |
1 |
2004 |
| Behavioral |
non-local/distant healing/prayer |
1 |
2004 |
| Drug |
non-nucleoside reverse transcriptase inhibitor |
1 |
2007 |
| Drug |
non-nucleoside reverse transcriptase inhibitor (nnrti) |
1 |
2014 |
| Drug |
non-nucleoside reverse transcriptase inhibitor (nrtis) |
1 |
2005 |
| Biological |
non pulsed dendritic cell untreated patients |
1 |
2006 |
| Biological |
non pulsed dendritic cell vaccine |
1 |
2006 |
| Other |
nonadaptive wm cogmed training |
1 |
2015 |
| Drug |
norbuprenorphine |
1 |
2016 |
| Drug |
norgestimate) |
1 |
2006 |
| Dietary Supplement |
normal dose vitamin d |
1 |
2015 |
| Dietary Supplement |
normal dose vitamin d/calcium |
1 |
2015 |
| Drug |
normosol-r |
1 |
2006 |
| Drug |
normosol-r enema |
1 |
2008 |
| Drug |
npep |
1 |
2017 |
| Drug |
nrti |
1 |
2011 |
| Drug |
nrtis (abc, ftc, ftc |
1 |
2002 |
| Drug |
nrtis (abc, ftc, ftc/tdf, 3tc, 3tc/azt, d4t, tdf, ddc, azt) |
1 |
2002 |
| Behavioral |
nthp |
1 |
2016 |
| Other |
nucleic acid amplification testing |
1 |
2011 |
| Drug |
nucleo(side) |
1 |
2009 |
| Drug |
nucleo(side)/(tide) reverse transcriptase inhibitors (nrtis) |
1 |
2009 |
| Drug |
nucleoside |
1 |
2002 |
| Drug |
nucleoside reverse transcriptase inhibitor (nrti) |
1 |
2014 |
| Drug |
nucleoside reverse transcriptase inhibitor (nrtis) |
1 |
2012 |
| Drug |
nucleotide reverse transcriptase inhibitor (nrti) |
1 |
2017 |
| Other |
nurse-led npep |
1 |
2017 |
| Behavioral |
nurse case management |
1 |
2016 |
| Behavioral |
nutrition-related text messaging |
1 |
2008 |
| Behavioral |
nutrition counselling |
1 |
2007 |
| Behavioral |
nutritional |
1 |
2007 |
| Drug |
nvp ir 200 mg (viramuneâ®) |
1 |
2014 |
| Drug |
nvp xr 300 mg (kcr 20%) |
1 |
2014 |
| Drug |
nvp xr 300 mg (kcr 25%) |
1 |
2014 |
| Drug |
nvp xr 400 mg (kcr 20%) |
1 |
2014 |
| Drug |
nvp xr 400 mg (kcr 25%) |
1 |
2014 |
| Drug |
nvp, azt |
1 |
2008 |
| Drug |
nvp, truvada |
1 |
2008 |
| Drug |
nvp/azt |
1 |
2005 |
| Biological |
nyvac |
1 |
2013 |
| Biological |
nyvac-b |
1 |
2009 |
| Biological |
nyvac-c |
1 |
2007 |
| Biological |
nyvac-hiv-pt1 |
1 |
2013 |
| Biological |
nyvac-hiv-pt1 vaccine |
1 |
2013 |
| Biological |
nyvac-hiv-pt4 |
1 |
2013 |
| Biological |
nyvac-hiv-pt4 vaccine |
1 |
2013 |
| Drug |
ofloxacin |
1 |
2002 |
| Drug |
olanzapine |
1 |
2009 |
| Drug |
omega-3-acid ethyl esters 90 |
1 |
2006 |
| Dietary Supplement |
omega-3 fatty acid supplementation with fish oil |
1 |
2015 |
| Dietary Supplement |
omega-3 fatty acid supplementation with fish oil/tlc nutritional intervention. |
1 |
2015 |
| Dietary Supplement |
omega-3 fatty acids |
1 |
2015 |
| Drug |
omeprazole |
1 |
2006 |
| Drug |
once-daily abc |
1 |
2013 |
| Drug |
once-daily abc/3tc |
1 |
2013 |
| Behavioral |
one-way sms intervention group |
1 |
2014 |
| placebo |
one injection of placebo at w0, w4, w8, w20 |
1 |
2005 |
| Biological |
one injection of placebo at w0, w4, w8, w20/at w4, w8,w20 |
1 |
2005 |
| Biological |
one injection of vcp1452 at w0, w4, w8 |
1 |
2005 |
| Biological |
one injection of vcp1452 at w0, w4, w8/w20 |
1 |
2005 |
| Biological |
one injection of vcp1452 at w4, w8 |
1 |
2005 |
| Biological |
one injection of vcp1452 at w4, w8/w20 |
1 |
2005 |
| Drug |
one nucleoside |
1 |
2010 |
| Drug |
ongoing cart regimen |
1 |
2014 |
| Other |
online access to a personal health record |
1 |
2009 |
| Drug |
open label tenofovir tablet |
1 |
2009 |
| Other |
optimized art linkage package |
1 |
2019 |
| Drug |
optimized background arv therapy |
1 |
2008 |
| Drug |
optimized background arvs |
1 |
2004 |
| Drug |
optimized background regimen |
1 |
2007 |
| Drug |
optimized background regimen (obr) |
1 |
2019 |
| Drug |
optimized background therapy (obt) |
1 |
2004 |
| Behavioral |
optimized pitc |
1 |
2017 |
| Drug |
optional switch group) |
1 |
2005 |
| Procedure |
oral biopsy |
1 |
2016 |
| Drug |
oral contraceptive |
1 |
2015 |
| Procedure |
oral exam |
1 |
2004 |
| Procedure |
oral hiv screening |
1 |
2010 |
| Drug |
oral lenacapavir |
1 |
2019 |
| Drug |
oral methamphetamine |
1 |
2019 |
| Drug |
oral rilpivirine (rpv) |
1 |
2018 |
| Drug |
oral rpv |
1 |
2018 |
| Drug |
oral tablets |
1 |
2006 |
| Drug |
oral tdf |
1 |
2017 |
| Drug |
oral tdf/ftc |
1 |
2017 |
| Device |
oraquick fingerstick |
1 |
2016 |
| Diagnostic Test |
oraquick hiv self test - choice |
1 |
2017 |
| Diagnostic Test |
oraquick hiv self test/atomo hiv self test - both |
1 |
2017 |
| Device |
oraquick in home |
1 |
2014 |
| Device |
oraquick in home/sure check hiv tests |
1 |
2014 |
| Device |
oraquick swab |
1 |
2016 |
| Drug |
ortho-cyclen |
1 |
2011 |
| Drug |
ortho cyclen / efavirenz |
1 |
2006 |
| Drug |
ortho evra |
1 |
2005 |
| Drug |
ortho novum 1 |
1 |
2005 |
| Drug |
ortho novum 1/35 |
1 |
2005 |
| Drug |
ortho tri-cyclen (ethinyl estradiol |
1 |
2006 |
| Drug |
ortho tri-cyclen (ethinyl estradiol / norgestimate) |
1 |
2006 |
| Drug |
ortho tri-cyclen lo |
1 |
2006 |
| Drug |
ortho tri-cyclen lo (ethinyl estradiol |
1 |
2006 |
| Drug |
ortho tri-cyclen lo (ethinyl estradiol / norgestimate) / atazanavir/ritonavir for 14 days then ortho tri-cyclen for 7 days |
1 |
2006 |
| Procedure |
osteopathic manipulative treatments |
1 |
2008 |
| Drug |
other anti-retroviral therapy |
1 |
2012 |
| Behavioral |
our family our future |
1 |
2017 |
| Drug |
over-encapsulated efavirenz |
1 |
2010 |
| Behavioral |
own |
1 |
2015 |
| Behavioral |
own adherence |
1 |
2015 |
| Behavioral |
own adherence group |
1 |
2016 |
| Behavioral |
own/group level adherence |
1 |
2015 |
| Drug |
oxazepam |
1 |
1999 |
| Biological |
p24:ty-vlp |
1 |
1999 |
| Biological |
p24ce1/2 pdna vaccine admixed with full-length p55^gag pdna vaccine |
1 |
2018 |
| Drug |
p2g12 |
1 |
2011 |
| Biological |
p55^gag pdna vaccine |
1 |
2017 |
| Combination Product |
package of hiv care |
1 |
2018 |
| Drug |
palifermin |
1 |
2006 |
| placebo |
palifermin placebo |
1 |
2006 |
| Drug |
para-aminohippurate infusion |
1 |
2010 |
| Drug |
para-aminosalicylic acid (pas) |
1 |
2002 |
| Behavioral |
parent support film |
1 |
2019 |
| Other |
participant choice of counselor |
1 |
2013 |
| Behavioral |
paths sexual communication toolkit |
1 |
2019 |
| Other |
patient-centered monitoring |
1 |
2017 |
| Behavioral |
patient experience group chat |
1 |
2017 |
| Behavioral |
patient mentor intervention |
1 |
2010 |
| Drug |
pba (sodium phenylbutyrate) |
1 |
2012 |
| Biological |
pbs |
1 |
2005 |
| Drug |
pc-1005 gel |
1 |
2018 |
| Drug |
pclus 3-18 mn |
1 |
1999 |
| Drug |
pclus 6.1 mn |
1 |
1999 |
| Behavioral |
peer-driven intervention |
1 |
2008 |
| Behavioral |
peer-facilitated community support group |
1 |
2015 |
| Other |
peer-mentors |
1 |
2015 |
| Behavioral |
peer advocates |
1 |
2006 |
| Behavioral |
peer education among commercial sex workers |
1 |
2006 |
| Behavioral |
peer education among commercial sex workers/clients |
1 |
2006 |
| Behavioral |
peer education model |
1 |
2010 |
| Behavioral |
peer health care system navigators |
1 |
2009 |
| Behavioral |
peer health workers |
1 |
2008 |
| Behavioral |
peer health workers intervention |
1 |
2008 |
| Behavioral |
peer health workers/mobile phone intervention |
1 |
2008 |
| Behavioral |
peer hiv education program |
1 |
2002 |
| Behavioral |
peer mentor intervention |
1 |
2005 |
| Behavioral |
peer support/mentoring |
1 |
2009 |
| Other |
peerâ€referral incentive program to increase vmmc uptake |
1 |
2013 |
| Drug |
peg-interferon alpha-2a |
1 |
2016 |
| Drug |
peg-intron |
1 |
2002 |
| Biological |
pegifn alfa-2a |
1 |
2011 |
| Drug |
peginterferon alfa-2a / ribavirin for 12 weeks |
1 |
2006 |
| Drug |
peginterferon alfa-2a, ribavirin, epoetin-î² |
1 |
2006 |
| Drug |
peginterferon alfa2a |
1 |
2005 |
| Biological |
peginterferon alpha-2a (pegasysâ®) |
1 |
2005 |
| Drug |
pegintron |
1 |
2014 |
| Drug |
pegylated-interferon-alfa-2a |
1 |
2012 |
| Drug |
pegylated interferon-alpha (pegasys) |
1 |
2009 |
| Drug |
pegylated interferon-alpha2a |
1 |
2015 |
| Drug |
pegylated interferon alfa-2a / ribavirin |
1 |
2009 |
| Drug |
pegylated interferon alfa-2a/ribavirin |
1 |
2009 |
| Drug |
pegylated interferon alpha-2a |
1 |
2011 |
| Drug |
pegylated interferon alpha 2a |
1 |
2005 |
| Drug |
pegylated interferon alpha 2b (peg-ifn-î±2b) |
1 |
2018 |
| Drug |
pegylated interferon alpha 2b (pegintron) |
1 |
2011 |
| Drug |
peldesine |
1 |
1999 |
| Biological |
pennvax-g dna vaccine |
1 |
2010 |
| Biological |
pennvax b |
1 |
2007 |
| Biological |
pennvaxâ®-gp hiv-1 dna vaccine |
1 |
2015 |
| Drug |
pentasa vs align |
1 |
2018 |
| Drug |
pentoxifylline |
1 |
1999 |
| Drug |
peptide construction 3, synthetic |
1 |
1999 |
| Drug |
peptide t |
1 |
2000 |
| Biological |
peptide vaccine (afo-18) |
1 |
2009 |
| Biological |
peptides on autologous dendritic cells |
1 |
2009 |
| Procedure |
peripheral lymphocyte infusion |
1 |
1999 |
| Behavioral |
personal interview group |
1 |
2008 |
| Other |
pet scan |
1 |
2009 |
| Drug |
pf-04776548 |
1 |
2010 |
| Biological |
pga2/js2 plasmid dna vaccine |
1 |
2002 |
| Biological |
pga2/js7 dna vaccine |
1 |
2009 |
| Biological |
pgdc |
1 |
2018 |
| Biological |
pgdc / conserved hiv peptides |
1 |
2018 |
| Biological |
pgdc / inactivated whole autologous hiv |
1 |
2018 |
| Biological |
pgdc / no antigen |
1 |
2018 |
| Biological |
pgdm1400 / pgt121 (mtd iv) |
1 |
2017 |
| Biological |
pgdm1400 / pgt121 / vrc07-523ls (20mg/kg / 20mg/kg / 20 mg/kg iv) |
1 |
2017 |
| Biological |
pgdm1400 / pgt121/placebo (10mg/kg / 10mg/kg iv) |
1 |
2017 |
| Biological |
pgdm1400 / pgt121/placebo (30mg/kg / 30mg/kg iv) |
1 |
2017 |
| Biological |
pgdm1400 / pgt121/placebo (3mg/kg / 3mg/kg iv) |
1 |
2017 |
| Biological |
pgdm1400/placebo (10mg/kg iv) |
1 |
2017 |
| Biological |
pgdm1400/placebo (30mg/kg iv) |
1 |
2017 |
| Biological |
pgdm1400/placebo (3mg/kg iv) |
1 |
2017 |
| Biological |
pgt121 (mtd iv) |
1 |
2017 |
| Biological |
pgt121 10mg |
1 |
2016 |
| Biological |
pgt121 10mg/kg iv |
1 |
2016 |
| Biological |
pgt121 30mg |
1 |
2016 |
| Biological |
pgt121 30mg/kg iv |
1 |
2016 |
| Biological |
pgt121 3mg |
1 |
2016 |
| Biological |
pgt121 3mg/kg iv |
1 |
2016 |
| Biological |
pgt121 3mg/kg sc |
1 |
2016 |
| Behavioral |
pharmaceutical care |
1 |
2009 |
| Procedure |
pharmacokinetic sampling |
1 |
2007 |
| Procedure |
pharmacokinetic study |
1 |
2005 |
| Drug |
phenytoin |
1 |
2010 |
| Other |
phi-patients |
1 |
2009 |
| Behavioral |
physical activity |
1 |
2017 |
| Behavioral |
physical activity attention control |
1 |
2017 |
| Other |
physician management |
1 |
2006 |
| Drug |
physiological saline |
1 |
2009 |
| Drug |
pis (amp, idv, lpv |
1 |
2002 |
| Drug |
pis (amp, idv, lpv/r, nfv, sqv, rtv) |
1 |
2002 |
| placebo |
placebo (0.9% sodium chloride injection usp (saline)) |
1 |
2016 |
| placebo |
placebo (10mg |
1 |
2017 |
| placebo |
placebo (30mg |
1 |
2017 |
| placebo |
placebo (3mg |
1 |
2017 |
| placebo |
placebo (nacl 0.9%) vaccine group |
1 |
2016 |
| placebo |
placebo (saline) |
1 |
2010 |
| placebo |
placebo (universal hec placebo) |
1 |
2007 |
| placebo |
placebo for aidsvax(r) b |
1 |
2013 |
| Biological |
placebo for aidsvax(r) b/e |
1 |
2013 |
| placebo |
placebo for alvac-hiv |
1 |
2013 |
| placebo |
placebo for arabinoxylan rice bran |
1 |
2016 |
| placebo |
placebo for bms-936559 |
1 |
2014 |
| placebo |
placebo for dna |
1 |
2013 |
| placebo |
placebo for dna-hiv-pt123 |
1 |
2014 |
| placebo |
placebo for dna-hiv-pt123 vaccine |
1 |
2013 |
| placebo |
placebo for dna con-s env |
1 |
2014 |
| placebo |
placebo for dna mosaic env |
1 |
2014 |
| placebo |
placebo for dna nat-b env |
1 |
2014 |
| Biological |
placebo for dna/nyvac |
1 |
2013 |
| placebo |
placebo for dolutegravir (dtg) |
1 |
2015 |
| placebo |
placebo for doravirine |
1 |
2012 |
| placebo |
placebo for efavirenz |
1 |
2012 |
| placebo |
placebo for gsk1265744 tablets |
1 |
2014 |
| placebo |
placebo for gsk2838232 tablets |
1 |
2017 |
| placebo |
placebo for hepatitis b vaccine |
1 |
2013 |
| placebo |
placebo for km-023 |
1 |
2011 |
| placebo |
placebo for maraviroc (mvc) |
1 |
2015 |
| placebo |
placebo for mper-656 liposome vaccine |
1 |
2019 |
| placebo |
placebo for mva-cmdr |
1 |
2014 |
| placebo |
placebo for nyvac-hiv-pt1 vaccine |
1 |
2013 |
| placebo |
placebo for nyvac-hiv-pt4 vaccine |
1 |
2013 |
| placebo |
placebo for oral cab |
1 |
2017 |
| placebo |
placebo for oral tdf |
1 |
2017 |
| Drug |
placebo for oral tdf/ftc |
1 |
2017 |
| placebo |
placebo for romidepsin |
1 |
2013 |
| placebo |
placebo for tetanus vaccine |
1 |
2013 |
| placebo |
placebo for vgx-410 (mifepristone) |
1 |
2006 |
| placebo |
placebo injection |
1 |
2014 |
| placebo |
placebo injection (normal saline) |
1 |
2011 |
| placebo |
placebo intravaginal ring |
1 |
2007 |
| placebo |
placebo matching gsk3640254 mesylate salt |
1 |
2018 |
| placebo |
placebo matching with bms-955176 |
1 |
2013 |
| placebo |
placebo monotherapy |
1 |
2004 |
| placebo |
placebo mva-cmdr vaccine |
1 |
2010 |
| placebo |
placebo of curcumin |
1 |
2017 |
| placebo |
placebo ointment |
1 |
2008 |
| placebo |
placebo pennvax-g vaccine |
1 |
2010 |
| placebo |
placebo pib |
1 |
2016 |
| placebo |
placebo tablet |
1 |
2014 |
| placebo |
placebo tablets |
1 |
2012 |
| placebo |
placebo to bic |
1 |
2020 |
| Drug |
placebo to bic/ftc/taf |
1 |
2020 |
| placebo |
placebo to fdc dor |
1 |
2020 |
| Drug |
placebo to fdc dor/isl |
1 |
2020 |
| placebo |
placebo to match injectable suspension |
1 |
2011 |
| placebo |
placebo to raltegravir |
1 |
2014 |
| placebo |
placebo to reformulated raltegravir |
1 |
2014 |
| placebo |
placebo to the child |
1 |
2006 |
| placebo |
placebo version of rgp120 |
1 |
1999 |
| Biological |
placebo version of rgp120/hiv-1mn |
1 |
1999 |
| Biological |
placebo version of rgp120/hiv-1sf2 |
1 |
1999 |
| placebo |
placebo with peg-inf |
1 |
2016 |
| placebo |
placebo, then dipyridamole |
1 |
2014 |
| Behavioral |
planning prompts |
1 |
2019 |
| Device |
plastibell |
1 |
2009 |
| Behavioral |
plasticity-based adaptive cognitive remediation (pacr) |
1 |
2015 |
| Biological |
plg |
1 |
2003 |
| Biological |
plg microparticles |
1 |
2003 |
| Dietary Supplement |
pmt25341 |
1 |
2016 |
| Biological |
pneumococcal 7-valent conjugate vaccine |
1 |
2005 |
| Biological |
pneumococcal conjugate vaccine, heptavalent |
1 |
2002 |
| Biological |
pneumococcal polysaccharide vaccine |
1 |
2005 |
| Biological |
pneumococcal vaccine, polyvalent (23-valent) |
1 |
2002 |
| Biological |
pneumococcal vaccines |
1 |
2007 |
| Biological |
pneumococcal vaccines / cpg 7909 |
1 |
2007 |
| Biological |
pneumovaxâ„¢23 |
1 |
2019 |
| Procedure |
poc (point-of-care) cd4 |
1 |
2013 |
| Procedure |
poc (point-of-care) cd4/ (cluster of differentiation 4) count |
1 |
2013 |
| Diagnostic Test |
poc vl |
1 |
2019 |
| Diagnostic Test |
poc vl/targeted drm testing. |
1 |
2019 |
| Device |
point-of-care (poc) viral load (vl) testing |
1 |
2019 |
| Device |
point-of-care (poc) viral load (vl) testing/refresher training |
1 |
2019 |
| Diagnostic Test |
point-of-care viral load testing |
1 |
2017 |
| Device |
point of care hiv rna pcr |
1 |
2011 |
| Drug |
poly i-poly c12u |
1 |
2002 |
| Biological |
polyenv1 |
1 |
2003 |
| Biological |
polyenv1 vaccine |
1 |
2005 |
| Behavioral |
popular opinion leader |
1 |
2005 |
| Behavioral |
popular opinion leader (pol) |
1 |
2008 |
| Drug |
portia |
1 |
2019 |
| Behavioral |
positive choice |
1 |
2007 |
| Behavioral |
positive steps |
1 |
2011 |
| Behavioral |
positively smoke free |
1 |
2010 |
| Behavioral |
post-release (group 2) |
1 |
2009 |
| Behavioral |
post-test counseling |
1 |
1999 |
| Procedure |
postpartum hiv counseling |
1 |
2004 |
| Procedure |
postpartum hiv counseling/testing |
1 |
2004 |
| Drug |
pravastatin sodium |
1 |
1999 |
| Drug |
pravastatin/raltegravir |
1 |
2008 |
| Behavioral |
prayer |
1 |
2004 |
| Behavioral |
pre- |
1 |
1999 |
| Behavioral |
pre-/post-test counseling |
1 |
1999 |
| Behavioral |
pre-release (group 1) |
1 |
2009 |
| Drug |
pre-study antiretroviral regimen |
1 |
2008 |
| Dietary Supplement |
prebiotics |
1 |
2013 |
| Dietary Supplement |
prebiotics/glutamine |
1 |
2013 |
| Drug |
pregabalin |
1 |
2005 |
| Drug |
prep |
1 |
2017 |
| Behavioral |
prep information (active control) |
1 |
2014 |
| Other |
prep promotion package |
1 |
2017 |
| Drug |
prep with truvadaâ® |
1 |
2017 |
| Device |
prepexâ„¢ device |
1 |
2012 |
| Drug |
pretomanid |
1 |
2002 |
| Behavioral |
preventing aids through live movement |
1 |
2005 |
| Behavioral |
preventing aids through live movement/sound (palms) |
1 |
2005 |
| Behavioral |
prevention empowerment intervention for young women |
1 |
2009 |
| Behavioral |
prevention for positives component: counseling |
1 |
2010 |
| Behavioral |
prevention for positives component: counseling/soc |
1 |
2010 |
| Behavioral |
prevention for positives component: soc |
1 |
2010 |
| Behavioral |
prevention package |
1 |
2013 |
| Biological |
prevnar-13 |
1 |
2018 |
| Biological |
prevnar 13â„¢ |
1 |
2019 |
| Drug |
prezista |
1 |
2015 |
| Behavioral |
pride |
1 |
2017 |
| Behavioral |
printed materials |
1 |
2006 |
| Drug |
pro 140 |
1 |
2005 |
| Drug |
pro 140 sc injections |
1 |
2016 |
| Drug |
pro 2000/5 |
1 |
2005 |
| Drug |
pro 2000/5 gel |
1 |
2003 |
| Drug |
pro 2000/5 gel (p) |
1 |
2004 |
| Dietary Supplement |
probiotic compound |
1 |
2015 |
| Behavioral |
problem solving counseling |
1 |
2005 |
| Drug |
procysteine |
1 |
1999 |
| Biological |
profectus hiv mag pdna vaccine |
1 |
2010 |
| Behavioral |
progressive resistance |
1 |
2005 |
| Behavioral |
progressive resistance exercise training |
1 |
2007 |
| Behavioral |
progressive resistance/aerobic training |
1 |
2005 |
| Behavioral |
project able |
1 |
2008 |
| Behavioral |
project adhere |
1 |
2017 |
| Behavioral |
project enhance |
1 |
2005 |
| Behavioral |
project icare |
1 |
2008 |
| Behavioral |
project jumpstart |
1 |
2019 |
| Behavioral |
project khanya |
1 |
2018 |
| Behavioral |
project power hiv risk-reduction intervention |
1 |
2010 |
| Behavioral |
project pride |
1 |
2018 |
| Behavioral |
project trac: tracking |
1 |
2018 |
| Behavioral |
project trac: tracking/reducing alcohol consumption |
1 |
2018 |
| Drug |
proleukin |
1 |
2001 |
| Behavioral |
promotion of adherence to arv medications |
1 |
2003 |
| Drug |
prophylaxis of opportunistic infections |
1 |
2007 |
| Drug |
prophylaxis of opportunistic infections/support treatment |
1 |
2007 |
| Drug |
protease inhibitor tipranavir |
1 |
2002 |
| Drug |
protease inhibitors (pis) |
1 |
2005 |
| Biological |
protein |
1 |
2016 |
| Biological |
protein/mf59 vaccine |
1 |
2016 |
| Drug |
prothionamide |
1 |
2002 |
| Other |
provided by community pharmacists |
1 |
2017 |
| Behavioral |
provider visit incentive (pvi) |
1 |
2011 |
| Behavioral |
provision of hiv self-test |
1 |
2019 |
| Behavioral |
provision of hiv self-test with commitment |
1 |
2019 |
| Behavioral |
provision of hiv self-test with commitment/planning prompts |
1 |
2019 |
| Behavioral |
provision of multiple self-tests |
1 |
2017 |
| Behavioral |
proyecto sol |
1 |
2008 |
| Biological |
pulsed dendritic cell vaccine |
1 |
2006 |
| Drug |
pyridostigmine |
1 |
2016 |
| Drug |
pyridostigmine tablets |
1 |
2007 |
| Biological |
quadrivalent live attenuated influenza vaccine |
1 |
2015 |
| Other |
qualitative interview |
1 |
2019 |
| Other |
quality-of-life assessment |
1 |
2018 |
| Device |
quantiferon tb gold in-tube |
1 |
2008 |
| Other |
questionnaire administration |
1 |
2018 |
| Other |
questionnaires by outreaching methodology |
1 |
2020 |
| Drug |
quinine sulfate |
1 |
1999 |
| Behavioral |
quit |
1 |
2019 |
| Drug |
r-chop |
1 |
2007 |
| Drug |
r-containing haart. |
1 |
2013 |
| Drug |
r (drug) |
1 |
2005 |
| Drug |
r monotherapy (kaletra) |
1 |
2009 |
| Drug |
r qd |
1 |
2010 |
| Drug |
r twice a day |
1 |
2010 |
| Drug |
r) (tablet |
1 |
2005 |
| Drug |
r) tablet with nucleoside |
1 |
2006 |
| Drug |
r, nfv, sqv, rtv) |
1 |
2002 |
| Biological |
rabies de novo antigen |
1 |
2005 |
| Biological |
rabies vaccine |
1 |
2002 |
| Drug |
racivir |
1 |
2002 |
| Drug |
racivir, a non-nucleoside reverse transcriptase inhibitor |
1 |
2005 |
| Biological |
rad35 |
1 |
2008 |
| Biological |
rad35 env a |
1 |
2010 |
| placebo |
rad35 placebo |
1 |
2008 |
| Biological |
rad5 env c |
1 |
2011 |
| Biological |
rad5 gag-pol env a |
1 |
2010 |
| Biological |
rad5 gag-pol env a/b/c |
1 |
2010 |
| placebo |
rad5 placebo |
1 |
2008 |
| Biological |
radiolabeled autologous seminal fluid |
1 |
2010 |
| Biological |
radiolabeled normosol-r |
1 |
2010 |
| placebo |
ral placebo |
1 |
2008 |
| Drug |
raltegravir (isentress) |
1 |
2010 |
| Drug |
raltegravir (isentressâ„¢) |
1 |
2013 |
| Drug |
raltegravir (mk-0518) |
1 |
2007 |
| Drug |
raltegravir (mk0518) |
1 |
2007 |
| Drug |
raltegravir / truvada |
1 |
2008 |
| Drug |
raltegravir 1200 mg |
1 |
2015 |
| Drug |
raltegravir 400 mg/12hours |
1 |
2011 |
| Drug |
raltegravir bid |
1 |
2010 |
| Drug |
raltegravir film-coated tablet |
1 |
2012 |
| Drug |
raltegravir in combination with 2 nrtis (dual nucleoside reverse transcriptase inhibitor) |
1 |
2009 |
| Drug |
raltegravir oral granules for suspension (20 mg |
1 |
2007 |
| Drug |
raltegravir oral granules for suspension (20 mg/ml) |
1 |
2007 |
| Drug |
raltegravir poloxamer film coated tablet |
1 |
2007 |
| Drug |
raltegravir qd |
1 |
2009 |
| Drug |
raltegravir single dose |
1 |
2010 |
| Drug |
raltegravir switch |
1 |
2012 |
| Drug |
raltegravir, darunavir |
1 |
2011 |
| Drug |
raltegravir, darunavir/r |
1 |
2011 |
| Drug |
raltegravir. |
1 |
2008 |
| Drug |
raltegravir/2 nucleoside/nucleotide reverse transcriptase inhibitor (nrti) |
1 |
2017 |
| Drug |
raltegravir/darunavir/ritonavir |
1 |
2010 |
| Drug |
raltegravir/emtricitabine/tenofovir |
1 |
2008 |
| Drug |
raltegravir/hyper-immune bovine colostrum |
1 |
2008 |
| Drug |
raltegravir/lopinavir/ritonavir |
1 |
2008 |
| Drug |
raltegravir/maraviroc in combination |
1 |
2010 |
| Drug |
raltegravir/truvada |
1 |
2008 |
| Drug |
raltegravir; maraviroc; darunavir; ritonavir; tenofovir |
1 |
2009 |
| Drug |
raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine |
1 |
2009 |
| Drug |
raluridine |
1 |
1999 |
| Behavioral |
ramp prep initiation, adherence, |
1 |
2017 |
| Behavioral |
ramp prep initiation, adherence,/retention intervention |
1 |
2017 |
| Diagnostic Test |
rapid hiv test |
1 |
2017 |
| Diagnostic Test |
rapid testing |
1 |
2019 |
| Behavioral |
rbt |
1 |
2011 |
| Biological |
rc529-se |
1 |
2005 |
| Drug |
rdea806 1000 mg |
1 |
2008 |
| Drug |
rdea806 400 mg |
1 |
2008 |
| Drug |
rdea806 600 mg |
1 |
2008 |
| Drug |
rdea806 800 mg |
1 |
2008 |
| Dietary Supplement |
ready to use supplementary food |
1 |
2013 |
| Behavioral |
reality check |
1 |
2017 |
| Biological |
recombinant fowlpox vector |
1 |
2003 |
| Biological |
recombinant hiv-1 tat protein |
1 |
2007 |
| Biological |
recombinant human growth hormone |
1 |
2006 |
| Drug |
recombinant human interleukin-7 |
1 |
2004 |
| Drug |
recombinant interleukin-2 |
1 |
2017 |
| Drug |
recombinant lactoferrin |
1 |
2013 |
| Biological |
recombivax |
1 |
2005 |
| Other |
recommended standard of care |
1 |
2007 |
| Behavioral |
recovery management |
1 |
2011 |
| Other |
recto-colic biopsies |
1 |
2013 |
| Other |
reduced number of pills |
1 |
2009 |
| Behavioral |
reducing alcohol consumption |
1 |
2018 |
| Behavioral |
reducing the risk |
1 |
2009 |
| Behavioral |
reengagement |
1 |
2019 |
| Behavioral |
reengagement/assessment mobile program |
1 |
2019 |
| Behavioral |
referral of partners |
1 |
2009 |
| Behavioral |
referral to care |
1 |
2017 |
| Drug |
reformulated raltegravir |
1 |
2014 |
| Procedure |
reiki; subtle energy therapy |
1 |
2002 |
| Behavioral |
reinitiation schedule |
1 |
2003 |
| Behavioral |
relapse prevention text messaging |
1 |
2019 |
| Behavioral |
reminders |
1 |
2018 |
| Behavioral |
remote delivery |
1 |
2018 |
| Biological |
remune |
1 |
2005 |
| Biological |
remune/alvac |
1 |
2005 |
| Drug |
repatha (evolocumab) |
1 |
2016 |
| Behavioral |
retention intervention |
1 |
2017 |
| Device |
reveal g4 |
1 |
2014 |
| Behavioral |
rewards for testing hiv-negative |
1 |
2017 |
| Drug |
reyataz / epzicom |
1 |
2010 |
| Drug |
reyataz / norvir / truvada |
1 |
2010 |
| Biological |
rfpv-hiv (env |
1 |
2005 |
| Biological |
rfpv-hiv (env/gag [tbc-f357] / tat/rev/nef-rt [tbc-f349]) |
1 |
2005 |
| Biological |
rfpv-hiv (rfpv-hiv env |
1 |
2004 |
| Biological |
rfpv-hiv (rfpv-hiv env/gag / rfpv-hiv tat/rev/nef-rt) |
1 |
2004 |
| Biological |
rfpv-hiv tat |
1 |
2004 |
| Drug |
ribavirin (copegus) |
1 |
2009 |
| Drug |
ribavirin for 12 weeks |
1 |
2006 |
| Dietary Supplement |
rice bran arabinoxylan compound (rbac) |
1 |
2014 |
| Drug |
rif |
1 |
2015 |
| Drug |
rifabutin in combination with efavirenz |
1 |
2008 |
| Drug |
rifabutin in combination with lopinavir |
1 |
2008 |
| Drug |
rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1 |
1 |
2008 |
| Drug |
rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2 |
1 |
2008 |
| Drug |
rifabutin in combination with lopinavir/ritonavir |
1 |
2008 |
| Drug |
rifabutin in combination with nevirapine |
1 |
2008 |
| Drug |
rifampicin |
1 |
2002 |
| Drug |
rifampicin 600 mg |
1 |
2013 |
| Drug |
rifapentine (rpt) |
1 |
2019 |
| Drug |
rillusâ® |
1 |
2018 |
| Drug |
rilpivirine (rpv) |
1 |
2015 |
| Drug |
rilpivirine injectable suspension |
1 |
2017 |
| Drug |
rilpivirine long-acting parenteral formulation (rpvâ€la) |
1 |
2015 |
| Drug |
rilpivirine tablets |
1 |
2017 |
| Drug |
rilpivirine) 50mg |
1 |
2019 |
| Behavioral |
risk-reduction counseling |
1 |
1999 |
| Drug |
ritonavir-boosted atazanavir |
1 |
2005 |
| Drug |
ritonavir-boosted fosamprenavir |
1 |
2005 |
| Drug |
ritonavir-boosted lopinavir |
1 |
2009 |
| Drug |
ritonavir ( |
1 |
2007 |
| Drug |
ritonavir (aluvia) |
1 |
2007 |
| Drug |
ritonavir (dose reduction) |
1 |
2008 |
| Drug |
ritonavir (drv |
1 |
2011 |
| Drug |
ritonavir (kaletraâ®) |
1 |
2007 |
| Drug |
ritonavir (kaletraâ®) tablets |
1 |
2008 |
| Drug |
ritonavir (nrv) |
1 |
2005 |
| Drug |
ritonavir (rtv) 100 mg |
1 |
2009 |
| Drug |
ritonavir (second line strategy under evaluation) |
1 |
2009 |
| Drug |
ritonavir (who recommended second line) |
1 |
2009 |
| Drug |
ritonavir : 2 capsules (500 mg) |
1 |
2006 |
| Drug |
ritonavir 100 mg once a day |
1 |
2008 |
| Drug |
ritonavir 100 mg once daily |
1 |
2009 |
| Drug |
ritonavir 100 mg oral tablet |
1 |
2018 |
| Drug |
ritonavir 100 mg tablets |
1 |
2017 |
| Drug |
ritonavir 100 mg twice daily |
1 |
2009 |
| Drug |
ritonavir 100mg |
1 |
2010 |
| Drug |
ritonavir 100mg oad |
1 |
2011 |
| Drug |
ritonavir 100mg twice day |
1 |
2008 |
| Drug |
ritonavir 4:1 |
1 |
2014 |
| Drug |
ritonavir boosted atazanavir |
1 |
2011 |
| Drug |
ritonavir boosted atazanavir / 2 nrtis |
1 |
2011 |
| Drug |
ritonavir boosted atazanavir / lamivudine |
1 |
2011 |
| Drug |
ritonavir capsules |
1 |
2010 |
| Drug |
ritonavir drug interaction |
1 |
2008 |
| Drug |
ritonavir for 14 days then ortho tri-cyclen for 7 days |
1 |
2006 |
| Drug |
ritonavir high dose |
1 |
2014 |
| Drug |
ritonavir low dose |
1 |
2014 |
| Drug |
ritonavir low dose ( 70% of who recommended dosing table) |
1 |
2009 |
| Drug |
ritonavir monotherapy |
1 |
2005 |
| Drug |
ritonavir oral solution |
1 |
2010 |
| Drug |
ritonavir qd |
1 |
2010 |
| Drug |
ritonavir simplification strategy |
1 |
2005 |
| Drug |
ritonavir standard dose according to who simplified dosing table |
1 |
2009 |
| Drug |
ritonavir then atazanavir |
1 |
2010 |
| Drug |
ritonavir with 2 nucleoside rtis |
1 |
2005 |
| Drug |
ritonavir with two nucleoside analogs |
1 |
2009 |
| Drug |
ritonavir withdrawal, atazanavir 200 mg |
1 |
2012 |
| Drug |
ritonavir withdrawal, atazanavir 200 mg/12h |
1 |
2012 |
| Drug |
ritonavir(r) |
1 |
2003 |
| Drug |
ritonavir), african potato (hypoxis obtusa) |
1 |
2010 |
| Drug |
ritonavir/saquinavir |
1 |
2008 |
| Drug |
rivastigmine |
1 |
2011 |
| Drug |
rlipivirine |
1 |
2011 |
| Biological |
rmva-hiv (env |
1 |
2005 |
| Biological |
rmva-hiv (env/gag [tbc-m358] / tat/rev/nef-rt [tbc-m335)]) |
1 |
2005 |
| Biological |
rmva-hiv (rmva-hiv env |
1 |
2004 |
| Biological |
rmva-hiv (rmva-hiv env/gag / rmva-hiv tat/rev/nef-rt) |
1 |
2004 |
| Biological |
rmva-hiv tat |
1 |
2004 |
| Drug |
ro 24-7429 |
1 |
1999 |
| Drug |
rosiglitazone |
1 |
2002 |
| Drug |
rosiglitazone maleate |
1 |
2006 |
| Other |
routine hiv testing |
1 |
2008 |
| Behavioral |
routine referral to care |
1 |
2008 |
| Drug |
routine three-drug antiretroviral prophylaxis |
1 |
2008 |
| Drug |
rpv-la loading dose |
1 |
2018 |
| Drug |
rpv-la maintenance dose |
1 |
2018 |
| Drug |
rpv / drv/r |
1 |
2013 |
| Drug |
rpv 50 mg |
1 |
2015 |
| Drug |
rpv fdc |
1 |
2016 |
| Drug |
rtv 100mg tab |
1 |
2010 |
| Drug |
rtv oral solution |
1 |
2004 |
| Biological |
rubella virus vaccine, live |
1 |
2005 |
| Drug |
ruxolitinib |
1 |
2015 |
| Biological |
rvsv hiv envc vaccine |
1 |
2016 |
| Biological |
saavi dna-c2 vaccine |
1 |
2007 |
| Biological |
saavi mva-c vaccine |
1 |
2007 |
| Drug |
saccharomyces boulardii |
1 |
1999 |
| Other |
safer conception strategies |
1 |
2018 |
| Behavioral |
safer sex skills building (ssb) |
1 |
2008 |
| Biological |
salmonella typhi cvd 908-hiv-1 lai gp 120 (vvg 203) |
1 |
1999 |
| Drug |
salvage antiretroviral therapy including raltegravir |
1 |
2008 |
| Procedure |
salvage therapy |
1 |
2007 |
| Other |
same-day art initiation |
1 |
2016 |
| Drug |
saquinavir (inviraseâ®) |
1 |
2007 |
| Drug |
saquinavir 500 formulation |
1 |
2005 |
| Drug |
saquinavir mesylate |
1 |
2002 |
| Drug |
saquinavir, lopinavir, ritonavir |
1 |
2006 |
| Drug |
saquinavir/ritonavir : 2 capsules (500 mg) / 12 hours |
1 |
2006 |
| Biological |
sav001-h |
1 |
2009 |
| Genetic |
sb-728mr-t |
1 |
2014 |
| Behavioral |
sbirt |
1 |
2012 |
| placebo |
sc placebo for vrc01 |
1 |
2014 |
| Drug |
sch-d (vicriviroc) |
1 |
2004 |
| Behavioral |
screening for stis |
1 |
2009 |
| Behavioral |
screening for stis/counseling |
1 |
2009 |
| Behavioral |
screening interview |
1 |
2016 |
| Drug |
seasonal trivalent inactivated influenza vaccine (vaxigripâ®) |
1 |
2013 |
| Other |
seaweed, spirulina, seaweed |
1 |
2010 |
| Other |
seaweed, spirulina, seaweed / spirulina |
1 |
2010 |
| Dietary Supplement |
selenium |
1 |
2005 |
| Behavioral |
self-acceptance based intervention |
1 |
2015 |
| Behavioral |
self-administrated questionnaire |
1 |
2018 |
| Other |
self-collected hpv test |
1 |
2013 |
| Behavioral |
self-help materials |
1 |
2016 |
| Diagnostic Test |
self-testing education |
1 |
2019 |
| Diagnostic Test |
self-testing education/promotion |
1 |
2019 |
| Biological |
semen sampling, specific biological exams |
1 |
2011 |
| Diagnostic Test |
serology hiv |
1 |
2019 |
| Biological |
serostim |
1 |
2010 |
| Biological |
sev-g(np) (0.2ml, 2x10^7 ciu) |
1 |
2012 |
| Biological |
sev-g(np) (0.2ml, 2x10^8 ciu) |
1 |
2012 |
| Behavioral |
sexual health [wash] |
1 |
2017 |
| Behavioral |
sexual health counseling |
1 |
2014 |
| Behavioral |
sexual risk intervention |
1 |
2009 |
| Other |
sham acupuncture |
1 |
2007 |
| Device |
shang ring |
1 |
2015 |
| Device |
shang ring circumcision |
1 |
2009 |
| Procedure |
short cycle antiretroviral therapy |
1 |
2003 |
| Behavioral |
short message services to support arv therapy adherence |
1 |
2010 |
| Biological |
shrna-modified cd34 |
1 |
2018 |
| Biological |
shrna-modified cd34/ cells |
1 |
2018 |
| Procedure |
sigmoid biopsy |
1 |
2007 |
| Combination Product |
silicone elastomer vaginal ring |
1 |
2012 |
| Drug |
silymarin (milk thistle) |
1 |
2001 |
| Procedure |
simplified follow-up approach of arv treatment |
1 |
2006 |
| Behavioral |
single care-related counseling session |
1 |
2017 |
| Behavioral |
single care-related counseling session/referral to care |
1 |
2017 |
| Drug |
single dose nevirapine |
1 |
2004 |
| Drug |
single dose nevirapine to the mother |
1 |
2006 |
| Drug |
single dose nevirapine to the mother/placebo to the child |
1 |
2006 |
| Drug |
single dose nevirapine to the mother/to the child |
1 |
2006 |
| Drug |
single dose of genvoyaâ® |
1 |
2018 |
| Drug |
single dose of genvoyaâ®/a single 800 mg dose of darunavirâ® |
1 |
2018 |
| placebo |
single dose placebo to the mother |
1 |
2006 |
| Drug |
single dose placebo to the mother/to the child |
1 |
2006 |
| Behavioral |
single group workshop on coping effectiveness training |
1 |
2008 |
| Drug |
sitamaquine |
1 |
1999 |
| Behavioral |
skills-building intervention |
1 |
2008 |
| Behavioral |
skills building |
1 |
2008 |
| Behavioral |
skills building with motivational interviewing |
1 |
2008 |
| Behavioral |
skillz-girl enhanced football curriculum |
1 |
2020 |
| Device |
skyn monitor field test with ema app |
1 |
2018 |
| Device |
skyn monitor lab session 1 |
1 |
2018 |
| Device |
skyn monitor lab session 2 |
1 |
2018 |
| Behavioral |
smartbrain |
1 |
2008 |
| Device |
smartphone |
1 |
2016 |
| Other |
smartphone application |
1 |
2016 |
| Behavioral |
sms |
1 |
2018 |
| Other |
smz prophylaxis |
1 |
2011 |
| Behavioral |
soc |
1 |
2010 |
| Behavioral |
soccer league |
1 |
2014 |
| Behavioral |
soccer league (sl) |
1 |
2014 |
| Behavioral |
soccer league/vocational training (sl-v) |
1 |
2014 |
| Behavioral |
social capital intervention |
1 |
2018 |
| Behavioral |
social marketing video |
1 |
2015 |
| Behavioral |
social media platform |
1 |
2016 |
| Behavioral |
social network-based adherence intervention |
1 |
2016 |
| Behavioral |
social network leader endorsement |
1 |
2015 |
| Behavioral |
social network training |
1 |
2017 |
| Other |
sodium chloride |
1 |
2011 |
| Other |
sodium chloride for injection usp, 0.9% |
1 |
2016 |
| Biological |
sodium chloride injection (0.9%) |
1 |
2005 |
| Drug |
sof/vel |
1 |
2015 |
| Drug |
sof/vel for 12 weeks |
1 |
2015 |
| Drug |
sof/vel for 6 weeks |
1 |
2015 |
| Drug |
sofosbuvir/daclatasvir |
1 |
2017 |
| Drug |
sofosbuvir/ledipasvir fixed dose |
1 |
2014 |
| Drug |
sofosbuvir/velpatasvir |
1 |
2017 |
| Behavioral |
solve-it |
1 |
2008 |
| Drug |
somatotropin (human) |
1 |
2017 |
| Drug |
somatropin |
1 |
2002 |
| Drug |
somatropin (recombinant human growth hormone) |
1 |
2003 |
| Drug |
sorbitol |
1 |
2015 |
| Behavioral |
sound (palms) |
1 |
2005 |
| Other |
south african recommendation guided arv (tdf |
1 |
2011 |
| Other |
south african recommendation guided arv (tdf/ftc/efv) initiation |
1 |
2011 |
| Dietary Supplement |
soy biscuit |
1 |
2007 |
| Other |
soy pretzel |
1 |
2016 |
| Drug |
sp01a |
1 |
2006 |
| Other |
spanish brief computer risk assessment session |
1 |
2009 |
| Other |
spanish computer counseling session |
1 |
2009 |
| Behavioral |
spiritual growth group |
1 |
2002 |
| Drug |
spironolactone |
1 |
2020 |
| Other |
spirulina |
1 |
2010 |
| Biological |
srl-172 |
1 |
2003 |
| Biological |
stable ch505tf gp120 |
1 |
2019 |
| Drug |
stable haart |
1 |
2007 |
| Behavioral |
staff-delivered intervention sessions |
1 |
2014 |
| Behavioral |
stage based counseling |
1 |
2007 |
| Behavioral |
stand hiv risk reduction intervention |
1 |
2015 |
| Other |
standard (static) computer alerts |
1 |
2008 |
| Behavioral |
standard adherence counselling |
1 |
2017 |
| Behavioral |
standard adherence counselling/patient experience group chat |
1 |
2017 |
| Behavioral |
standard adherence support |
1 |
2006 |
| Drug |
standard art vs mega art |
1 |
2002 |
| Behavioral |
standard care with healthy living |
1 |
2007 |
| Behavioral |
standard clinic-based vct |
1 |
2005 |
| Procedure |
standard follow-up approach of arv treatment |
1 |
2006 |
| Combination Product |
standard hiv care |
1 |
2018 |
| Behavioral |
standard hiv risk-reduction counseling |
1 |
2008 |
| Behavioral |
standard hiv testing |
1 |
2010 |
| Behavioral |
standard hiv testing with information only |
1 |
2011 |
| Behavioral |
standard hiv testing/counseling |
1 |
2010 |
| Behavioral |
standard htc |
1 |
2016 |
| Behavioral |
standard medication adherence counseling |
1 |
2010 |
| Behavioral |
standard of care - control arm |
1 |
2012 |
| Behavioral |
standard of care adherence support (active control) |
1 |
2014 |
| Other |
standard of care central laboratory vl testing |
1 |
2019 |
| Other |
standard of care central laboratory vl testing/refresher training |
1 |
2019 |
| Behavioral |
standard prevention case management (pcm) |
1 |
2005 |
| Device |
standard public health text |
1 |
2008 |
| Other |
standard screening tests |
1 |
2016 |
| Other |
standard treatment regimen |
1 |
2008 |
| Behavioral |
standard versus enhanced risk reduction counseling |
1 |
2007 |
| Drug |
stavidine |
1 |
2004 |
| Drug |
stavudine (d4t), lamivudine (3tc), nevirapine (nvp) |
1 |
2008 |
| Drug |
stavudine extended-release, lamivudine, efavirenz |
1 |
2005 |
| Drug |
stavudine fixed-dose tablet |
1 |
2006 |
| Drug |
stavudine, efavirenz, lamivudine |
1 |
2005 |
| Behavioral |
std prevention curriculum |
1 |
2008 |
| Behavioral |
std risk reduction |
1 |
2008 |
| Behavioral |
std risk reduction intervention |
1 |
2011 |
| Behavioral |
stepping stones |
1 |
2006 |
| Behavioral |
stepping stones short |
1 |
2006 |
| Procedure |
sti (structured treatment interruption) |
1 |
2006 |
| Behavioral |
sti counseling |
1 |
2015 |
| Other |
sti/drug holiday |
1 |
2009 |
| Behavioral |
stick to it |
1 |
2010 |
| Behavioral |
stigma-relieving |
1 |
2018 |
| Drug |
stocrin (efavirenz) |
1 |
2006 |
| Drug |
stop statin |
1 |
2012 |
| Drug |
stop statin/switch to an antiretroviral drug with less impact on lipid metabolism |
1 |
2012 |
| Other |
stopped cotrimoxazole prophylaxis |
1 |
2013 |
| Drug |
stopping nucleosides |
1 |
2005 |
| Drug |
stopping nucleosides/continuing lopinavir/ritonavir monotherapy |
1 |
2005 |
| Behavioral |
strengths-based case management |
1 |
2010 |
| Drug |
stribild (elvitegravir, cobicistat, emtricitabine |
1 |
2013 |
| Drug |
stribild (elvitegravir, cobicistat, emtricitabine/tenofovir) |
1 |
2013 |
| Behavioral |
structured daily diary |
1 |
2013 |
| Behavioral |
structured ecosystems therapy (set) |
1 |
2006 |
| Drug |
structured treatment interruptions |
1 |
2006 |
| Drug |
study nnrti |
1 |
2009 |
| Drug |
study pi |
1 |
2009 |
| Drug |
subcutaneous lenacapavir |
1 |
2019 |
| Drug |
subjects do not receive study medication in this study 202094 |
1 |
2015 |
| Drug |
sulfadoxine-pyrimethamine intermittent preventive treatment |
1 |
2005 |
| Drug |
sulfamethoxazole |
1 |
1999 |
| Drug |
sulfamethoxazole (ts) |
1 |
2014 |
| Drug |
sunitinib malate |
1 |
2009 |
| Behavioral |
supervised exercise |
1 |
2005 |
| Behavioral |
support group |
1 |
2007 |
| Drug |
support treatment |
1 |
2007 |
| Behavioral |
supportive therapy for adherence to art (behavior) |
1 |
2005 |
| Device |
sure check hiv tests |
1 |
2014 |
| Device |
sustained-release intraocular drug delivery system |
1 |
1999 |
| Drug |
sustiva (efavirenz) |
1 |
2005 |
| Drug |
sustivaâ® (efavirenz) |
1 |
2004 |
| Drug |
switch to an antiretroviral drug with less impact on lipid metabolism |
1 |
2012 |
| Drug |
switch to drv |
1 |
2017 |
| Drug |
switch to drv/cobicistat / 3tc |
1 |
2017 |
| Drug |
switch to dtg / 3tc |
1 |
2017 |
| Drug |
switch to dtg / ftc |
1 |
2017 |
| Drug |
switching azt |
1 |
2006 |
| Drug |
switching to lpv |
1 |
2009 |
| Drug |
switching to lpv/r monotherapy (kaletra) |
1 |
2009 |
| Drug |
switching; dose reduction |
1 |
2006 |
| Behavioral |
symptom management manual |
1 |
2005 |
| Combination Product |
symtuza |
1 |
2019 |
| Combination Product |
symtuza/dolutegravir |
1 |
2019 |
| Dietary Supplement |
synbiotic 2000 |
1 |
2008 |
| Procedure |
syndromic treatment of sexually transmitted infections |
1 |
2006 |
| Drug |
syngeneic lymphocytes (cd4 |
1 |
1999 |
| Drug |
syngeneic lymphocytes (cd4/) cultured with okt3 (ortho)/interleukin-2 (chiro |
1 |
1999 |
| Biological |
syntex adjuvant formulation |
1 |
1999 |
| Procedure |
systemic counselling for sti patients |
1 |
2006 |
| Drug |
t-20 |
1 |
2001 |
| Device |
t-spot.tbâ® |
1 |
2008 |
| Biological |
t cell vaccination |
1 |
2006 |
| Biological |
t lymphocytes |
1 |
2012 |
| Drug |
t20 |
1 |
2007 |
| Drug |
taf (low dose) |
1 |
2013 |
| Drug |
taf 10 mg fdc |
1 |
2017 |
| Drug |
taf based regimen (tbr) |
1 |
2018 |
| Drug |
taf with a boosted protease inhibitor |
1 |
2017 |
| Drug |
taf with a boosted protease inhibitor/ldv/sof |
1 |
2017 |
| Drug |
taf/cobicistat |
1 |
2002 |
| Drug |
taf/evg insert |
1 |
2019 |
| Drug |
taf/ritonavir |
1 |
2002 |
| Behavioral |
tailored cue cards |
1 |
2010 |
| Behavioral |
tailored information |
1 |
2011 |
| Behavioral |
tailored information program for safer sex |
1 |
2009 |
| Other |
taking care of me video |
1 |
2018 |
| Drug |
tamoxifen |
1 |
2017 |
| Drug |
tap water enema |
1 |
2008 |
| Diagnostic Test |
targeted drm testing. |
1 |
2019 |
| Drug |
targeted prep counseling |
1 |
2017 |
| Biological |
tat protein |
1 |
2008 |
| Biological |
tbc-3b |
1 |
2003 |
| Biological |
tbc-fpv |
1 |
2004 |
| Biological |
tbc-m4 |
1 |
2009 |
| Biological |
tbc-mva |
1 |
2004 |
| Biological |
tbc-mva/tbc-fpv |
1 |
2004 |
| Drug |
tdf-ftc-mvc ivr |
1 |
2014 |
| Drug |
tdf-ftc ivr |
1 |
2014 |
| Drug |
tdf 300 mg |
1 |
2008 |
| Drug |
tdf 300 mg fixed-dose combination tablet |
1 |
2012 |
| Drug |
tdf 300 mg oral tablet |
1 |
2018 |
| Drug |
tdf 300mg |
1 |
2007 |
| Drug |
tdf ivr |
1 |
2014 |
| Drug |
tdf with a boosted protease inhibitor |
1 |
2017 |
| Drug |
tdf, 3tc, 3tc |
1 |
2002 |
| Drug |
tdf/3tc/efv / telmisartan |
1 |
2015 |
| Drug |
tdf/3tc/efv only |
1 |
2015 |
| Other |
tdf/ftc |
1 |
2010 |
| Drug |
tdf/ftc dose schedule for arm a |
1 |
2020 |
| Drug |
tdf/ftc dose schedule for arm b |
1 |
2020 |
| Drug |
tdf/ftc placebo tablets |
1 |
2016 |
| Drug |
tdf/ftc tablets |
1 |
2016 |
| Behavioral |
tech2check |
1 |
2018 |
| Drug |
telaprevir interactions |
1 |
2012 |
| Behavioral |
telephone-administered coping improvement therapy |
1 |
2006 |
| Behavioral |
telephone-administered supportive-expressive therapy |
1 |
2006 |
| Drug |
telinavir |
1 |
1999 |
| Drug |
telzirâ® |
1 |
2005 |
| Drug |
tenofovi-emtricitabine (tdf |
1 |
2006 |
| Drug |
tenofovi-emtricitabine (tdf/ftc) tablet |
1 |
2006 |
| Drug |
tenofovir-emtricitabine |
1 |
2005 |
| Drug |
tenofovir (tfv) ivr |
1 |
2018 |
| Drug |
tenofovir (truvada) |
1 |
2006 |
| Drug |
tenofovir (viread) |
1 |
2007 |
| Drug |
tenofovir (viread)/lopinavir/ritonavir (aluvia) |
1 |
2007 |
| Drug |
tenofovir / emtricitabine / atazanavir-ritonavir |
1 |
2007 |
| Drug |
tenofovir / emtricitabine / efavirenz |
1 |
2007 |
| Drug |
tenofovir / emtricitabine / lopinavir-ritonavir |
1 |
2007 |
| Drug |
tenofovir / emtricitabine / raltegravir. |
1 |
2008 |
| Drug |
tenofovir / emtricitabine, lopinavir/ritonavir |
1 |
2009 |
| Drug |
tenofovir 1% gel |
1 |
2010 |
| Drug |
tenofovir 300 mg |
1 |
2011 |
| Drug |
tenofovir 300mg |
1 |
2010 |
| Drug |
tenofovir af 25 mg |
1 |
2018 |
| Drug |
tenofovir alafenamid fumarate |
1 |
2007 |
| Drug |
tenofovir alafenamide fumarate (taf) |
1 |
2002 |
| Drug |
tenofovir alafenamide/emtricitabine |
1 |
2019 |
| Drug |
tenofovir df 300 mg qd |
1 |
2007 |
| placebo |
tenofovir df placebo |
1 |
2008 |
| Drug |
tenofovir disoproxil fumarate (dor |
1 |
2017 |
| Drug |
tenofovir disoproxil fumarate (tdf) 300 mg |
1 |
2009 |
| Drug |
tenofovir disoproxil fumarate (tdf)/lamivudine (3tc) |
1 |
2018 |
| Drug |
tenofovir disproxil fumrarate |
1 |
2006 |
| Drug |
tenofovir emtricitabine raltegravir |
1 |
2009 |
| placebo |
tenofovir placebo |
1 |
2008 |
| Drug |
tenofovir(tdf) |
1 |
2015 |
| Drug |
tenofovir(tdf)/lamivudine(3tc)/efavirenz(efv) |
1 |
2015 |
| Drug |
tenofovir) |
1 |
2013 |
| Drug |
tenofovir, emtricitabine, maraviroc |
1 |
2012 |
| Drug |
tenofovir, emtricitabine, raltegravir |
1 |
2012 |
| Drug |
tenofovir/bi 201335 |
1 |
2011 |
| Drug |
tenofovir/emtricitabine (truvada)/nevirapine |
1 |
2007 |
| Drug |
tenofovir/emtricitabine (truvada)/zidovudine |
1 |
2007 |
| Drug |
tenofovir/emtricitabine fdc |
1 |
2013 |
| Drug |
tenofovir/emtricitabine/efavirenz |
1 |
2007 |
| Drug |
tenofovir/emtricitabine/efavirenz (atripla) |
1 |
2007 |
| Drug |
terizidone |
1 |
2002 |
| Drug |
terizidone/cycloserine |
1 |
2002 |
| Drug |
tesamorelin |
1 |
2014 |
| Other |
testing (hct) |
1 |
2017 |
| Drug |
testosterone |
1 |
2001 |
| Biological |
tetanus |
1 |
2000 |
| Biological |
tetanus toxoid |
1 |
2000 |
| Biological |
tetanus toxoids |
1 |
2000 |
| Biological |
tetanus toxoids adsorbed |
1 |
2000 |
| Biological |
tetanus/diphtheria toxoids adsorbed |
1 |
2000 |
| Behavioral |
text messaging intervention |
1 |
2015 |
| Behavioral |
text messaging support |
1 |
2017 |
| Behavioral |
text messaging/ema |
1 |
2011 |
| Behavioral |
text reminders, counseling, |
1 |
2012 |
| Behavioral |
text reminders, counseling,/link coordination |
1 |
2012 |
| placebo |
thalidomide placebo |
1 |
2003 |
| Device |
the prepex a novel device for adult male circumcision |
1 |
2010 |
| Behavioral |
theory-based counseling program |
1 |
2006 |
| Dietary Supplement |
theragran-m |
1 |
2010 |
| Dietary Supplement |
theragran-m; ensure plus |
1 |
2010 |
| Procedure |
therapeutic conventional surgery |
1 |
2015 |
| Procedure |
therapeutic drug monitoring |
1 |
2004 |
| Procedure |
therapeutic drug monitoring (tdm) |
1 |
2002 |
| Device |
thermocoagulation |
1 |
2019 |
| Biological |
threonyl muramyl dipeptide |
1 |
1999 |
| Biological |
thv01-1 |
1 |
2014 |
| Biological |
thv01-2 |
1 |
2014 |
| Drug |
thymic humoral factor |
1 |
1999 |
| Drug |
time-driven dosing |
1 |
2010 |
| Behavioral |
time-matched control (tm) |
1 |
2019 |
| Behavioral |
time-matched health education |
1 |
2008 |
| Other |
time of starting antiretroviral therapy |
1 |
2011 |
| Drug |
tipranavir (tpv) |
1 |
2014 |
| Drug |
tipranavir (with low dose ritonavir) |
1 |
2005 |
| Drug |
tipranavir medium dose |
1 |
2014 |
| Drug |
tipranavir/ ritonavir |
1 |
2006 |
| Drug |
tipranavir/ritonavir |
1 |
2006 |
| Drug |
tipranavir/ritonavir (dose reduction) |
1 |
2008 |
| Drug |
tivicay |
1 |
2015 |
| Drug |
tivicay (dtg) |
1 |
2016 |
| Behavioral |
tlc nutritional intervention |
1 |
2015 |
| Dietary Supplement |
tlc nutritional intervention. |
1 |
2015 |
| Drug |
tld: fixed dose combination of tenofovir, lamivudine |
1 |
2019 |
| Drug |
tld: fixed dose combination of tenofovir, lamivudine/dolutegravir antiretroviral therapy |
1 |
2019 |
| Drug |
tmc120 (dapivirine) vaginal ring |
1 |
2008 |
| Drug |
tmc125 once daily |
1 |
2007 |
| Drug |
tmc125 twice daily |
1 |
2007 |
| Drug |
tmc207; nevirapine |
1 |
2009 |
| placebo |
tmc278 (rilpivirine) la; placebo |
1 |
2009 |
| Drug |
tmc278 150 mg |
1 |
2005 |
| Drug |
tmc278 25 mg |
1 |
2005 |
| Drug |
tmc278 75 mg |
1 |
2005 |
| Drug |
tmc278 la |
1 |
2014 |
| Drug |
tmc278 la 1200mg intramuscular injection |
1 |
2012 |
| Drug |
tmc278 la 600mg intramuscular injection |
1 |
2012 |
| Drug |
tmc278; omeprazole |
1 |
2009 |
| Drug |
tmc310911 150 mg twice daily |
1 |
2009 |
| Drug |
tmc310911 300 mg once daily |
1 |
2009 |
| Drug |
tmc310911 300 mg twice daily |
1 |
2009 |
| Drug |
tmc310911 75 mg twice daily |
1 |
2009 |
| Drug |
tmc435 |
1 |
2011 |
| Drug |
to the child |
1 |
2006 |
| Drug |
tocilizumab |
1 |
2014 |
| Other |
tokafatso programmatic intervention |
1 |
2013 |
| Drug |
topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream) |
1 |
2015 |
| Drug |
topical vaginal application of uc-781 gel |
1 |
2005 |
| Behavioral |
tough talks clinic |
1 |
2018 |
| Behavioral |
tough talks online |
1 |
2018 |
| Drug |
tpv oral solution |
1 |
2004 |
| Behavioral |
traditional connect |
1 |
2013 |
| Behavioral |
training |
1 |
2014 |
| Biological |
transcutaneous mode of administration |
1 |
2005 |
| Biological |
transient ch505tf gp120 |
1 |
2019 |
| Drug |
transporter probe substrates |
1 |
2015 |
| Behavioral |
trauma-informed cognitive behavioral therapy enhanced (ti-cbte) |
1 |
2015 |
| Behavioral |
trauma writing |
1 |
2003 |
| Behavioral |
treat |
1 |
2013 |
| Drug |
treatment a |
1 |
2018 |
| Drug |
treatment a: mk-1439 100 mg film coated tablet |
1 |
2015 |
| Behavioral |
treatment as usual |
1 |
2011 |
| Drug |
treatment b |
1 |
2018 |
| Drug |
treatment b: mk-1439 150 mg tablet (40% drug loaded granule) |
1 |
2015 |
| Drug |
treatment c |
1 |
2018 |
| Drug |
treatment c: mk-1439 150 mg tablet (30% drug loaded granule) |
1 |
2015 |
| Drug |
treatment d |
1 |
2018 |
| Drug |
treatment d: mk-1439 150 mg tablet (50% drug loaded granule) |
1 |
2015 |
| Drug |
treatment discontinuation |
1 |
2017 |
| Drug |
treatment e |
1 |
2018 |
| Drug |
treatment e: mk-1439 100 mg tablet (30% drug loaded granule) |
1 |
2015 |
| Drug |
treatment f |
1 |
2018 |
| Behavioral |
treatment interruption/reinitiation schedule |
1 |
2003 |
| Behavioral |
treatment regimen change |
1 |
2002 |
| Procedure |
treatment services |
1 |
2009 |
| Drug |
treatment simplification |
1 |
2014 |
| Drug |
trichosanthin |
1 |
1999 |
| Device |
trigridâ„¢ delivery system |
1 |
2007 |
| Drug |
trimethoprim |
1 |
1999 |
| Biological |
trimix_100 |
1 |
2015 |
| Biological |
trimix_300 |
1 |
2015 |
| Drug |
triple therapy |
1 |
2019 |
| Drug |
triple therapy with ritonavir |
1 |
2010 |
| Biological |
trivalent inactivated influenza vaccine |
1 |
2013 |
| Biological |
trivalent mrkad5 hiv-1 gag |
1 |
2009 |
| Biological |
trivalent mrkad5 hiv-1 gag/pol/nef vaccine (1x10^11 vp/dose) |
1 |
2009 |
| Biological |
trivalent mrkad5 hiv-1 gag/pol/nef vaccine (3x10^10 vp/dose) |
1 |
2009 |
| Biological |
trivalent mrkad5 hiv-1 gag/pol/nef vaccine (3x10^6 vp/dose) |
1 |
2009 |
| Biological |
trivalent mrkad5 hiv-1 gag/pol/nef vaccine (3x10^7 vp/dose) |
1 |
2009 |
| Biological |
trivalent mrkad5 hiv-1 gag/pol/nef vaccine (3x10^8 vp/dose) |
1 |
2009 |
| Biological |
trivalent mrkad5 hiv-1 gag/pol/nef vaccine (3x10^9 vp/dose) |
1 |
2009 |
| Other |
trofile estaâ® (diagnose test) |
1 |
2010 |
| Drug |
truvada (fixed dose combination of tenofovir |
1 |
2006 |
| Drug |
truvada (fixed dose combination of tenofovir / emtricitabine) / stocrin (efavirenz) |
1 |
2006 |
| Drug |
truvada (fixed dose combination of tenofovir / emtricitabine) / zidovudine (zdv) / abacavir (abc) |
1 |
2006 |
| Drug |
truvada (fixed dose combination of tenofovir / emtricitabine)/ ritonavir/atazanavir (r/atv) |
1 |
2006 |
| Drug |
truvada (tdf |
1 |
2006 |
| Drug |
truvada (tdf/ftc) alone |
1 |
2006 |
| Drug |
truvada (tenofovir df |
1 |
2005 |
| Drug |
truvada (tenofovir df / emtricitabine) |
1 |
2005 |
| Drug |
truvada / raltegravir |
1 |
2008 |
| Drug |
truvada tablet |
1 |
2019 |
| Drug |
truvada/raltegravir |
1 |
2010 |
| Drug |
truvadaâ„¢ |
1 |
2014 |
| Drug |
tuberculin purified protein derivative |
1 |
1999 |
| Drug |
tucaresol tablets 25 mg |
1 |
2006 |
| Drug |
tums |
1 |
2015 |
| Drug |
tumsâ® ultra strength |
1 |
2012 |
| Biological |
tuti-16 (0.03mg) |
1 |
2009 |
| Biological |
tuti-16 (0.1mg) |
1 |
2009 |
| Biological |
tuti-16 (0.2mg) |
1 |
2010 |
| Biological |
tuti-16 (0.6mg) |
1 |
2009 |
| Drug |
tvd 300 |
1 |
2012 |
| Drug |
tvd 300/200 qd |
1 |
2012 |
| Drug |
tvr |
1 |
2012 |
| Drug |
twice-daily abc |
1 |
2013 |
| Drug |
twice-daily abc/3tc |
1 |
2013 |
| Biological |
twinrix for atn 024 |
1 |
2005 |
| Biological |
twinrix for atn 025 |
1 |
2005 |
| Behavioral |
two-way sms intervention |
1 |
2014 |
| Drug |
two nrtis |
1 |
2014 |
| Drug |
two nucleosides |
1 |
2010 |
| Drug |
uc-781 |
1 |
2007 |
| Drug |
uc-781 microbicide gel (0.1% |
1 |
2006 |
| Drug |
uc-781 microbicide gel (0.1%/0.25%) |
1 |
2006 |
| placebo |
uc-781 placebo |
1 |
2007 |
| Drug |
uc 781 |
1 |
2007 |
| Behavioral |
unity in diversity |
1 |
2008 |
| placebo |
universal placebo gel |
1 |
2011 |
| Drug |
universal prep counseling |
1 |
2017 |
| Behavioral |
updated chd risk profiles |
1 |
2005 |
| Other |
urgent art |
1 |
2012 |
| Procedure |
use of creatine monohydrate (a dietary supplement) |
1 |
2007 |
| Other |
usual care/incentives |
1 |
2015 |
| Other |
usual care/peer-mentors |
1 |
2015 |
| Behavioral |
usual clinical care |
1 |
2019 |
| Behavioral |
usual clinical care/counseling |
1 |
2019 |
| Biological |
v114 |
1 |
2019 |
| Biological |
v520 |
1 |
2009 |
| Biological |
v526 |
1 |
2009 |
| Biological |
vacc-4x high dose |
1 |
2011 |
| Biological |
vacc-4x low dose |
1 |
2011 |
| Biological |
vacc-4x medium dose |
1 |
2011 |
| Biological |
vaccine |
1 |
2016 |
| placebo |
vaccine placebo |
1 |
2004 |
| Behavioral |
vaccine preparedness |
1 |
1999 |
| Drug |
valacyclovir hydrochloride |
1 |
1999 |
| Drug |
valproic acid |
1 |
1999 |
| Drug |
vaqta injectable product |
1 |
2017 |
| Drug |
varenicline tartrate |
1 |
2008 |
| Biological |
vedolizumab (brand name entyvio) |
1 |
2017 |
| Drug |
vel |
1 |
2015 |
| Drug |
vel for 12 weeks |
1 |
2015 |
| Drug |
vel for 6 weeks |
1 |
2015 |
| Drug |
velpatasvir |
1 |
2017 |
| Biological |
vgx-3100 |
1 |
2018 |
| Drug |
vgx-410 (mifepristone) |
1 |
2006 |
| Device |
vicriviroc (mk-4176) intravaginal ring (ivr) |
1 |
2015 |
| Drug |
vicriviroc maleate |
1 |
2008 |
| Drug |
vicriviroc maleate 20 mg |
1 |
2005 |
| Drug |
vicriviroc maleate 30 mg |
1 |
2005 |
| Behavioral |
video (group-delivered video-based intervention) |
1 |
2008 |
| Behavioral |
video discussion group |
1 |
2005 |
| Drug |
videx ec |
1 |
2005 |
| Biological |
vif, env pdna vaccine |
1 |
2016 |
| Drug |
vincristine sulfate |
1 |
2018 |
| Device |
vioone hiv profile supplemental assay |
1 |
2018 |
| Behavioral |
vip app that delivers hiv-related symptom strategies. |
1 |
2017 |
| Behavioral |
vip app without hiv-related symptom strategies. |
1 |
2017 |
| Behavioral |
viral suppression component: fi |
1 |
2010 |
| Behavioral |
viral suppression component: soc |
1 |
2010 |
| Drug |
viread |
1 |
2006 |
| Drug |
viread (tenofovir df) |
1 |
2005 |
| Drug |
viread (tenofovir disoproxil fumarate) |
1 |
2005 |
| Other |
virological monitoring |
1 |
2011 |
| Other |
virtual hospital |
1 |
2010 |
| Behavioral |
virtual reality |
1 |
2015 |
| Procedure |
visual oral screening examination |
1 |
2016 |
| Dietary Supplement |
vitamin a |
1 |
2005 |
| Dietary Supplement |
vitamin a / beta carotene |
1 |
2005 |
| Drug |
vitamin d (cholecalciferol) |
1 |
2012 |
| Drug |
vitamin d (cholecalciferol)/pba (sodium phenylbutyrate) |
1 |
2012 |
| Drug |
vitamin d control dose |
1 |
2012 |
| Dietary Supplement |
vitamin d supplement |
1 |
2007 |
| Drug |
vitamin d supplementation- |
1 |
2012 |
| Dietary Supplement |
vitamin d3 (cholecalciferol) |
1 |
2013 |
| Dietary Supplement |
vitamin d3 50,000 iu |
1 |
2012 |
| placebo |
vitamin d3 placebo |
1 |
2012 |
| Drug |
vitamin d3, 10000 intl units oral capsule |
1 |
2018 |
| Drug |
vivitrol- intramuscular naltrexone (depot-formulation) |
1 |
2010 |
| Drug |
vm-1500/placebo |
1 |
2015 |
| Behavioral |
vocational training (sl-v) |
1 |
2014 |
| Behavioral |
voluntary brief hiv counseling |
1 |
2008 |
| Behavioral |
voluntary brief hiv counseling/testing |
1 |
2008 |
| Behavioral |
voluntary counselling |
1 |
2006 |
| Behavioral |
voluntary counselling/hiv testing in anc for pmtct |
1 |
2006 |
| Behavioral |
voluntary longer, more detailed hiv counseling |
1 |
2008 |
| Behavioral |
voluntary longer, more detailed hiv counseling/testing |
1 |
2008 |
| Biological |
vrc-diluent013-dil-vp |
1 |
2005 |
| Drug |
vrc-hivadv014-00 |
1 |
2005 |
| Biological |
vrc-hivadv014-00-vp booster |
1 |
2005 |
| Biological |
vrc-hivadv014-00-vp vaccine |
1 |
2012 |
| Drug |
vrc-hivadv027-00-vp |
1 |
2007 |
| Drug |
vrc-hivadv038-00-vp |
1 |
2007 |
| Biological |
vrc-hivdna-016-00-vp |
1 |
2009 |
| Biological |
vrc-hivdna009-00-vp (gag-pol-nef-multiclade-env) with adjuvant vrc-adjdna004-il2-vp |
1 |
2003 |
| placebo |
vrc-hivdna016-00-vp placebo |
1 |
2005 |
| Drug |
vrc-hivdna016-00, vrc-hivadv014-00 |
1 |
2006 |
| Drug |
vrc-hivmab01060-00-ab (vrc01) |
1 |
2016 |
| Drug |
vrc-hivmab060-00-ab |
1 |
2013 |
| Biological |
vrc-hivmab080-00-ab (vrc01ls) |
1 |
2015 |
| Biological |
vrc-hivrgp096-00-vp |
1 |
2018 |
| Biological |
vrc rad5 vaccine (rad5 gag-pol |
1 |
2011 |
| Biological |
vrc rad5 vaccine (rad5 gag-pol/env a/b/c) |
1 |
2011 |
| Biological |
vrc07-523ls (20mg |
1 |
2017 |
| Biological |
vrchivadv014-00-vp |
1 |
2009 |
| Genetic |
vrx496-modified autologous t cells |
1 |
2005 |
| Genetic |
vrx496-transduced autologous cd4 t cells |
1 |
2008 |
| Biological |
vsv-indiana hiv gag vaccine |
1 |
2011 |
| Biological |
vsv hiv gag vaccine |
1 |
2012 |
| Drug |
w spl7013 gel (vivagelâ„¢) |
1 |
2006 |
| Biological |
w20 |
1 |
2005 |
| Behavioral |
waitlist |
1 |
2018 |
| Behavioral |
wave-tw |
1 |
2020 |
| Behavioral |
we test |
1 |
2020 |
| Behavioral |
web-based tailored smoking cessation intervention |
1 |
2012 |
| Behavioral |
weekly hiv sensitization text messages |
1 |
2015 |
| Behavioral |
weekly quizzes |
1 |
2017 |
| Dietary Supplement |
wheat biscuit |
1 |
2007 |
| Other |
wheat pretzel |
1 |
2016 |
| Procedure |
white blood cell infusion |
1 |
1999 |
| Behavioral |
wirelessly observed therapy |
1 |
2015 |
| Device |
wise app with fitness reminders |
1 |
2017 |
| Device |
wise app with medication adherence reminders |
1 |
2017 |
| Drug |
wobenzym |
1 |
1999 |
| Behavioral |
women’s |
1 |
2017 |
| Behavioral |
women’s relationship-focused hiv counseling |
1 |
2006 |
| Behavioral |
women’s relationship-focused hiv counseling/testing |
1 |
2006 |
| Behavioral |
women’s/sexual health [wash] |
1 |
2017 |
| Behavioral |
wonderous wetlands |
1 |
2008 |
| Behavioral |
writing about daily events |
1 |
2003 |
| Behavioral |
writing tasks |
1 |
2017 |
| Biological |
wt-gag-tcr modified t cells |
1 |
2009 |
| Device |
xpert device |
1 |
2015 |
| Behavioral |
young women’s health coop (ywhc) |
1 |
2016 |
| Behavioral |
youth-friendly health services |
1 |
2005 |
| Behavioral |
youth condom promotion |
1 |
2005 |
| Behavioral |
youth condom promotion/distribution |
1 |
2005 |
| Behavioral |
youthrive |
1 |
2017 |
| Drug |
zdv long (mother)-long (infant): comparison of zidovudine durations |
1 |
2006 |
| Drug |
zdv long (mother)-short (infant): comparison of zidovudine durations |
1 |
2006 |
| Drug |
zdv short (mother)-long (infant): comparison of zidovudine durations |
1 |
2006 |
| Drug |
zdv short (mother)-short (infant): comparison of zidovudine durations |
1 |
2006 |
| placebo |
zerit (stavudine) placebo |
1 |
2005 |
| Biological |
zero dose |
1 |
2011 |
| Drug |
zfn modified cd4 |
1 |
2015 |
| Drug |
zfn modified cd4/ t cells |
1 |
2015 |
| Biological |
zfn modified t cells |
1 |
2009 |
| Drug |
ziagen |
1 |
2004 |
| Drug |
zidovudine (azt), lamivudine (3tc), nevirapine (nvp) |
1 |
2008 |
| Drug |
zidovudine (azt)/ didanosine (ddi)/ nevirapine (nvp) |
1 |
2008 |
| Drug |
zidovudine (azt)/interleukin-2 (il2) |
1 |
1999 |
| Drug |
zidovudine (zcv) |
1 |
2005 |
| Drug |
zidovudine,lamivudine,abacavir |
1 |
2006 |
| Drug |
zidovudine/lamivudine |
1 |
2003 |
| Drug |
zidovudine/lamivudine (combivir) |
1 |
2006 |
| Drug |
zidovudine/lamivudine (combivirâ®) |
1 |
2006 |
| Dietary Supplement |
zinc |
1 |
2007 |
| Drug |
zinc supplementation |
1 |
2005 |
| Drug |
zintevir |
1 |
1999 |
| Drug |
zoledronic acid |
1 |
2008 |